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  Abstract 
 
B cells have been proven to have a significant role in liver fibrosis. We postulate 
that enrichment of B cell subsets in hepatic diseases may implicate this 
population in liver pathogenesis. When comparing total B cells from human 
immune and non-immune-mediated liver disease explants, we found an 
enrichment of CD20+ B cells in PBC. Furthermore, phenotypic characterization 
of 11 B cell subsets in matched liver and blood highlighted an enriched naïve 
peripheral population, and activated B cell subsets in livers. Newly identified 
CD19+CD24-CD38- and CD19+CD24-CD38int B cells were also augmented in 
livers compared to matched blood. Furthermore, CD24-CD38- B cells were 
elevated in PBC and formed aggregates in tissues, whereas CD24-CD38int B 
cells localized around bile ducts and along fibrotic tracts in PBC. CD24-CD38int 
B cells secreted pro-inflammatory (IL-6, IFN-γ) and immunosuppressive (IL-10) 
cytokines following stimulation with CpG compared to other B cell subsets, 
implying that CD24- B cells may play a role in liver disease pathogenesis. Our 
findings suggest that B cells may be influential in hepatic disease progression 
and pathogenesis. Elucidating their role further could provide possible 
therapeutic targets for prevention or treatment of chronic liver disease. 
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1.1. THE FUNCTION OF B CELLS 
 
B lymphocytes form part of the adaptive immune system and contribute to between 
5–10% of the total human lymphocyte population (5). They are defined through their 
expression of membrane-bound surface immunoglobulin molecules known as B cell 
receptors (BCR) (6), which are able to recognize cognate antigen through the 
variable region. 
 
Like macrophages and dendritic cells (DCs), B cells act as professional antigen 
presenting cells (APCs), which internalize antigens via the BCR (7), and process 
them into antigen peptides via lysosomal degradation. These peptides are then 
presented to T helper cells along with co-stimulatory signals, causing T cell 
activation, clonal expansion and the general sustenance of effector T cell responses 
to pathogens (6, 7). This highlights the importance of B cells in linking the innate and 
adaptive immune systems, as well as in effectively propagating the adaptive immune 
response through T cell activation. 
 
MHC class II presentation of antigenic peptides to activated T helper cells, 
consequently leads to B cell activation through signal transduction; initiating B cell 
proliferation and differentiation into antibody producing plasma cells and memory B 
cells (Figure 1) (6-8). Long lived memory B cells produce rapid secondary 
responses upon re-exposure to the primary antigen, whereas antibodies released by 
the plasma cells neutralize antigens, opsonize antigens for destruction, and activate 
the membrane attack complex (MAC) via the complement pathway to initiate 
? ??
bacterial lysis (6). These processes triggered by B cell activation are important in the 
immediate removal of circulating pathogens. 
 
 
 
  
 
Figure 1 – B cell activation. After initially binding an antigen to the B cell 
receptor (BCR), B cells internalize antigen and present it on MHC class II. A 
helper T cell recognizes the MHC class II–antigen complex and activates the 
B cell. As a result, memory B cells and plasma cells are produced (9). Image 
adapted from Rye C et al. 2012 (10).  
 
? ??
Once activated, B cells enhance cell-mediated immunity by boosting T cell 
responses via production of pro-inflammatory cytokines TNF-α, IFN-γ and IL-12 (11, 
12). Conversely, B cells also control inflammation through the release of regulatory 
cytokines such as IL-10 and TGF-β from regulatory B cells (Bregs) (13, 14) See 
Table 1. In this way, the production of both pro-inflammatory and anti-inflammatory 
cytokines highlights their importance in immunoregulation in response to antigens.  
Table 1 - B cell subtypes and their cytokine production. B cells produce specific cytokines 
depending on their exposure to the surrounding environment. B cells exposed to Th1 cells produce 
Be 1 cytokines and those exposed to Th2 cells produce Be 2 Type cytokines (15-21). 
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B cell function also extends beyond cytokine production, where they are involved in 
MAIT cell activation (Mucosal-associated invariant T cells), which are MHC class Ib-
restricted innate-like lymphocytes with anti-bacterial functions (22). Furthermore, B 
cells are pivotal in maintaining secondary lymphoid organ (SLO) structure (23) and 
also impact follicular T helper (Tfh) cells (24), which explains the ability of B cells to 
orchestrate and shape inflammatory responses.  
B cells have been implicated in the pathogenesis of multiple diseases. They are 
important in optimal activation of CD4+/CD8+ T-cells during anti-tumour responses 
(23) (25), and have also been implicated in autoimmune diseases such as Systemic 
Lupus Erythematosus (SLE) (26, 27), rheumatoid arthritis (28) and type 1 diabetes 
(29) through auto-antibody production. For this reason, B cells have been an 
attractive target for therapeutic intervention using drugs such as rituximab, which 
knocks out CD20+ B cells via monoclonal antibody and has proven effective in 
treating autoimmune diseases such as PBC (30), autoimmune hepatitis (31) and 
rheumatoid arthritis (32). 
Overall, B cells are essential in playing multiple roles in inflammation, and disease. It 
is firstly important to establish whether these B cell functions are assigned to 
particular B cell subsets. Consequently, this would broaden our understanding of 
how B cells could be targeted therapeutically in the future to effectively combat 
disease.  
 
? ??
1.2. B CELL DEVELOPMENT 
?????? ??????????????????????????????? ??????
 
In order to understand B cell biology, it is important to understand the origin of B 
cells. B cell development is well characterized in the mouse, where the fetal liver is 
the main site of B lymphopoiesis during embryonal life (33). The development of pre-
B cell colonies has been described on day 15 within fetal liver cells, with these 
colonies increasing with gestational age and peaking at day 19 (33). This 
development of early B lymphopoiesis has been described as a two part process, 
the first of which requires the presence of stromal cells to encourage the 
differentiation of B220- cells to B220+ cells. The second step requires the presence 
of IL-7 to encourage proliferation and differentiation of B220+IgM- cells to become 
IgM+ (33).  
 
Stromal cells in the bone marrow provide cell-cell contacts with developing B cells 
and also produce cytokines and chemokines, creating an ideal microenvironment for 
B cell maturation, differentiation and development (34-36). B cell development in the 
bone marrow occurs independently of antigen and is essential in regulating the 
construction of antigen receptors (BCR), as well as ensuring that each B cell has 
one specificity. The bone marrow also provides an environment for self-reactive B 
cells to be deleted and useful B cells to be exported to the periphery (6).  
 
Stages of B cell differentiation in the bone marrow are defined by various phases of 
surface immunoglobulin (Ig) gene arrangement. Progenitor pro-B cells derive from 
pluripotent hematopoietic stem cells, which in the mouse are defined by cell surface 
expression of B220, CD43 and c-kit (37). Pro-B cells are the earliest known B cell 
? ??
lineage, where rearrangement of the Ig heavy-chain locus occurs; DH to JH joining 
occurs at the early pro-B cell stage followed by VH-DJH joining at the late pro-B cell 
stage (37, 38). Efficient VDJH joining results in expression of an intact heavy chain, 
which leads to pre-B cell development (6, 37). Here, the heavy chain is expressed 
alone intracellularly as well as transiently at the cell surface along with a surrogate 
light chain, forming a pre-B cell receptor (37, 38). Expression of the pre-B cell 
receptor initiates cell divisions leading to the formation of small-pre cells, where the 
VJ light chain (VJL) of the Ig molecule begins to rearrange (6). Once rearrangement 
of the heavy and light chains is complete, a complete IgM molecule is assembled 
and expressed on the surface of the immature B cell (6), which then leaves the bone 
marrow to mature in the periphery (6, 39) (See Figure 2). 
 
 
 
 
 
? ??
      
 
 
 
Figure 2 – Stages of B cell development in the bone marrow (6). B cells develop 
from a haematopoietic stem cell, though to pro- and pre-B cell stages, and finally to 
an immature B cell which then continues maturation in the periphery. Figure adapted 
from Murphy et al., 2011. 
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In order to regulate B cell development, B cells undergo positive and negative 
selection in the bone marrow. Positive selection occurs when developing B cells bind 
to environmental and self-antigens with low affinity via the pre-B receptor. This 
ligand binding generates survival signals which promotes B cell survival and 
development (6). 
Negative selection occurs when immature B cells are tested for strong reactivity 
against autoantigens. Self-reactive B cells encounter one of three fates (6, 40), the 
first of which is clonal deletion or receptor editing in the bone marrow. When 
developing B cells express receptors that recognize multivalent ligands, for example, 
ubiquitous self cell-surface molecules such as those of the MHC, they are deleted 
from the repertoire, via clonal deletion. These B cells either undergo receptor editing, 
so that the self-reactive receptor specificity is deleted, or the cells themselves 
undergo programmed cell death or apoptosis (6, 41, 42). Secondly, immature B cells 
which bind soluble self-antigens and are able to cross-link the BCR, downregulate 
their surface IgM receptor expression, before migrating into the peripheral lymphoid 
tissues (6). Although these B cells express IgD and migrate to the periphery, they 
are unresponsive to antigen, therefore rendering them anergic. If in competition with 
other peripheral B cells, these B cells are rapidly lost. 
Thirdly, it is also possible for immature B cells that bind soluble self-antigens with 
low affinity to not receive any signal as a result of this interaction. These B cells 
mature normally to express both IgM and IgD at the cell surface, and are potentially 
self-reactive, however they are classed as clonally ignorant as their ligand is present 
but is unable to activate them (6) (See Figure 3) 
? ???
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Figure 3 – Stages of B cell selection in the bone marrow (6). There are four 
possible outcomes for self-reactive immature B cells, which is dependent on the type 
of ligand to which they are capable of binding. These fates include cell death by 
apoptosis; the production of a new receptor known as receptor editing; the induction 
of a permanent state of unresponsiveness to antigen known as anergy; and 
ignorance. Figure adapted from Murphy et al., 2011. 
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Once developed, immature B cells leave the bone marrow and enter the peripheral 
blood as transitional B cells, which have been identified in mice (T1, T2, and T3) and 
in humans (T1 and T2) (43, 44). Transitional B cells are the intermediate cells 
between immature B cells in the bone marrow and fully mature naïve B cells  
(CD19+CD20+IgM+IgD+CD38-) in peripheral blood and secondary lymphoid tissues 
(45).  It has been proposed that after being selected for self-tolerance and leaving 
the bone marrow, transitional B cells undergo a series of peripheral checks to ensure 
that they will not develop into autoimmune plasma cells (46). Those that survive 
these peripheral checks are then able to develop further into mature naive B cells, 
which express IgD and IgM (Figure 2) (47, 48). These B cells remain naïve and 
circulate through peripheral lymphoid tissues until they encounter their specific 
foreign antigen via their surface BCR (6). Just as in mice, mature naive B cells in 
human lymphoid tissues can be stimulated by foreign antigen and activated by T 
cells to form germinal centers (GC), where class-switch recombination (CSR) and 
somatic hypermutation (SHM) takes place to produce plasma cells and memory cells 
(6). This overall response to antigens by B cells is known as the humoral immune 
response (6). 
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1.3. B CELL STIMULATION AND ACTIVATION 
 
Induction of cytokine production from B cells requires stimulation and activation. In 
vivo this usually takes place either via T cell-dependent activation, or T cell-
independent activation (6). 
?????? ?????????? ?????????????????????
During T cell-dependent activation, B cells internalize and degrade BCR bound 
antigen via receptor mediated endocytosis (Signal 1 to B cell), and present antigen 
peptides on MHC class II receptors to the TCR on T cells, triggering T cell activation. 
The activated T cell then provides the B cell with a secondary signal through the 
production of cytokines such as IL-4 and IL-21, and the surface protein CD40L.  
Engagement of both the BCR and CD40 via α-BCR and IgM/IgD crosslinking in vitro 
results in classical synergistic activation of B cells (49), resulting in B cell expansion, 
differentiation and cytokine production (6, 50). B cell activation under these 
conditions can be measured by monoclonal antibody (mAb) production, B cell 
differentiation, blast formation and proliferation using FACS analysis and thymidine 
uptake respectively (51-53). However, one group has postulated that naïve B cells 
required three stimulations for activation: 1. Stimulation via antigen:BCR, 2. Co-
stimulation through T cell ligation of CD40 and 3. Activation of TLRs (54).  
The importance of B cells in CD4+ T cell activation has been highlighted in several B 
cell depletion experiments, especially autoimmune disease-related studies (55-57). 
Autoimmune hepatitis is considered a T cell mediated disease. However, one study 
has shown that AIH patients refractory to conventional treatment have been 
successfully treated with anti-CD20-mediated B-cell depletion with rituximab (58). 
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Following B cell depletion, patients harboured significantly fewer antigen-
experienced CD4+ and CD8+ T cells, and T-cell proliferation was significantly 
reduced. This is primarily due to the fact that B cells served as antigen-presenting 
cells to CD4+ T cells, and their reduction caused reduced antigen presentation to T 
cells, and consequently, reduced T cell activation (58). Another report showed that B 
cell depletion via rituximab in MS patients resulted in reduced secretion of soluble 
products (lymphotoxin and TNF-α) from activated B cells (59). Consequently, this 
significantly diminished proinflammatory responses of CD4+ and CD8+ T cells, in 
vivo and ex vivo (59). These findings provided novel insights into the mechanisms 
that facilitate B and T cell interactions, and highlighted the therapeutic effects of B 
cell depletion in human autoimmune diseases. 
?????? ?????????? ?????????????????
 
T cell-independent activation usually occurs through antigens such as foreign 
polysaccharides (e.g. LPS) or unmethylated CpG DNA, which causes direct B cell 
activation through binding to toll-like receptors (TLRs) on the B cell surface (60). 
Other T cell-independent antigens consist of highly repetitive structural epitopes (e.g. 
on encapsulated bacteria) (61). These repetitive antigens cause extensive cross-
linking of the BCRs consequently leading to B cell activation (60).  
 
 
Toll-like receptors (TLRs) are germ-line encoded receptors, which recognise a broad 
range of microbial antigens, and in combination with signaling through the BCR, are 
known to play a role in B cell development and differentiation (62). Ligation of TLRs 
causes them to mount immune responses to infection by initiating downstream 
signaling, although the outcome of TLR signaling in B cells is context dependent 
? ???
(63). Thirteen vertebrate members of the TLR family have been identified, however 
human B cells are known to differentially express TLR1–10, where signaling 
following ligation orchestrates inflammation (62). TLR signaling also causes cytokine 
production, proliferation, antibody production, increased antigen uptake and 
presentation (63). 
TLR expression is varied amongst B cell subsets. Resting B cells express low levels 
of TLR7, TLR9 and TLR10, however they temporarily upregulate expression upon 
BCR-crosslinking and CD40L or TLR stimulation (64). Naïve B cells express low 
levels of TLR9 and TLR10 but upon activation, these TLRs are expressed at high 
levels (64). TLR6, TLR7, TLR9 and TLR10 on the other hand, are highly expressed 
in memory B cells, where expression of TLR1, TLR2 and TLR4 expression is low 
(64). PB/PC express TLR 1–8 and express particularly high levels of TLR9 and 
RP105 (65). 
TLR4 is expressed on the surface of B cells and is ligated by LPS (65). Its 
expression and function is elevated on B cells in inflammatory disease patients upon 
stimulation through surface IgM and CD40 combined with IL-4 (66). Previous studies 
showed that TLR4 stimulation can cause decreased IL-10 production in inflammatory 
disease patients, which is coupled with TLR4-induced increases in pro-inflammatory 
cytokine production (67). This highlighted B cell TLR4 ligation contributed to 
systemic inflammation through multiple mechanisms. However, TLR4 ligation on B 
cells does not just provide an inflammatory signal, as murine studies have also 
highlighted the importance of TLR4 signaling in anti-inflammatory responses, where 
LPS stimulation has been found to increase IL-10 production from murine B10 cells 
as a result of TLR4 signaling (68, 69). 
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RP105 is a TLR4 homologue capable of signaling by using the same downstream 
cascades as TLR4 (70). This molecule’s expression across B cell subsets is not well 
elucidated. However, functionally, RP105- B cells have been shown to play a role in 
inflammation by producing autoantibodies therefore participating in the 
pathophysiology of SLE (71). Furthermore, RP105 stimulation of B cells combined 
with LPS or CpG results in proliferation and differentiation of B cells and increased 
secretion of IL-6, IL-10 and TNF-α (70).  
CpG is commonly used to stimulate B cells via TLR9 in order to induce their 
proliferation and production of cytokines such as IL-10 in vitro in the presence of 
phorbol 12-myristate 13-acetate (PMA) (72) (73). TLR9 is expressed intracellularly 
within endosomal compartments by binding to DNA rich in CpG motifs (65). TLR7 is 
expressed intracellularly and is important in binding to single stranded RNA (ssRNA) 
resulting in B cell proliferation and CSR (65). Stimulation of both TLR7 and TLR9 
ligands results in B cell secretion of IL-6, IL-8 and IL-10 (74-77). IL-1β and IL-2 
secretion in particular have been detected in response to B cell-specific CpG-ODN 
stimulation (75). Genetic deficiency of TLR7 or TLR9 often leads to reduced 
production of antibodies (78), and increased expression of TLR7 on B cells causes 
susceptibility to autoimmune diseases (79). 
?????? ????????????????????? ????????
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Different B cell subsets require different combinations of stimulations in order to 
become activated (80, 81). For example, memory B cells proliferate and differentiate 
more readily than naïve B cells in response to TLR stimulation (65), whereas most 
studies agree that both CD40L and BCR signals are required for proliferation and 
differentiation of naïve B cells and Bregs (50). B cells release different cytokines and 
? ???
perform different functions depending on their exposure to different conditions and 
forms of activation (82-85). Studies showed that naïve B cells only required single 
TLR9 engagement for activation through CpG oligodeoxynucleotide (86, 87). 
Bregs are known to appear under inflammatory conditions. This population can be 
stimulated most commonly via TLR9 or TLR4, to secrete IL-10; a cytokine involved 
in dampening inflammation (69, 88, 89). In fact, in mice, IL-10-producing B cells 
have also been shown to be stimulated via BCR signaling, TLR2/TLR4/MYD88, 
CD40/CD40L, IL-21/IL-21L and BAFF (90, 91). These IL-10 producing Bregs can be 
found within subpopulations in mice such as B1a, transitional, FO and MZ B cells 
(89). Recently, Bouaziz et al. demonstrated that stimulation of human B cells with 
anti-Ig and CpG enriched CD27+ memory and CD38hi transitional B cell 
compartments, and induced IL-10 secretion (92). Mauri et al. also demonstrated that 
human Bregs were CD19+CD24hiCD38hi transitional B cells in the peripheral blood of 
healthy individuals, as following CD40 stimulation, this population was able to 
produce IL-10 (93). On the contrary, B cells can also contribute to inflammation, 
where stimulation of CD20+ B cells with leptin significantly increases production of 
pro-inflammatory cytokines IL-6 and TNF-α (12). Follicular B cells can be primed to 
become effector B cells following stimulation by Th1 cells and antigen, to make 
cytokines associated with type 1 immune responses such as IFN-γ and IL-12. 
However B cells primed by Th2 cells and antigen are associated with allergic 
immune responses, and secrete IL-2, IL-13 and IL-4 (15).  
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Secondary lymphoid organs (SLOs) located in the periphery, such as the spleen and 
lymph nodes, are the sites of lymphocyte activation by antigens (6). Key features of 
SLOs are the presence of lymphoid follicles, which can be classified as primary, 
secondary, or tertiary. Primary follicles contain aggregates of FDCs and B cells, 
which have not experienced antigen-driven responses (94). The B cells contained 
within these follicles are mostly naïve, and are mobile, therefore allowing free B cell 
recirculation in search of antigen. Secondary follicles arise following B cell exposure 
to antigen, and are a result of B cell activation (95). These follicles contain germinal 
centers (GCs) with mature and differentiated B cell populations (94). Tertiary 
lymphoid structures (TLS) effectively represent secondary lymphoid follicles, 
however are not located in a typical SLO (6, 95). Ectopic lymphoid structures can 
also exist outside of SLOs, and represent primary follicle-like structures that are less 
well developed compared to TLS (94) (Figure 4). 
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Figure 4 – Comparing the secondary lymphoid follicle structure to the tertiary 
lymphoid structure (TLS). Structure of a typical SLO (left), which can contain either 
primary or secondary B cell follicles. Primary follicles contain mostly naive B cell and 
FDC clusters, whereas secondary follicles contain more mature, organised germinal 
centers. A TLS (right) is similar to secondary follicles but is situated in peripheral 
tissues, which are ectopic to the SLO. DC: dendritic cell, FDC: Follicular Dendritic 
Cell, HEV: High Endothelial Venule, GC: Germinal Centre. Adapted from Pimenta et 
al., 2014 (96). 
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Germinal centers form following T cell-dependent reactions within B cell follicles, 
where rapidly proliferating cells differentiate into high-affinity antibody-producing 
plasma cells and memory cells which are able to specifically target exogenous 
antigens (6). This GC reaction propagates robust immune protection and rapid 
memory, which is achieved via immunoglobulin diversifying events, somatic 
hypermutation (SHM), and immunoglobulin class switching, class switch 
recombination (CSR), respectively (6, 95). SHM encourages the selection of 
hypermutated antibodies with very high affinity for antigen, and CSR permits the 
changing of antibody effector functions through a switch in isotype (95).  
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Germinal centers develop 3–4 days after antigen exposure and can persist for 
several weeks depending on the type of antigenic stimulus (97, 98). Initiation of the 
GC reaction involves recognition of antigen presented by DCs, which are recognised 
by mature follicular B cells via the BCR (99). Following this recognition, the follicular 
B cell migrates to the T cell zone border within the SLO (95, 99). T cell and B cell 
interactions involving CD40L ligation promote survival, activation and proliferation of 
B cells. At this point, B cells commit to one of two paths, one of which leads to the 
GC reaction, and the other resulting in plasmablast development. Plasmablast 
development involves migration to extrafollicular regions with subsequent class 
switching but with minimal SHM (99, 100). It is here that extrafollicular plasmablasts 
are able to provide a more rapid, but less targeted antibody response (99).  
In the GC pathway, B cell recruitment to the GC microenvironment occurs depending 
on the specific expression of chemokine receptors, particularly CXCR5 (101). 
CXCR5 attracts B cells towards the lymphoid follicle, and the G Protein Coupled 
Receptor (EBI2) is downregulated, thereby promoting migration to extrafollicular B 
cell sites, and increasing GC commitment (101). The transcription factor Bcl-6 
promotes differentiation into GC specific B cells and also encourages CD4 T cell 
differentiation into specialised T follicular helper cells (TFH), which play a significant 
role in germinal centers (95, 102). Once within the follicle, the newly activated B cells 
known as GC precursor B cells, proliferate (102). This displaces the occupying 
mature B cells into the peripheral area known as the marginal / mantle zone, which 
signifies the start of the GC reaction (101, 102). The procedure of GC initiation is 
illustrated in Figure 5. 
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Figure 5 – The dynamics of Germinal Centre initiation. GCs take an estimated 7 
days to mature (102). T cell help and CD40 ligation are essential in the initiation of 
the reaction. Proportions of B cells do not enter the GC and instead commit to a 
plasmablast phenotype. Dark zone and light zone compartmentalisation occurs in 
the later stages of the reaction. Figure adopted from De Silva et al., 2015. 
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As the B cell blasts rapidly proliferate in the GC, 2 compartments are established: 
the dark zone and the light zone, which are surrounded by naive follicular mantle B 
cells (101). The dark zone contains rapidly proliferating B cells known as 
centroblasts, which express the proliferation antigen ki-67, localise close to T cell 
areas, and have decreased surface immunoglobulin expression (103). The density of 
B cells is lower in the light zone which contains a network of surrounding FDCs and 
TFH cells (104). Light-zone B cells are small, non-proliferating cells known as 
centrocytes, which express surface immunoglobulins, undergo antibody selection, 
? ???
CSR and differentiation into plasma cells and memory B cells (101, 104). 
Compartmentalization of GC B cells into dark and light zones is dependent on the 
presence of CXCL12 and CXCL13 chemokines. Centroblasts expressing high levels 
CXCR4 receptor are attracted to the dark zone via the CXCL12 ligand, and 
centrocytes expressing low levels of CXCR4 and high levels of CXCR5 are attracted 
to the CXCL13 ligand, which is more concentrated in the light zone (105).  
GC derived B cells and plasma cells undergo affinity maturation in the dark zone 
(SHM), resulting in the production of specific, high affinity antibodies. SHM is driven 
by AID, which is highly expressed in centroblasts. It occurs in rapidly proliferating 
centroblasts via point mutations within the IgV genes, resulting in the production of 
diverse immunoglobulins with varying affinities (106, 107).  
These B cells are then ready for antigen-driven selection and CSR, which takes 
place in the light zone. The benefits of selection for GC B cells with high affinity 
BCRs in the light zone are survival and expansion, with subsequent differentiation 
and exit from the GC or recycling into the dark zone for further SHM (106, 107).  
FDCs and TFH cells are important accessory cells in the GC light zone, which aid in 
the selection process for GC B cells through prolonged antigen presentation. Once 
in the light zone, GC B cells have upregulated MHC class II and increased antigen 
uptake and processing capabilities compared to other subsets en(108). FDCs are a 
major source of CXCL13 in GC light zones and do not express MHC II molecules, 
however are essential in trapping and retaining unprocessed antigen in the form of 
immune complexes through Fc and complement receptors (104). In this way, they 
serve as long-term antigen deposits, therefore are important for selection of high-
? ???
affinity GC B-cell clones, as well as the generation and maintenance of immunologic 
memory (104).  
The amount of antigenic peptide-MHC complex found on the surface of centrocytes 
correlates to the affinity of the surface Ig, BCR signaling and subsequent 
endocytosis of antigen. This impacts the level of TFH help and therefore, selection 
(109). TFH cells are CXCR5 expressing CD4+ T cells, which are crucial for induction 
of GC responses as they provide B cell survival signals via CD40, Il-4, Il-21 and 
BAFF (109). This extracellular survival signaling is particularly influential for the fate 
of GC B cells as they are prone to apoptosis, due to the significant their 
downregulation of the anti-apoptotic molecule Bcl-2 (110). As well as inducing B cell 
survival and differentiation, TFH cell-dependent paracrine activation of B cells also 
results in the induction of AID (109). 
AID is the principal enzyme responsible for CSR in the light zone. Its mechanism 
involves an intrachromosomal deletion recombination event, which includes AID-
mediated DNA breaks in the Switch (S) region, a locus of tandem repeats upstream 
of the CH gene. AID driven DNA lesions in the S region is then followed by end-
joining recombination of the S and CH regions, resulting in altered isotypes from 
IgM, such as IgD, IgG, IgA or IgE (111).  
Finally, it should be noted that selection mechanisms are not only targeted to 
eliminate low affinity B cells via apoptosis, but also to remove autoreactive B cells 
(101). A schematic illustration of a GC is shown below in Figure 6. 
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Figure 6 – The Germinal Centre reaction. A schematic diagram of the germinal 
center reaction. Light zone and dark zone compartmentalisation is highlighted, as 
well as respective sites of mechanisms of affinity maturation, such as somatic 
hypermutation and class switch recombination (107). Selection, CSR and 
differentiation events are also shown in the light zone and are mediated by FDCs 
and TFH cells. Figure adopted from Klein et al., 2008. 
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1.4. THE B CELL COMPARTMENT IN HUMANS AND 
MICE 
?
?????? ???????????????????????????????
 
B cell development is well characterized in the mouse, however antigen markers 
used to define stages in human B cell development differ (112, 113), highlighting 
differences in the B cell compartment between mice and humans (113). Follicular B-
2 cells comprise the major B cell subset in the mouse, which are also found in 
humans. These cells generate immune responses against thymus-dependent 
antigens and require T cell help to experience GC reactions, leading to the 
generation of high affinity antibodies with increased antigen specificity (2, 6). In 
addition to this, ‘B-1 cells’ are a specialized murine subset which has not yet been 
definitively identified in humans (114-116). Furthermore, although marginal zone B-
cells (MZ B-cells) are present in mice and humans, their functions and locations 
differ slightly between the two (117).  
 
B-1 cells are a population of B cells located in the murine peritoneal cavities (118). 
They are the main producers of natural, highly polyspecific (crossreactive) IgM 
antibodies in the mouse, which bind both self and microbial antigens (119-121). 
Despite lacking immunological memory and the ability to undergo affinity maturation, 
B-1 cells are more efficient at presenting antigens than B-2 cells (122). They are 
able to maintain tissue homeostasis through their production of ‘natural IgM 
antibodies’ and possess the ability to bind altered self-antigens, such as those 
expressed by apoptotic cells (123). Unlike follicular B-2 cells which are replaced by 
new cells from the murine bone marrow, B-1 cells are able to self-renew in the 
? ???
periphery (124), and are split into B-1a and B-1b subpopulations according to their 
levels of CD5 expression. Whereas B-1a cells are 
IgMhiIgDloCD45loCD23lo/−CD43+CD5+, B-1b cells express all B-1a cell surface 
markers except CD5 (CD5-) (125). B-1b cells are also regulated separately from B-
1a cells, fulfill distinct immune functions, and appear to develop in line with B-2 cells 
(123).  
 
The marginal zone (MZ) is enriched with macrophages, DCs and MZ B cells (117). 
In rodents, this region develops 3-4 weeks after birth (126, 127). MZ B cells are 
defined as mature, non-circulating B cells, which anatomically localize to the spleen 
(128, 129). In mice, these cells can be clearly defined from follicular B cells and B-1 
cells via their high expression of sIgM, CD21, CD1 and CD9 (128, 130, 131). 
Similarly to B-1 cells, MZ B cells react in a T cell-independent manner to antigens 
such as LPS and self-antigens (132-135). They provide the first line of defense 
against systemic blood-borne antigens which enter the circulation and become 
trapped in the spleen (132, 133). Compared to follicular B-2 cells, MZ B cells have a 
lower threshold for activation and have the ability to differentiate rapidly into antibody 
producing plasma cells (133, 134, 136), thereby contributing to an accelerated 
primary immune response. 
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Although the mouse model provides an insight into B cell development and disease, 
the markers used to define B cell subsets in mice are not always recapitulated in 
humans (See Figure 7). Additionally, conflicting arguments over markers used to 
define specific human B cell subsets still exist.  
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For example, the B1 extrafollicular compartment contributes to one of the two B cell 
compartments in mice (CD19+B220+), but has thus far eluded identification in 
humans. Although a study in 2011 described human B1 subsets with the phenotype 
CD20+CD27+CD43+CD70- in peripheral blood (116), there have been no further 
studies since which corroborate these findings. The existence of human MZ B cells 
also proves to be controversial. Although MZ B cells in humans 
(CD19+IgM+IgD+CD27+) share many similarities with murine MZ B cells   
(B220+CD19+CD21hiCD22hiIgMhiCD9+IgDlo), striking differences also exist (113, 
134). The B cell subsets which contribute to the human B cell compartments are 
discussed in more detail below.?
?
???????? ?????????????????????????
?
Mature naïve B cells predominantly reside in lymphoid follicles of secondary and 
tertiary lymphoid organs, such as spleen and lymph nodes; therefore are known as 
follicular (FO) B cells (137). Just as in rodents, FO B cells in humans make up the 
largest B cell subset, and can be characterized as CD19+IgD+CD38-CD27- B cells 
(138-140). Immune responses are usually propagated in lymphoid organs where 
highly organized follicular lymphoid structures termed ‘germinal centers’ (GC) exist 
(6); identified by the presence of FDCs (follicular dendritic cells), and T cell zones 
which lie adjacent to B cell zones (141). This structure permits activated FO B cells 
to interact with activated T helper cells, thereby resulting in FO B cells mounting 
immune responses to T cell-dependent antigens (137, 141). One study in human 
tonsil identified the presence of a B cell subset with a unique phenotype 
(IgD+CD38−CD23-CD71+) (142). This subset was described as being the founder 
? ???
cell of the GC reaction and appeared to be morphologically distinct, presenting an 
intermediate phenotype between naïve B cells and GC B cells (a pro-GC cell) (142).  
???????? ????????????? ?????????????
 
Once activated by antigen specific T cells, pro-GC B cells enter the GC to become 
centroblasts (IgD−/CD38+/CD77+), which form the GC dark zone. Centroblasts 
proliferate, differentiate, diversify their immunoglobulins and increase their affinity for 
antigen through processes such as SHM (143), where they then migrate to the light 
zone of the GC and differentiate into centrocytes (IgD−/CD38+/CD77−) (142). 
Centrocytes undergo selection by competing for survival signals through Tfh cells in 
the presence of FDCs, during which CSR can occur (6, 141, 144). While most 
CD77hi GC B cells are centroblasts and CD77lo GC B cells are centrocytes, some 
centroblasts and centrocytes both express intermediate levels of CD77. Some 
studies even argue that the CD77− population represents a heterogeneous subset of 
cells, comprising centroblasts, centrocytes, and plasmablasts (145).  
 
???????? ??????????????????????????? ? ??????????????
 
Following the GC reaction, the maturing B cell receives signals to leave the GC as a 
memory cell (CD19+CD20+CD27+CD38-) or plasmablast (CD19+CD20-
CD27hiCD38hiCD138-) (6). Plasmablasts are immature plasma cells, which secrete 
fewer antibodies than mature plasma cells. They proliferate rapidly and circulate in 
the peripheral blood where they are later recruited to bone marrow or mucosa 
niches. Depending on their chemokine receptor expression and stimuli in these 
niches, plasmablasts may receive the necessary survival factors to differentiate into 
antibody producing plasma cells (CD19+CD20-CD38hiCD27hiCD138+), through 
? ???
positive expression of the extracellular matrix (ECM) receptor: syndecan-1 (CD138) 
(85, 146-148). The low plasma cell counts found in healthy human blood (2/μL) 
makes the detailed characterisation of plasma cells difficult, and few studies 
characterizing these cells have been performed in tissues other than secondary 
lymphoid tissues (149, 150). 
 
Memory B cells can be defined by SHM of rearranged immunoglobulin genes and 
fast recall responses to antigens. CD27+ B cell expression is a hallmark for SHM 
and memory, where CD27+ B cells contain a heterogeneous memory population of 
‘pre-switched’ (CD19+IgM+IgD-CD27+) B cells and ‘post-switched’ human MZ B 
cells (otherwise known as natural effector cells) (CD19+IgM+IgD+CD27+) (151-154). 
A study in 2011 described six B cell subsets known to contain genetic hallmarks of 
memory, with findings demonstrating that human memory B cells originate from 
three distinct GC-dependent and independent maturation pathways (154). More 
recently a double negative (CD19+IgD-CD27-) B cell population has been identified 
as an additional memory subset, mainly due to the majority of these cells harboring 
mutated Igs (155-157). These cells contained fewer SHM compared to ‘post-switch’ 
MZ B cells, implying that these cells may be representative of a distinct memory B 
cell lineage (158, 159). 
 
 
 
 
 
? ???
???????? ???????????????????
?
Regulatory B cells (Bregs) act as immunosupressors by preventing expansion of 
pro-inflammatory lymphocytes and pathogenic T cells through IL-10 and TGF-β 
production. The importance of Breg development and their role in suppressing 
chronic inflammation has already been highlighted in mice (14, 160-162), where 
many Breg subsets have been described to date. Such subsets include transitional 2 
marginal-zone precursor cells (T2-MZP), B10 cells (CD5+CD1dhi), MZ B cells, 
CD138+ plasma cells and plasmablasts (72, 73, 163-168).  
 
A range of Breg cells in humans have also been described, despite current findings 
being unable to reconcile the various phenotypes of human Breg cells. Human Bregs 
have most commonly been identified as CD19+CD24hiCD38hiCD1dhi and 
CD19+CD24hiCD27+ B cells (69, 93, 169). Upon in vitro CD40 engagement, 
peripheral CD19+CD24hiCD38hi B cells have been found to produce high levels of 
IL-10, and were the only subset able to suppress Th1 differentiation (93). As well as 
inhibiting Th1 responses and Th17 differentiation, CD19+CD24hiCD38hi Bregs were 
also able to convert CD4+ T cells into Tregs and Tr1 cells. (169) One study found 
that stimulation of B cells isolated from human spleen and blood via CpG-B + anti-Ig, 
led to an increase of IL-10 producing B cells within the memory (CD27+) and 
transitional (CD38hi) B cell populations (92). More recently, TIM-1 and CD9 have 
also been described as unique markers for the identification of human (170), and 
human and murine(171, 172) IL-10+ Breg subpopulations, respectively. Specifically, 
frequencies of TIM-1+ IL-10+ B cells were found to be significantly decreased in 
systemic sclerosis patients compared to healthy controls, and decreased numbers of 
IL-10 producing CD9+ and CD27− B cell subsets were discovered in pemphigus 
? ???
patients. To date, a number of reports describe different Breg subsets present in 
humans and their mechanisms of suppression, summarized in Table 2 below.  
 
Table 2 – Phenotypes of human Breg cells. A list of reports describing human 
Breg cells and their mechanisms of suppression. 
 
???????? ?????????? ??????????
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?????????
??????
??????????? ?????? ?????
 
Interestingly, a study in 2010 described that over 70% of CD19+CD1dhiCD5+ 
human B cells previously reported to be regulatory in murine inflammation models, 
were also contained within the human transitional CD19+CD24hiCD38hi IL-10 
producing B cell subset in SLE patients (93). This population of CD19+CD24hiCD38hi 
B cells isolated from the peripheral blood of patients with SLE lacked the 
suppressive capacity possessed by their counterparts in healthy individuals (93). 
Further studies in MS patients with helminth infections have demonstrated higher 
? ???
frequencies of IL-10-producing CD19+CD1dhi B cells, which play a role in 
suppressing T cell proliferation and IFN-γ production, resulting in a better clinical 
outcome (178). Studying the role of Bregs in SLE patients undergoing rituximab 
therapy (B cell depletion) has generally provided useful insight into Breg 
contributions to the maintenance of tolerance(48, 179). A higher immature to 
memory ratio correlated with long-term remission in rituximab treated patients, 
suggesting that repopulation with immature Bregs may have associations with 
improved disease outcome (48, 179, 180). This is further supported by results in 
another cohort of rituximab-treated SLE patients, where normalization of CD1d 
expression on newly repopulated CD19+CD24hiCD38hi B cells corresponded to 
improved clinical responses, and normalization of the iNKT cell numbers and 
function, which were otherwise impaired in SLE patients (181). Collectively, these 
studies highlight the importance of Bregs in immune regulation and prevention of 
human autoimmune diseases. 
Depletion of B cells via the anti-CD20 monoclonal antibody rituximab has 
widespread use in the treatment of patients with autoimmune disorders such as MS, 
in which B cells were not previously considered to be significant (182). This B cell-
depletion has been proven to boost B cell regulatory functions, including restoration 
of IL-10 production and the Th1/Th2 balance, recruitment of regulatory T cells, and 
TGF-β release leading to apoptosis of effector T cells (183).  
 
Studies have shown that the timing of rituximab administration is important in 
restoring the balance between effector and Breg cells. In animal models, depletion of 
Bregs prior disease induction can aggravate autoimmune responses, and rituximab 
? ???
therapy can exacerbate diseases such as ulcerative colitis and psoriasis (184-186). 
One study demonstrated that in a mouse model of MS (EAE), depletion of B cells 
after antigen stimulation abrogated inflammatory responses to this antigen. 
However, B cell depletion prior to antigen stimulation resulted in an exacerbation of 
the immune response, which is thought to be attributed to the depletion of IL-10 
producing CD1dhiCD5+ regulatory B cells (164). B cell depletion therapy has also 
been associated with increased rejection in transplantation. One clinical study 
administered rituximab as an induction therapy in patients undergoing renal 
transplantation. However the study was suspended shortly after recruitment, owing 
to an increased incidence of acute cellular rejection in the rituximab group (186). 
Similar to the mouse study, it was hypothesized that depletion of immunoregulatory 
B cells may have contributed to this increased rejection in the rituximab-treated 
patient cohort (186) 
???????? ????????????????????
?
Murine B1 cells (CD19hiCD43+CD23-CD1dint) in mice are known to express and 
produce high levels of natural IgM serum antibodies, which bind to a range of 
antigens with low affinity (123, 187). Until recently, a human B1 equivalent had not 
been identified. However in 2011, one study identified human B1 cells as a 
CD20+CD27+CD43+CD70− population of cells, contributing to 5–10% of B cells in 
umbilical cord and adult peripheral blood (116). This population was classified based 
on spontaneous IgM secretion, efficient T cell stimulation, and tonic intracellular 
signaling (116). However, these findings proved controversial, with subsequent 
findings concluding that this B cell phenotype was most likely a pre-plasmablast or 
? ???
memory B cell subset (188-190). Since 2011, there have been no further reports on 
these cells in the literature. 
 
???????? ?????? ??????????????????????????
 
Many differences exist between the murine and human MZ B cell subsets, however 
their main commonality is their ability to mount rapid T cell-independent immune 
responses to blood borne antigens (bacteria & viruses) recruited to splenic follicular 
areas. Unlike the short development time in mice, MZs in humans take up to two 
years to develop, and are generally less well organized in comparison to the mouse 
(2, 126, 129, 191). In mice the MZ population is a heterogeneous population, where 
over 80% of MZ B cells are naïve (B220+CD19+CD21hiCD22hiIgMhiCD9+IgDlo) 
(129, 191). However, in humans, MZ B cells begin as naïve, but rapidly diversify 
through SHM, which is triggered by a poorly understood process (129, 192). As a 
result of these rapid mutations, many human MZ B cells appear to be identical to 
somatically mutated, IgM+ memory cells (CD19+CD27+IgD+IgM+), leading many to 
believe that MZ B cells represent a memory population (129, 191, 192). In fact, some 
studies argue that human CD19+IgM+IgD+CD27+ B cells are not MZ B cells but are 
memory B cells responding to T cell-independent antigens which leave the GC 
reaction prior to switching to other isotypes (193, 194). 
 
Although the spleen is required for MZ B cell generation in mice and men, murine 
MZ B cells solely localize to the spleen, whereas human IgM+CD27+ B cells freely 
recirculate (137, 195) and localize to various other anatomical sites (129, 154). It is 
? ???
unlikely however, that these differences between murine and human B cells affect 
the functional ability of MZ B cells to respond to blood-borne pathogens (129).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
?
?
?
?
?
?
?
? ???
1.5. THE LIVER ARCHITECTURE, FUNCTION AND 
MICROENVIRONMENT 
?????? ?????????????????????????
?
?
Weighing between 1.2–1.5 kilograms, the liver is the largest organ in the human 
body (196). It extends across the abdominal cavity and is situated next to the 
stomach, just inferior to the diaphragm (196). The liver consists of two main lobes: 
the left and right lobes, and two smaller lobes: the caudate and quadrate lobes, 
which can be viewed from the visceral surface (197). The right lobe is the larger of 
the two main lobes, and is separated by the falciform ligament anteriorly and the 
ligamentum teres inferiorly (196). Both ligaments provide a structural support by 
assisting in the suspension of the liver together with the walls of the abdomen (196). 
The liver receives a dual blood supply, receiving 80% of its nutrient-rich blood from 
the gut through the portal vein and the remaining 20% of oxygen rich blood from the 
heart via the hepatic artery (198) (See Figure 8A). These blood supplies mix on 
entry to the liver before travelling through a complex system of branched sinusoidal 
vessels (198),  where the blood then gathers at the central vein, and travels through 
the hepatic vein to the inferior vena cava to be re-oxygenated (196) (See Figure 
8B). The blood supply network further segments the liver into eight portions, each 
with its individual arterial blood supply and bile drainage system (198, 199). This 
separation of the liver permits parts of the liver to be removed with ease during 
instances such as liver resection surgery (199, 200). 
 
 
? ???
 
 
 
 
Figure 8 – The blood supply of the liver. Image adapted from adapted from 
Schwartz's Principles of Surgery, 9th edition, 2009 (201). A. Diagram to demonstrate 
the internal anatomy of the liver including the dual blood supply from the hepatic vein 
and the aorta. B. Histological anatomy of the liver lobule and portal triad (202).  
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?
The liver has over 500 different functions and contains the biggest reticulo-
endothelial cell network (203). Some of its functions include glycogen storage, 
detoxification, hormone production, digestion and metabolism (204). As well as 
metabolic functions, the liver also performs unique immunological roles, and is 
involved in maintaining peripheral tolerance as well as protecting against harmful 
pathogens (203, 205). Furthermore, over 1.5 liters of blood passes through the liver 
every minute, making it an important organ in immune cell transit (206).  
???????? ??????????
?
Bile is a substance which consists of water, bile salts, cholesterol and bilirubin (207, 
208). It is produced by hepatocytes in the liver to actively assist in the role of 
digestion, and travels through bile ducts before being stored in the gallbladder (205, 
207, 208).  As fat containing foods reach the duodenum, cells release a chemical 
hormone known as cholecystokinin, which stimulates the gallbladder to release bile 
through the bile ducts and into the duodenum (205). It is there that fats are 
emulsified which aids digestion (204, 207).  
???????? ? ??????????
?
As well as producing bile, hepatocytes of the liver are responsible for metabolizing 
carbohydrates, lipids, and proteins into biologically useful materials (204, 205, 208). 
Blood entering the liver through the hepatic portal vein is enriched in glucose from 
digested food (204). Hepatocytes metabolise carbohydrates into glucose, which can 
then be absorbed and stored as energy in the form of glycogen (204, 208, 209). The 
absorption and release of glucose by the hepatocytes helps to maintain homeostasis 
of blood glucose levels (210).  
? ???
Lipid metabolism involves the breakdown of fatty acids by hepatocytes to generate 
ATP, which is important for the contraction and relaxation of muscles (208). Glycerol, 
another lipid component, is converted into glucose by hepatocytes through the 
process of gluconeogenesis (209, 210). Hepatocytes can also produce lipids such as 
cholesterol, phospholipids, and lipoproteins that are used by other cells throughout 
the body (208, 211).  
 
The degradation of proteins and amino acids is another important metabolic process 
in the liver. Amino acids require metabolic processing before they can be used as an 
energy source in the form of ATP, carbohydrates or fats (209). Furthermore, amino 
acid metabolism can lead to the formation of enzymes required in urea production 
from nitrogen (208).  
 
???????? ????????????????
?
Hepatocytes are constantly monitoring the blood contents, which enter the liver from 
the gut through the hepatic portal circulation. They remove many toxic substances, 
which would otherwise pass into the rest of the body, causing damage (204, 208, 
212). Toxic substances such as alcohol and drugs such as paracetamol are 
metabolized by the liver into harmless, inactive metabolites, which can then be 
transformed into bile (204, 205, 208, 212).  
 
 
 
?
? ???
???????? ??????????
?
The liver stores several essential nutrients, vitamins, and minerals obtained from 
blood passing through the hepatic portal system (204, 208). Glucose is transported 
into hepatocytes under the influence of the hormone insulin and stored as the 
polysaccharide glycogen (208). Hepatocytes also absorb and store fatty acids from 
digested triglycerides (208). Vitamins A, D, E, K, and B12, and the minerals iron and 
copper – are also continuously stored by the liver (208), thereby providing a constant 
supply of these essential substances to the tissues of the body. The storage of these 
nutrients allows the liver to maintain the homeostasis of blood glucose (208). The 
liver is also responsible for the production of several vital protein components of 
blood plasma: prothrombin, fibrinogen, and albumins (208), which are important in 
blood clot formation and maintenance of the blood isotonic environment. 
 
?????? ?????????? ????????????????
?
Despite the human liver harboring a variety of cells, 60% of cells in the liver are 
parenchymal cells called hepatocytes, which account for 80% of the liver mass (205, 
213). Hepatocytes are large, polarized, polygonal epithelial cells, which are involved 
in many of the liver functions (refer to 1.5.2.). They form plates which are one cell 
thick, and their membranes are linked by tight junction proteins, allowing contact to 
be made with neighboring hepatocytes and other non-parenchymal cells (214). The 
hepatocyte apical surfaces form cannicular structures, allowing the secretion of bile 
which travels through the canaliculi and merges with the bile ducts (215). On the 
basolateral hepatocyte surfaces, the venous blood receives other secretions such as 
serum factors (216-218). 
? ???
The remaining 20% of liver cells are made up from non-parenchymal cells which 
include hepatic stellate cells (HSC), biliary epithelial cells (BEC) and hepatic 
sinusoidal endothelial cells (HSEC) (See Table 3 for parenchymal and non-
parenchymal cell functions) (213). Non-parenchymal cells also include immune cells 
such as Kupffer cells, NKT cells, PiT cells and hepatic DCs (213). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
? ???
Table 3 – The cellular composition of the liver. The roles and definitions of parenchymal and 
non-parenchymal cells located in the liver (213, 219-226). 
 Type of cell Function / definition 
Parenchymal cells Hepatocytes Involved in detoxification of 
drugs, protein synthesis and 
 storage, carbohydrate and 
fat metabolism 
 
Non-parenchymal cells Hepatic sinusoidal 
endothelial cells   
(HSEC) 
Removal of smaller particles 
from the circulation 
Biliary Epithelial Cells   
(BEC) 
Also known as 
cholangiocytes. Contributes 
to bile production, dilutes 
and neutralizes bile, and 
transports it to the gall 
bladder and duodenum. 
Hepatic Stellate Cells   
(HSC) 
Stores Vitamin A 
Kupffer cells 
(Liver specific 
macrophages) 
Intravascular tissue 
macrophages involved in 
the removal of large 
particles from the circulation 
NKT cells  
(Natural killer T cells) 
Involved in anti-tumour and 
anti-viral roles 
Hepatic Dendritic Cells Involved in phagocytosis 
and cytokine release in 
response to Toll-like 
receptor (TLR) stimulation 
PiT-cells  
(Liver-specific  
NK cells) 
NK cells located under 
fibroblasts and endothelial 
cells 
Activated human 
myofibroblast (aLMF) 
cells 
Only present in the injured 
liver. Transform from HSCs 
and are involved in 
angiogenesis and liver 
regeneration, however is 
also the cause for fibrosis. 
? ???
Hepatic B cells Not much known. Contained 
in lymphoid structures which 
are enriched in diseases 
such as HCV and PBC. 
Produces autoantibodies in 
PBC.  
Hepatic T cells CD8+ T cells outnumber 
CD4+ T cells. 
Effector/memory T cells are 
greater in liver than blood. T 
cells demonstrate a bias 
towards tolerance. Local 
presentation of antigen 
causes T cell inactivation, 
tolerance and apoptosis. 
 
Sinusoids are vascular channels which provide hepatocytes with blood and are 
located between hepatocyte plates (226). The sinusoidal walls are lined with an 
endothelial cell known as HSEC (215), which acts as a molecular sieve due to the 
presence of fenestrations and lack of a basement membrane. This permits nutrients 
and other factors to pass through and into the sub-endothelial space known as the 
Space of Disse (215), which contains various ECM components such as collagen, 
fibronectin (215, 227, 228) and stromal cells including HSC, which are in constant 
contact with hepatocytes (229, 230). As well as being involved in vitamin A storage 
(213, 231, 232), HSCs also respond to liver injury by transforming into a liver 
myofibroblast cell (aLMF cell) (232). aLMFs are responsible for collagen deposition 
which can lead to fibrosis (233). BEC make up 5% of total liver cells and are located 
in the biliary tract (226). They are often the first point of contact for pathogens, which 
enter the liver through the bile ducts, therefore respond to various pathogens 
through the production of cytokines (226, 234). The structure of the liver architecture 
as described is demonstrated below in Figure 9. 
? ???
 
 
Figure 9 – The architecture of the liver. Positioning and architecture of 
parenchymal and non-parenchymal cells present in the liver as well as the Space of 
Disse, otherwise known as the perisinusoidal space. Non-parenchymal cells 
demonstrated include HSEC, HSC, Kupffer cells and BEC (surrounding bile duct – 
not labeled). Adapted from Gordillo et al., 2015 (226, 235-237). 
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The blood from the gastrointestinal tract is rich in nutrients, harmless food antigens 
and pathogens that have breached the intestinal barrier (238). This blood passes 
through the liver via the portal vein, allowing hepatocytes to metabolize specific 
substances, whilst also exposing them to microbial antigens (239). Furthermore, the 
liver is exposed to cytokine-rich blood from the spleen and metabolite-rich blood 
from the systemic artery, and is the site of acute phase protein production, which 
also contributes to the liver immune function (239). These factors put constant 
pressure on the liver to induce tolerance to food antigens (240, 241). Although 
specialised immune cells, such as Kupffer and HSEC exist in the liver, other immune 
cells such as lymphocytes and NK cells also exist (240, 241).  
?????????? ??????????????????????????????????????????????
?
The fenestrated HSEC permits blood, Kupffer cells, DC’s and lymphocytes to pass 
from the sinusoids into the space of Disse, where they make contact with 
hepatocytes (240, 242). Furthermore, HSECs are important APCs, which have the 
ability to engulf antigens through mannose and scavenger receptors, and present 
exogenous antigen on MHC class I and II molecules with a similar proficiency to DCs 
(243, 244). The presented antigens then interact with naïve and CD8+ and CD4+ T 
cells migrating into the liver (245-247). In this way, it has been found that antigen 
presentation via HSECs leads to T cell tolerance (246, 248-250). 
 
 
?
? ???
?????????? ??????????????? ???????????
?
Kupffer cells are liver-resident macrophages located in the hepatic sinusoids, which 
phagocytose pathogens and foreign particles entering the liver. They represent 80-
90% of total macrophages in the body, and play a role in tolerance and immunity 
through T cell activation (251). Furthermore, Kupffer cells are also able to detect and 
bind bacterial pathogens via scavenger receptors, TLRs, complement and antibody 
receptors (252). This triggers Kupffer cell activation and drives cytokine and 
chemokine production, alerting other components of the immune system to the 
presence of harmful pathogens (253). 
?????????? ??????????????????????
?
Although numerous populations of DCs exist in the liver, liver derived DCs have a 
reduced capacity to drive T cell activation than DCs from other tissues (254, 255). 
This is in part due to their contact with HSECs and hepatocytes, as well as the 
presence of high IL-10 levels and low IL-12 levels in the liver (256, 257). Despite the 
function of liver-resident DCs under basal conditions, the efficiency of liver DCs to 
present antigens and to induce strong, antigen-specific activation of T cells can be 
inhibited by IL-10 or activation via TLRs (256, 258, 259). One study demonstrated 
that freshly isolated murine liver DC were refractory to the exogenous TLR-4 ligand, 
bacterial LPS. This led to impaired TLR9 signaling via CpG, reduced IL-12 and IFNγ 
production, and consequently, compromised T cell responses. The study went on to 
prove that this deficiency was associated with enhanced expression of negative 
regulators of TLR signaling (DAP12 and IRAK-M), and with inhibitory IL-6/STAT3 
activity by liver DCs (260). Similar experiments can be designed using B cells, to 
investigate whether hepatic B cells have reduced APC capacity and impaired 
? ???
cytokine production following TLR ligation.  
?????????? ????????? ???????????
?
PiT cells are known to be liver-specific NK cells (245, 249, 261, 262), which adhere 
to Kupffer cells and endothelial cells (263, 264). They contain large granules 
containing perforin and granzymes which aid in NK-mediated cytotoxicity against 
tumour cells (262). Furthermore, they release IFN-γ, which triggers hepatocytes, and 
HSECs to secrete CXCL9, consequently promoting T cell recruitment and immunity 
(261, 265). 
?
NKT cells are enriched in the liver and express a TCR which recognizes lipid antigen 
presented by the MHCI-like molecule CD1d (266). They represent a potent 
immunomodulatory lymphocyte population, which is able to actively patrol the liver 
vasculature in search of pathogens. When activated through pathogen interactions 
or cytokines, NKT cells either release anti-inflammatory cytokines causing immune 
suppression (267), or synthesise large amounts of IL-4 causing B cell activation and 
antibody release (268, 269). 
?????????? ?????????? ?????????
?
The liver contains both resident and transiting lymphocytes, which differ from those 
in tissues. An enrichment of CD8+ T cells exists in the liver as well as one of the 
largest γδ T cell populations (270, 271). Both hepatic CD4+ and CD8+ T cell 
populations are activated, where CD4+ T cells produce high levels of IL-4 and IFN-γ 
(5, 245, 272), although conflicting findings state that T cell responses are dampened 
in the liver (273, 274). Recent findings have also elucidated the distinct phenotypic 
and functional profile of MAIT cells, which are an abundant and distinctive T cell 
? ???
subset found enriched in both the gut and in the liver (275, 276). In humans, MAIT 
cells represent between ∼12% and 50% of T cells (277). This population expresses 
a specific TCR, has a unique ‘innate’ phenotype driven by the transcription factors 
RORγt and PLZF, and performs a broad range of effector functions (278, 279). 
Although previously associated with mucosal defenses and anti-bacterial functions, 
recent studies have established MAIT cells are also specifically activated by 
pathogenic viruses such as HCV in vivo and in vitro; driving cytokine release, 
Granzyme B upregulation, and a reduction of IFN-γ-mediated HCV replication in vitro 
(276).  
 
5?10% of lymphocytes in the liver are B cells, the majority of which express CD5 (5). 
However, further phenotyping and functional characterisation of human liver-resident 
B cells have been less widely illustrated (280). In mice, over 50% of intrahepatic 
lymphocytes are B cells, making the murine liver ideal for the study of hepatic B cells 
(5, 281, 282). Murine B cells have been found to display BCR-independent 
complement-mediated phagocytic activity, with bactericidal properties similar to 
Kupffer cells (282, 283). Additional studies have highlighted differences between 
hepatic B cells in response to LPS compared to lymphoid and splenic B cells. 
Results concluded that hepatic B cells produced significantly higher levels of pro-
inflammatory cytokines (IFN-γ, and TNF-α), and significantly lower levels of anti-
inflammatory cytokines (IL-10) in comparison to splenic B cells (283, 284). 
Furthermore, liver resident B cells demonstrated their ability to activate hepatic 
myeloid DCs to produce pro-inflammatory cytokines IL-6, 1L-12 and IFN-γ, 
compared to splenic B cells which inhibited their activation (284). Other data 
indicated that hepatic Bregs activated by TLR4 ligation secrete reduced IL-10 
? ???
compared with lymphoid tissue B cells, indicating a reduced regulatory capacity of 
Bregs in the liver (284). These studies implied that hepatic B cells may have initiated 
inflammatory processes in the liver and that liver resident B cells may have had a 
different role to B cells found in other tissues.  
 
The majority of studies with regard to intrahepatic B cells are in reference to murine 
studies. Although a few studies exist on B cells in the peripheral blood of liver 
disease patients, very few studies have been conducted in reference to B cells in the 
human liver. Table 4 below lists the main recent findings from investigations into 
human intrahepatic B cells (285). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
?
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Table 4 – Studies on visualizing or quantifying human intrahepatic B cells. A list of studies, 
findings, and conclusions on human liver B cells. 
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Despite the liver receiving cytokine-rich blood from the spleen, constitutive hepatic 
cytokine production is absent or low (284, 299). Hepatocytes harbor an array of 
cytokine and growth factor receptors, therefore making the liver highly susceptible to 
cytokine activity (300, 301). Cytokines are not only involved in the metabolism of 
amino acids, proteins, lipids and carbohydrates (301-304), but also play a role in 
liver regeneration (304). Increased pro-inflammatory cytokine production results in 
hepatic inflammation, cholestasis, fibrosis and ultimately liver failure (304). The 
various roles of cytokines in liver diseases can be viewed in Table 5. 
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Table 5 – Cytokines in liver disease. Table demonstrating cytokines and their effect / role in the 
liver. Adapted from (299, 301). 
Function / Effect in the liver Cytokines 
Cytokines involved in immune responses IL-2, IL-4, IL-7, IL-9, IL-12, IL-15, IL-
17 
Th1 cytokines   (IL-2, IFN-γ) 
Th2 cytokines   (IL-4, IL-5, IL-10) 
Pro-inflammatory cytokines IL-1α, IL-1β, TNF-α  
IL-6 type cytokines (IL-6, IL-11, LIF, 
OSM, CNTF, CT) 
IFN-γ 
IL-12 
IL-18 
Anti-inflammatory cytokines IL-1Ra 
Soluble IL-1 receptor type II 
Soluble TNFR p55/p75 
IL-10 
IL-4, IL-13 
Cytokines and acute liver failure Fas, Fas ligand 
TNF and TNFR p55/p75 
IFN-γ 
IL-18 
Fibrogenic cytokines TGF-β 
PDGF 
FGF 
Anti-fibrogenic cytokines IFN-α 
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Although lymphocytes are able to modify liver immune responses, non-immune cells 
such as stellate cells, BEC, HSEC also produce and respond to hepatic cytokines 
(299); contributing to local immunological potential. Infectious and non-infectious 
agents trigger cytokine production, and collectively the roles of the lymphocytes and 
liver cells determine the outcome of immunological stimulation in the liver (299, 301, 
304). 
Inflammatory cytokines such as IL-6, IFN-γ and TNF-α are produced by Kupffer cells 
and have been known to cause hepatocyte damage and acute liver damage leading 
to chronic liver disease (251, 299, 301). TNF-α in particular has been identified as a 
central mediator for apoptosis and necrotic damage in acute liver failure models, 
where infiltration of neutrophils and T cells also exists (299, 305). Furthermore, 
studies have proved that TNF-α levels are elevated in fatty liver disease, alcohol-
induced liver injury, hepatitis and autoimmune liver diseases (306-309). Despite 
being associated with liver injury, TNF-α has also proven to be essential in hepatic 
regeneration, where liver regeneration is impaired when TNF-α is blocked following 
chemical liver injury (301, 310-314). 
IL-6 is also an inflammatory cytokine which is also produced by macrophages, 
endothelial cells and T cells (251). In Kupffer cells, IL-6 production triggers the 
release of acute-phase proteins via the IL-6R on hepatocytes (299, 315), which 
emphasizes this cytokine’s ability to control local and systemic inflammatory 
reactions. IL-6 levels are also elevated in liver cirrhosis and non-alcoholic fatty liver 
disease, highlighting its negative impact on the liver (303, 309). Contrary to its 
damaging associations, IL-6 has also been found to have some beneficial roles in 
the liver. As well as inducing cell growth and T cell differentiation, IL-6 has an 
? ???
important role in liver regeneration and in preventing liver damage (316-318). It is 
also important in inducing B cell terminal differentiation and supporting B cell 
production of IgG (319). IL-6 secreting B cells also propagate B cell-driven 
pathogenesis of T cell-driven autoimmune diseases such as Experimental 
autoimmune encephalomyelitis (EAE) and multiple sclerosis (320). Collectively, 
these studies stress the relevance of pro-inflammatory cytokines in liver damage, 
control of liver inflammatory reactions and in liver regeneration. 
Important immunosuppressive and anti-inflammatory cytokines in the liver include 
TGF-β and IL-10 (301). Whilst activated Kupffer cells in the liver are a major source 
of inflammatory cytokines, they have also been found to secrete IL-10 and TGF-β in 
the non-inflamed liver (321) (322, 323). The importance of immunosuppressive 
cytokines in hepatic disease was highlighted in a study, which demonstrated that IL-
10 used to treat patients with chronic hepatitis C resulted in reduced hepatic fibrosis 
(324). Additional findings demonstrated that IL-10 knockout mice treated with CCL4 
to induce fibrosis, demonstrated significantly higher levels of fibrosis and hepatic 
TNF-α levels compared with wild-type controls (325). Other growth factors such as 
hepatocyte growth factor (HGF) have also been linked with the attenuation of liver 
fibrosis and increased hepatic regeneration (299, 301, 326). 
Not all anti-inflammatory cytokines are anti-fibrotic in the liver. TGF-β1 is the most 
common isoform found in the liver and is secreted by immune cells such as Kupffer 
cells, hepatic stellate cells and epithelial cells. As a paracrine and autocrine key 
mediator of increased deposition of ECM proteins, it is unsurprising that previous 
studies showed that the expression of TGF-β1 is upregulated in experimental 
models of CCL4 induced hepatic fibrosis (309, 327) (328).  
? ???
Growth factors such as B cell activating factor (BAFF) are also abundant in the liver. 
BAFF is a member of the tumor necrosis factor (TNF) superfamily and contributes to 
the survival and maturation of B cells (329, 330). It is a growth factor produced by 
macrophages, neutrophils, DCs, and T cells patients (330, 331). Its presence in the 
liver is significant, as studies show that BAFF levels are increased in the blood of 
liver disease patients, and that BAFF contributes to liver injury and disease 
development in patients suffering from autoimmune hepatic diseases (331-333) 
(332). 
 
 
 
 
 
 
 
 
 
 
 
? ???
1.6. CHRONIC LIVER DISEASES 
?
?
A broad range of immune mediated and non-immune mediated end-stage liver 
disease explants were used in this study to investigate the role of B cells in end-
stage chronic hepatic disease. Although hallmarks of all chronic liver diseases 
similarly progress from inflammation to fibrosis and cirrhosis, each disease is 
triggered by various contributing factors. For this reason the liver disease explants 
used can be categorised into three broad categories including: viral, autoimmune 
and environmental (dietary injury). 
?
?????? ????????????????
???????? ?????????????????????????????????????
?
Non-Alcoholic Fatty Liver Disease (NAFLD) encompasses a spectrum of diseases 
including hepatocellular steatosis, Non-Alcoholic Steatohepatitis (NASH), fibrosis 
and irreversible cirrhosis. NAFLD is caused by fat deposition and obesity, which 
leads to cytokine accumulation and oxidative stress in the liver (334) (309), resulting 
in liver cell injury and inflammation. NAFLD progresses to the chronic disease 
NASH, which resembles ALD, but occurs with little or no alcohol consumption (335). 
NASH is usually a silent disease with few or no symptoms, however progression of 
the diseases can result in cirrhosis, liver failure and hepatocellular carcinoma (HCC), 
which can lead to the manifestation of symptoms such as fatigue, weight loss, and 
weakness (334, 335). Although a relatively common disease, NASH is not 
definitively diagnosed from ‘fatty liver’ until a liver biopsy is taken to show fat 
accumulation along with inflammation and damage to liver cells. 
 
? ???
Innate immune cells, consisting of Kupffer cells, neutrophils, DCs and NK cells, have 
all been shown to play a role in the pathogenesis of NASH (336). Kupffer cells are 
activated by both pathogen-associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPs) leading to secretion of pro-inflammatory 
cytokines, such as TNF-α, IL-6, and IL-1β (251). This results in T cell activation and 
induction of apoptosis and HSCs. Furthermore DCs and NKT cells also appear to 
play an important protective role in NASH, as recent reports have shown that DC 
and NKT cell depletion results in worsening of NASH severity (337, 338). 
?
???????? ??????????????????????????????
?
Alcoholic Liver Disease (ALD) is a major cause of liver disease in Western countries. 
Caused by alcohol overconsumption, it encompasses fatty liver disease, alcoholic 
hepatitis, HCC and chronic hepatitis with liver fibrosis or cirrhosis.? ALD is 
characterized by inflammation, hepatocellular destruction and fat accumulation in 
hepatocytes. Surprisingly, of all chronic heavy drinkers, only 15–20% develop 
hepatitis or cirrhosis, where risk factors include gender, genetic factors, pattern of 
drinking and diet (339). Like NASH patients, in the early stages, patients with ALD 
exhibit subtle and often no abnormal physical findings, unless detected through 
abnormal liver enzyme readings and liver biopsies, which are mostly 
indistinguishable from symptoms of NAFLD (339).  
 
Both innate and adaptive immune responses contribute to ALD. It has been shown 
that chronic alcohol consumption increases gut permeability, allowing bacteria to 
enter the blood stream to the liver (340, 341). These bacteria activate hepatic 
Kupffer cells via TLRs and NOD-like receptors (NLRs), which then secrete the pro-
? ???
inflammatory cytokines IL-6 and TNF-α (340). These cytokines then attract more 
immune cells that contribute to liver injury. Furthermore, in alcoholic hepatitis, 
neutrophils are recruited to the intralobular region of the liver, where inflammatory 
mediators such as IL-8 and IL-17 chemokines, play a pivotal role in neutrophil 
infiltration in ALD (342). Th17 cells have also been identified in peripheral blood of 
alcoholic cirrhosis patients, and have been shown to correlate with disease severity 
(343). Other effects of alcohol on the liver include oxidative stress, lipid peroxidation, 
and acetaldehyde toxicity (344).  
?
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Primary biliary cirrhosis (PBC) is an autoimmune disease, which mainly affects 
women. It characterized by the slow progressive destruction of small bile ducts 
leading to the accumulation of bile and toxins in the liver. This results in liver cell 
damage, inflammation, fibrosis and cirrhosis (345, 346). PBC is usually diagnosed 
through liver enzyme tests, the detection of anti-mitochondrial antibodies (AMAs), 
detection of other autoantibodies (anti-nuclear antibodies (ANAs) and abdominal 
ultrasound (346). Though predominantly asymptomatic, some PBC sufferers 
experience extreme fatigue, itching and jaundice.  
 
The cause of PBC has an immunological basis, where 95% of patients have AMAs 
an against pyruvate dehydrogenase complex (PDC-E2), an enzyme complex found 
in mitochondria (347, 348). A significant proportion of B cells which form 10% of the 
inflammatory infiltrate present within the portal tract, produce antibodies which are 
reactive against PDC epitopes (349). Furthermore, T cells have also been found to 
? ???
play a pivotal role in the autoimmune response in PBC, where studies have shown 
that there is overlap in the PDC-E2-specific T and B cells, where CD4+ and CD8+ T 
cells contribute to a significant proportion of the inflammatory infiltrate within the 
portal tracts of patients with PBC (350, 351) (352).  
???????? ??? ?????????????????????????????????
?
Primary sclerosing cholangitis (PSC) is a chronic liver disease strongly associated 
with inflammatory bowel disease and ulcerative colitis (353), and is more commonly 
found in men. It is characterized by a progressive course of cholestasis (decreased 
bile duct flow) with inflammation and fibrosis of the larger intrahepatic and 
extrahepatic bile ducts, which leads to liver cirrhosis, portal hypertension and HCC 
(353, 354).  
 
The aetiology of PSC is still relatively unknown. Immune responses against self-
antigens in the bile ducts have been proposed to play an important role in the 
pathogenesis, as large numbers of autoantibodies are detected in PSC patients 
(286). Anti-neutrophil cytoplasmic antibodies (ANCA) in particular are a fairly 
consistent feature of PSC occurring in up to 88% of patients (355). However, 
controversy exists as to whether PSC should be termed an autoimmune or merely 
immune-mediated disease, because the specificity of these antibodies is generally 
low, and the frequencies vary largely between different studies (355). Other possible 
contributors to PSC disease pathogenesis are the portal tract infiltrate of functional T 
cells, a restricted T cell receptor repertoire, and aberrant expression of HLA 
molecules on BEC (356, 357). These may assist in the initiation of the immune 
response by admission of bacteria into the portal circulation through the diseased 
? ???
and permeable bowel wall. Furthermore, blood levels of TNF-α, IL-10, and IL-8 (a 
neutrophil activation marker) were found to be significantly higher in PSC compared 
to patients with alcoholic cirrhosis or normal controls. However, this did not correlate 
with ANCA titers (351). 
?
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Hepatitis B and C virus infections (HBV and HCV respectively) can be 
asymptomatic. However, chronic infection can cause hepatocyte destruction, 
inflammation, fibrosis and cirrhosis, leading to liver failure and HCC disorders (358, 
359). HCV in particular has also been linked with diabetes, autoimmune thyroiditis 
and B cell lymphoproliferative disorders (360, 361).  
 
HCV is characterised by lymphocytic infiltrates which aggregate to form tertiary 
structures and GCs (362). Successful clearance of HCV infection involves activation 
of NK cells, processing of viral antigens by dendritic and Kupffer cells and 
consequent activation of CD4+ and cytotoxic CD8+ T cells through IFN-γ production. 
Cytotoxic T cells then cause direct lysis of infected cells and inhibit viral replication 
through cytokine production (363). An inefficient immune system, and in particular 
failure of NK cells, dendritic cells, and CD4+ cells, can lead to ineffective cytokine 
responses leading to failure in in eliminating HCV. In some cases, although humoral 
and cellular immune responses are induced, persistent infection is generally 
associated with weak CD4+ and CD8+ T cell responses (364, 365).  
 
In HBV, it is the adaptive immune response, which is thought to be responsible for 
viral clearance and disease pathogenesis (366). During successful clearance of viral 
? ???
infection, the antibody response clears circulating virus particles and prevents viral 
spread within the host, whilst the vigorous T cell responses eliminate infected cells. 
The T cell responses to HBV are vigorous in acutely infected patients who 
successfully clear the virus and weak in chronically infected patients, suggesting that 
clearance of HBV is T cell dependent (366)  
?
?????? ????????????
?
It is necessary to study the ‘normal’ B cell subset composition of a healthy donor 
liver, however ‘normal’ liver tissue is difficult to obtain. During this study, donor livers 
rejected for transplants due to being steatotic and resection margins from HCC 
livers, under chemotherapy, were used to approximate ‘healthy tissues.’ These 
models are not representative of the normal immunological liver environment, which 
will be taken into consideration during analysis of the results. 
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1.7. CO-CULTURE MODELS TO STUDY THE EFFECTS OF 
LIVER CELLS ON B CELL BIOLOGY 
?
?
I was interested in identifying how B cells interact with the liver microenvironment. To 
address this question, B cells were co-cultured with liver cell lines which will be 
described further in the method section (Chapter 2).  
?????? ??????????
?
LX2 cells are a human HSC line, originally developed to help elucidate pathways of 
human hepatic fibrosis (367). Following activation into fibrogenic myofibroblast-like 
cells, HSCs contribute to collagen accumulation during chronic liver disease (368, 
369). To overcome issues of species specificity and culture variability, and to provide 
a stable and unlimited source of human HSCs that are homogenous, two 
immortalized HSC cell lines were developed (367). SV40 T antigen immortalization 
and spontaneous immortalisation in low serum conditions were used to produce LX-
1 and LX-2 cell lines respectively. These cell lines have been extensively 
characterised and retain key features of cytokine signaling, neuronal gene 
expression, retinoid metabolism, and fibrogenesis, making them highly suitable for 
culture based studies of human hepatic fibrosis. LX2s in particular, have high 
transfectability and ability to withstand serum free conditions. As a well-characterized 
cell line, the LX2 hepatic stellate cell line was used in co-cultures with B cells to 
mimic interactions with stellate cells (367). 
 
 
? ???
????? ????????????
?
Hepatic portal fibroblasts are responsible for generating collagen, 
glycosaminoglycans, elastic fibers and glycoproteins (370). This accumulation of 
ECM causes liver fibrosis, which is present in the majority of chronic liver diseases 
(371). Fibrosis can result in cirrhosis, liver failure, and portal hypertension which 
often requires liver transplantation (372). It is well established that fibroblasts are 
derived from activated stellate cells (371). Unlike epithelial cells, fibroblasts do not 
form a flat monolayer and lack a basal lamina (370). Lymphocytes including B cells 
are most frequently found lining the fibrotic septa during liver inflammation (373). 
Little is known about the contribution of this interaction to B cell biology, yet a role for 
B cells in liver fibrogenesis has been postulated, where one study showed that in B 
cell–deficient, CCl4-treated mice, there was deceased liver fibrosis and collagen 
deposition in comparison with CCl4-treated WT BALB/c mice. Mice with normal B cell 
numbers that lacked Ig or contained low Ig in their serum were found to develop a 
similar degree of CCl4-induced liver fibrosis when compared with wild type mice 
(282, 374). This led to the hypothesis that in the absence of B cells the ability of 
macrophages to clear expiring hepatocytes was enhanced, and that B cells 
contributed to fibrosis in an antibody and T cell-independent manner (282, 374). In 
mice with experimentally induced liver fibrosis, lymphocytes were only found in the 
proximity of activated HSC/aLMF, suggesting that there is a direct interaction 
between liver myofibroblasts and infiltrating lymphocytes (373). Furthermore, 
previous studies have found that transient interactions between integrins (such as 
fibronectin, β1, α4 and α5 integrins) and the ECM matrix may favor B cell migration 
along collagen (375). This suggests that B cells may stimulate fibroblasts by directly 
interacting at sites of liver damage to facilitate the matricellular changes associated 
? ???
with fibrosis and chronic inflammation, or by forming contact-dependent interactions 
with other cells that favor a profibrotic microenvironment (373). It is also possible that 
B cells produce the profibrotic cytokine IL-6, which may contribute to liver fibrosis by 
inducing the differentiation of HSCs into myofibroblasts, inducing fibroblast 
proliferation, and increasing collagen and tissue inhibitor of metalloproteinase (TIMP) 
synthesis (374).  
?
?
?????? ???????????????????????????????
?
BEC, or cholangiocytes, line a complex network of conduits, which make up the 
biliary tree in the liver (226). Although BEC only comprise 3–5% of cells within the 
liver, they are essential for the formation of bile ducts in the liver and assist with the 
transport of bile into the duodenum (226, 376, 377). The function of BEC varies 
across the biliary tree. For example, when bile passes through large BEC lined 
channels, the bile is alkalinized and diluted via BEC’s secretory and absorptive 
processes (226, 376, 377). However, BEC lining small bile ducts also possess 
proliferative capabilities, plasticity and a ‘reparative’ phenotype in certain disease 
conditions (226). Furthermore, these cells are targeted by autoantibodies in 
autoimmune conditions such as PBC (345) and are also damaged in PSC (378, 
379), therefore their potential interactions with B cells and/or plasma cells may be of 
clinical importance.  
?
?
?
?
? ???
?????? ??????????????????????????????????????????????
?
HSECs are one of the first cell populations in the liver to become exposed to blood 
components therefore have an important role in receptor-mediated clearance of 
endotoxins and bacteria. The most defining feature of HSEC are the presence of 
multiple fenestrae throughout the cell, which acts as a mechanical sieve, facilitating 
the transfer of nutrients and molecules from the sinusoidal space to the hepatic 
parenchyma, and restricting the access of blood bound compounds to the 
parenchyma (380). Although HSEC have been shown to rarely express cell 
adhesion molecules such as selectins, other adhesion proteins such as vascular 
adhesion protein (VAP-1), ICAM-1, VCAM-1, and CLEVER-1, aid B cell 
transmigration through HSEC layers, and are responsible for capturing leukocytes 
and recruiting them to areas of inflammation (380-382). While P-selectin has been 
found to be weakly expressed in portal endothelial cells (383), there are no reports of 
P-selectin being expressed on HSEC specifically. Some B cells are found in the 
sinusoids, although consequences of the potential interaction between B cells and 
HSEC have not yet been identified.  
 
 
 
 
 
 
 
 
?
? ???
1.8. PROJECT AIMS 
?
The precise composition of the B cell compartment in the human liver remains 
uncharted. I hypothesize that as a tolerogenic organ, the human liver harbors a 
range of defined B cell subsets, and that distinct disease mechanisms across liver 
diseases imprint unique B cell signatures reflecting relevant populations in the liver. 
 
I aimed to define the role of B cells in the human liver and hepatic inflammation. This 
would indicate the role of B cells in hepatic disease progression, providing a possible 
therapeutic target for the treatment or prevention of chronic liver disease.  
 
Firstly I wanted to develop a flow cytometry panel that would aid in the identification 
of B cell subsets in the human liver, and use immunohistochemistry (IHC) to localize 
B cells in liver tissues. By phenotypically characterizing B cell subsets in the liver, I 
will be able to determine whether subsets with specific functions are enriched in 
certain end-stage liver diseases, thereby assisting in thoroughly elucidating the role 
of B cells in hepatic disease. Identifying the location of B cells across liver diseases 
may indicate where and how B cells may contribute to liver damage and hepatic 
disease progression.  
 
Secondly, I wanted to compare B cell subsets in human blood and liver, as strong 
differences between liver and blood may further highlight the functional role of 
hepatic B cells, and indicate whether previously undefined B cell subsets are 
enriched in the liver compared to blood.  
 
? ???
Finally, I wanted to compare B cell populations in patients across various immune 
and non-immune-mediated liver disorders, as enrichment of specific B cell subsets in 
certain hepatic diseases may be indicative of a role of B cells in liver disease 
progression or prevention.  
 
 
 
 
 
 
 
 
 
 
 
 
 
? ???
 
 
 
 
 
 
 
 
???????????? ????????????? ???????
 
 
 
 
 
 
 
 
? ???
2.1. LIVER TISSUE SAMPLES 
?
Liver tissue explants were obtained from patients suffering from end stage hepatic 
disease, at the Queen Elizabeth Hospital, Birmingham. These samples were used 
following patient consent and were in approval with the local research ethics 
committee guidelines. The liver explants received were taken from patients with 
chronic end stage liver disease who were undergoing transplantation due to 
suffering from various etiologies such as PBC, PSC, ALD and NASH. Furthermore, 
liver tissue was also received in the form of donor livers from patients who had 
passed away, but were unsuitable for transplantation due to liver size or being too 
steatotic. These livers formed part of the ‘donor’ cohort. All tissues were processed 
promptly after collection to ensure that a high yield of viable liver infiltrating 
mononuclear cells were obtained (LIMCS), as well as HSEC and BEC which were 
isolated by Gill Muirhead and used in my co-culture experiments. 
 
 
 
 
 
 
 
 
 
?
? ???
2.2. MULTI-COLOUR FLOW CYTOMETRY 
?????? ??????????????????????????????????????????????
?
Flow cytometry provides both quantitative and qualitative data, analyzing various 
characteristics of single cells passing through a laser light beam. This procedure 
allows cells to be stained with fluorochromes for various markers and properties, 
where the fluorescence of these single cells can later be measured. As interception 
of the laser beam occurs, light is scattered and the fluorescent dyes used to mark 
the cells are excited. The ‘scattered’ light is collected and converted to an electric 
signal by photon multiplier tubes (PMT). Filters are able to direct the emitted light to 
different PMTs according to their wavelength (384). Cell populations can usually be 
identified according to their physical properties, such as size (defined by forward 
scatter) and granularity (defined by side scatter). Gates were drawn based on 
forward and side scatter around lymphocytes, whilst excluding debris and doublets 
(Fig. 10A). In order to control for autofluorescence and non-specific binding of 
antibodies, isotype matched control antibodies were used in each experiment. 
Negative controls were used to set the voltages by placing their histograms within 
the first decade in correspondence with the fluorochrome used to label the cells (Fig. 
10B). This meant that cells that demonstrated peaks beyond the first decade were 
considered as positive. However, the emission spectrum demonstrates a significant 
overlap of different dyes, which is a problem when using multi-colour flow cytometry. 
In this scenario, overlaps must be compensated, by running samples stained with 
individual fluorochromes. In my experiments I used compensation beads (OneComp 
eBeads, 01-1111-42, ebioscience, UK) to do this. Compensation is important to 
avoid detection of false positive signals. For example, if there is spectral overlap 
between flourochromes PE and FITC, it means light detected by FL1 (FITC) and FL2 
? ???
(PE) contains light from each other’s dye. FL2 can detect excess fluorescent signals 
due to the intensity of FITC emission, thereby leading to false positive PE signals. 
Therefore, by subtracting the total percentage of FITC signal generated in FL1 from 
the total PE signal generated from FL2, this overlap can be compensated (385) (Fig. 
10C). All compensation was performed following data collection using the 
compensation matrix within the FlowJo software.  
 
 
Figure 10 – Gating strategy and calibration of the flow cytometer. 
(A) Gating strategy of lymphocytes from LIMCs, followed by selection of single cells 
and the CD19+ population of B cells. (B) Histograms in the unstained sample of 
LIMCs, where all voltages are set to remain within the first decade, to allow accurate 
detection of positive staining. (C) A demonstration of the overlap, which can occur 
between voltages. This overlap needs to be compensated to allow accurate 
detection of positive staining.  
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?
Due to the large number of stains used on each panel, it was important to assess 
whether the Fortessa was more sensitive to picking up B cell subpopulations 
compared to the Dako CyAN. LIMCs from a patient with polycystic liver disease were 
isolated (As stated in 2.3.1.) and stained using B cell and Breg panels (Table 5–7 in 
3.3.3.). 2x panel stains were prepared for each Breg and B cell panel so that each 
sample could be run through both the Fortessa and the Dako CyAn. 
?
?
??
? 
? ???
 
The data from this comparison experiment (Fig. 7) shows that although percentages 
were slightly higher in samples collected using the Fortessa, the separation of 
populations were clearer when data was collected using the CyAn. Furthermore, 
many populations aggregated around the axis when collected with the Fortessa, 
making it difficult to place exact gates to quantify B cell subsets. For these reasons, 
the Dako CyAn was used to collect all patient data henceforth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
?
? ???
2.3. ROUTINE TECHNIQUES 
?
?????? ????????????????????????????? ???????????????????? ????
?
Liver tissue slices were weighed, macerated using scalpels and rinsed in cold sterile 
PBS until washes ran clear. The tissue was transferred to a stomacher 400 circulator 
bag (Seward Limited, UK) with 300ml of RPMI media (Gibco Life Technologies, UK), 
before being sealed and placed in the Stomacher 400 circulator machine (Seward 
Limited, UK) for 5 minutes at 260RPM. The liver-RPMI solution was then poured 
through a fine mesh beaker and washed through with sterile PBS. The filtrate was 
distributed into 50ml tubes (Corning incorporated, UK) prior to centrifugation for 5 
minutes at 750g. Pellets were pooled, washed and centrifuged several times until 
two 50ml tubes remained. These two 50ml tubes were washed and centrifuged for a 
further 5 minutes at 750g. The supernatant was disposed of and the pellet 
resuspended in >30ml PBS, allowing all residual debris to sink to the bottom of the 
tube. The new supernatant was then layered on 20ml of lympholyte cell separation 
media  (Cedarlane, UK), taking care to avoid the pellet of heavy sediment at the 
bottom of the tube. This was centrifuged at 700g for 20 min with no brake. 
The LIMC buffy coat layer was harvested and washed once with PBS prior to being 
resuspended in 1ml of FACS buffer (1% FBS diluted with sterile PBS) and counted 
using trypan blue (Sigma-Aldrich, UK).  
?
?
?
?
?
?
?
?
? ???
?????? ???????????????????????????
?
Consented unmatched and matched blood was received from the Queen Elizabeth 
Hospital from patients suffering from haemochromatosis. Blood was diluted 1:1 with 
PBS in 50ml tubes (Corning, UK) before being layered on 20ml of Lympholyte cell 
separation media (Cedarlane, UK). This was centrifuged at 700g for 20min with no 
brake. The PBMC buffy coat layer was harvested and washed once with PBS prior 
to being resuspended in 1ml of FACS buffer (1% FBS diluted with sterile PBS) and 
counted using trypan blue (Sigma-Aldrich, UK).  
?????? ????????????????????????????????
?
1.5 x 106 isolated LIMCs were distributed to each sample FACS tube (BD Falcon, 
UK) for staining. Compensation bead tubes were prepared using one drop of 
OneComp eBeads (eBiocences, 01-1111, UK) with 100μl of FACS buffer per FACS 
tube. Relevant antibodies and isotype-matched controls were then added at the 
dilution stated (Table 6 & 7 for old two-colour panels, Table 8–10 for updated three-
colour panels) and left to incubate for 20 minutes in the dark at room temperature. 
Following incubation, beads were washed in 1ml of FACS buffer, centrifuged for 5 
minutes at 750 and resuspended in 300μl of PBS. If required, some samples were 
fixed using 1% PFA (Sigma-Aldrich, UK) for 10 minutes at room temperature before 
being washed and resuspended in 300μl of PBS. Samples were stored at 8°C in the 
dark until data could be collected using the cyan flow cytometer (CyAn ADP 
Analyser, Beckman Coulter Inc., UK).  
Tables 6 and 7 below describe the initial two panel stains developed to identify seven B 
cell subsets. This panel was later expanded to a more extensive three eight-colour 
panels (Tables 8–10), which stained for over 11 B cell subsets.  
? ???
Table 6 – Antibodies and IMCs used in the old B cell panel 1. All IMCs were used at the same 
dilution as the matching antibody. This panel allowed the characterisation of memory, naïve, and 
natural effector cells. Plasma cells and plasmablasts were also identified using this panel. All 
antibodies used in this panel were from MACS, Miltenyi Biotec, UK  
 
Old Antibody Panel 
1- B cells 
Catalogue 
number 
Working 
dilution 
Isotype Matched Control   
(IMC) 
IMC 
catalogue 
number 
CD19-PerCP-Vio700, 
human 
 
130-097-686 
 
4/100 Mouse IgG1-PerCP-Vio700 
 
130-097-561 
 
CD38-PE-Vio770, 
human 
 
130-099-151 
 
1/100 Mouse IgG2b-PE-Vio770 
 
130-096-825 
 
CD138   (44F9)-
VioBlue, human 
 
130-098-202 
 
6/100 Mouse IgG1-VioBlue 
 
130-094-670 
 
Anti-IgD-APC, human 
 
130-094-553 
 
3/100 Mouse IgG1-APC 
 
130-092-214 
 
Anti-IgM-PE, human 
 
130-093-075 
 
3/100 Mouse IgG1-Pe 
 
130-092-212 
 
CD27-APC-Vio770, 
human 
 
130-098-597 
 
6/100 Mouse IgG1-APC-Vio770 
 
130-096-653 
 
 
 
 
Table 7 – Antibodies and IMCs used in Breg panel 2. All IMCs were used at the same dilution as 
the matching antibody. This panel allowed the characterisation of human B10 regulatory cells and 
transitional Breg cells. All antibodies used in this panel were from MACS, Miltenyi Biotec, UK  
 
Old Antibody 
Panel 2 – Bregs 
Catalogue 
number 
Working 
dilution 
Isotype Matched Control   
(IMC) 
IMC 
catalogue 
number 
CD19-PerCP-
Vio700, human 
 
130-097-686 4/100 Mouse IgG1-PerCP-Vio700 
 
130-097-561 
 
CD38-PE-Vio770, 
human 
 
130-099-151 1/100 Mouse IgG2b-PE-Vio770 
 
130-096-825 
 
CD1d-PE, human 
 
130-099-982 5/100 Mouse IgG2b-PE 
 
130-092-215 
 
CD24-APC, human 
 
130-095-954 1/500 Mouse IgG1-APC 
 
130-092-214 
 
CD5-VioBlue, 
human 
130-096-572 
 
3/100 Mouse IgG1-VioBlue 
 
130-094-670 
 
 
 
 
 
? ???
The following tables (Tables 8–10) describe three extended B cell panels which 
allowed the continued characterisation of the seven B cell subsets mentioned 
previously (See Tables 6 and 7), as well as the phenotypic characterisation of the 
newly identified CD24-CD38- and CD24-CD38int B cell populations. Furthermore, 
this panel allowed staining for four additional B cell subsets including GC B cells 
(CD77), activated B cell subsets (CD5 and CD69), class switched B cells through 
surface Ig expression (IgA, IgD, IgG, IgM) and the ‘human B-1 panel’ (CD19+CD70-
CD43+CD27+) as described by Griffin et al. 2011 J Exp Med.  
 
Table 8 – Antibodies and IMCs used in expanded B cell panel 1. All IMCs were used at the same 
dilution as the matching antibody. This panel allowed the characterisation of transitional, memory, 
naïve, GC, non class-switched, CD24-CD38- and CD24-CD38int B cell populations and natural 
effector cells. Plasma cells and plasmablasts were also identified using this panel.  
 
 
Expanded antibody 
Panel 1 
Catalogue 
number 
Working 
dilution 
Isotype Matched 
Control   (IMC) 
IMC catalogue  
number 
CD19 PeCy5, 
anti-human 
  (Biolegend, UK) 
302210 
 
1/200 Mouse IgG1- PeCy5   
(Biolegend, UK) 
400118 
CD24 APC anti-human 
  (MACS, Miltenyi Biotec, UK) 
130-095-954 
 
1/500 Mouse IgG1-APC 
  (MACS, Miltenyi Biotec, 
UK) 
130-092-214 
 
 CD38 
Pe-Vio770, anti-human 
  (MACS, Miltenyi Biotec, UK) 
130-099-151 
 
1/100 Mouse IgG2b-PE-Vio770 
  (MACS, Miltenyi Biotec, 
UK) 
130-096-825 
 
CD27-APC-Vio770, human 
  (MACS, Miltenyi Biotec, UK) 
 
130-098-597 
 
 
6/100 Mouse IgG1-APC-Vio770 
  (MACS, Miltenyi Biotec, 
UK) 
130-096-653 
 
CD138   (44F9)-VioBlue, anti-
human 
  (MACS, Miltenyi Biotec, UK) 
 
130-098-202 
 
6/100 Mouse IgG1-VioBlue 
  (MACS, Miltenyi Biotec, 
UK) 
130-094-670 
 
Anti-IgM-PE, anti-human 
  (MACS, Miltenyi Biotec, UK) 
 
130-093-075 
 
3/100 Mouse IgG1-PE 
  (MACS, Miltenyi Biotec, 
UK) 
130-092-212 
 
IgD BV510, Mouse anti-
human 
  (Biolegend, UK) 
 
563034 
 
4/100  Brilliant Violet 
510™ Mouse 
IgG2a   
(Biolegend, UK) 
 
 400268 
 
CD77 FITC, anti-human 
  (Biolegend UK) 
357104 
 
4/100  FITC Mouse IgM 
  (Biolegend, UK)  
401606 
 
 
 
?
?
?
?
?
?
 
? ???
 
Table 9 – Antibodies and IMCs used in expanded B cell panel 2. All IMCs were used at the same 
dilution as the matching antibody. This panel allowed the characterisation of CD24-CD38- and CD24-
CD38int B cell populations, B10 regulatory, activated and IgA expressing B cells.  
 
 
Expanded antibody 
Panel 2 
Company 
and 
catalogue 
number 
Working 
dilution 
Isotype Matched 
Control   (IMC) 
IMC catalogue 
number 
CD19 PeCy5, 
anti-human 
  (Biolegend, UK) 
302210 
 
1/200 Mouse IgG1- PeCy5 
  (Biolegend, UK) 
 
400118 
 
CD24 APC anti-human 
  (MACS, Miltenyi Biotec, 
UK) 
130-095-954 
 
1/500 Mouse IgG1-APC 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-092-214 
 
CD38 
Pe-Vio770, anti-human 
  (MACS, Miltenyi Biotec, 
UK) 
130-099-151 
 
1/100 Mouse IgG2b-PE-Vio770 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-096-825 
 
CD5-VioBlue, anti- human 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-096-572 
 
3/100 Mouse IgG1-VioBlue 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-094-670 
 
CD3 BV510, anti-human 
  (Biolegend, UK) 
317332 
 
1/100 Brilliant Violet 510 
Mouse IgG2a 
  (Biolegend, UK) 
Brilliant Violet 510™ 
Mouse IgG2a 
 
 
400268 
400268 
 
CD1d PE, anti-human 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-099-982 
 
 
5/100 Mouse IgG2b-PE 
  (MACS, Miltenyi Biotec, 
UK) 
130-092-215 
 
IgA FITC, Goat anti-
human 
  (Bethyl, UK) 
A80-102F 
 
2/100 Goat IgG FITC 
  (Southern Biotech, UK) 
 
0109-02 
 
CD69 APC-Vio770 
  (MACS, Miltenyi Biotec, 
UK) 
130-099-907 
 
4/100 Mouse IgG1 APC-Vio770 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-056-653 
 
 
?
?
?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
? ???
 
Table 10 – Antibodies and IMCs used in expanded B cell panel 3. All IMCs were used at the 
same dilution as the matching antibody. This panel allowed the characterisation of CD24-CD38- and 
CD24-CD38int B cell populations, human B1 (CD19+CD70-CD43+CD27+) and IgG expressing B 
cells.  
 
 
Expanded antibody 
Panel 3 
Company 
and 
catalogue 
number 
Working 
dilution 
Isotype Matched 
Control   (IMC) 
IMC catalogue 
number 
CD19 PeCy5, 
anti-human 
  (Biolegend, UK) 
302210 
 
1/200 Mouse IgG1- PeCy5 
  (Biolegend, UK) 
400118 
CD24 APC anti-human 
  (MACS, Miltenyi Biotec, 
UK) 
130-095-954 
 
1/500 Mouse IgG1-APC 
  (MACS, Miltenyi Biotec, UK) 
130-092-214 
 
CD38 
Pe-Vio770, anti-human 
  (MACS, Miltenyi Biotec, 
UK) 
130-099-151 
 
1/100 Mouse IgG2b-PE-Vio770 
  (MACS, Miltenyi Biotec, UK) 
 
130-096-825 
 
CD70 FITC, anti-human 
  (Biolegend, UK) 
355106 
 
4/100  FITC Mouse IgG1 
  (Biolegend, UK) 
400110 
 
CD43 APCCY7, anti-human 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-101-128 
 
1/100 Mouse IgG1 APC-Vio770 
  (MACS, Miltenyi Biotec, UK) 
130-056-653 
CD5-VioBlue, anti- human 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-096-572 
 
3/100 Mouse IgG1-VioBlue 
  (MACS, Miltenyi Biotec, UK) 
 
130-094-670 
 
CD27 PE, anti-human 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-093-185 
 
4/100 Mouse IgG1-PE 
  (MACS, Miltenyi Biotec, UK) 
130-092-212 
 
IgG BV510, anti-human 
  (BD Biosciences, UK) 
563247 
 
N/A Mouse IgG1-Brilliant Violet 510   
(Biolegend, UK) 
400172 
 
 
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
? ???
???????? ???????????????????????????????????????????
?
LIMCs were isolated from human liver as described in 2.3.1. LIMCs were the stained 
for age-associated B cells using the same process as described in 2.3.3. however 
using a different three colour panel as demonstrated in Table 11 below. 
 
Table 11 – Antibodies and IMCs used to identify exhausted and age related B cells. All IMCs 
were used at the same dilution as the matching antibody. This panel allowed the characterisation of 
age-associated B cells ABC phenotype IgD-CD21-CD23-CD11c+Tbet+CD80hi. 
 
Age related B cell 
panels 
Panel 
Number 
Company 
and 
catalogue 
number 
Working 
dilution 
Isotype Matched 
Control   (IMC) 
IMC catalogue 
number 
CD19 PeCy5, 
anti-human 
  (Biolegend, UK) 
All 302210 
 
1/200 Mouse IgG1- PeCy5 
  (Biolegend, UK) 
400118 
CD24 APC anti-human 
  (MACS, Miltenyi Biotec, 
UK) 
All 130-095-954 
 
1/500 Mouse IgG1-APC 
  (MACS, Miltenyi Biotec, 
UK) 
130-092-214 
 
CD38 
Pe-Vio770, anti-human 
  (MACS, Miltenyi Biotec, 
UK) 
All 130-099-151 
 
1/100 Mouse IgG2b-PE-Vio770 
  (MACS, Miltenyi Biotec, 
UK) 
 
130-096-825 
 
Anti-IgD-APC, human 
 
All 130-094-553 
 
3/100 Mouse IgG1-APC 
 
130-092-214 
 
CD27-APC-Vio770, 
human 
  (MACS, Miltenyi Biotec, 
UK) 
 
All 130-098-597 
 
6/100 Mouse IgG1-APC-Vio770 
  (MACS, Miltenyi Biotec, 
UK) 
130-096-653 
 
Brilliant Violet 421 anti-
Tbet antibody  
  (Biolegend, UK) 
All 644186 4/100 Mouse IgG1- Brilliant 
Violet 421 
  (Biolegend, UK) 
 
400158 
 
Alexa Fluor 488 anti-
human CD11c  
  (Biolegend, UK) 
 
1 301618 2/100 Mouse IgG1- Alexa Fluor 
488 
  (Biolegend, UK) 
400129 
CD21 PE, anti-human 
  (BD Biosciences, UK) 
1 354904 
 
1/200 Mouse IgG1-PE   
(Biolegend, UK) 
400112 
 
 
CD95 FITC, anti-human 
  (Biolegend, UK) 
2 305606 4/100 Mouse IgG1- FITC 
  (Biolegend, UK) 
400110 
CD23 PE, anti-human  
  (Biolegend, UK) 
 
2 338508 1/100 Mouse IgG1- PE 
  (Biolegend, UK) 
400112 
CD80 FITC, anti-human  
  (Biolegend, UK) 
 
3 305206 4/100 Mouse IgG1- FITC 
  (Biolegend, UK) 
400110 
IgE PE, anti-human 
  (Biolegend, UK) 
3 325506 4/100 Mouse IgG1- PE 
  (Biolegend, UK) 
400114 
 
?
?
? ???
?????? ????????????????????????????????????
?
After collecting events on the Dako CyAn flow cytometer, total CD19+ B cells and B 
cell subpopulations were gated from lymphocytes and single cells as shown in 
Figure 10A. Following the selection of total CD19+ B cells, specific gating strategies 
were used to quantify subpopulations of B cells. It was difficult to consolidate the 
literature when deciding the most appropriate way to phenotypically characterise B 
cell subsets. The majority of B cell subpopulations described in this project were 
defined according to the surface markers described in Van Zelm, 2007 and Allman et 
al, 2008. However, specific studies were used to investigate more recently defined 
human B cell subpopulations such as human B-1 cells, double negative memory and 
human MZ B cells (155, 195, 386). 
 
 
 
 
 
 
 
 
 
 
 
 
? ???
???????? ?????? ?????????????? ??????????????
?
Non-switched memory (natural effector/MZ) B cells and naïve B cells have been 
described as both CD38- and CD38+ populations (48, 93, 138). Therefore, to begin 
defining naïve and natural effector B cells, the CD38- to CD38+ population was 
selected, after which Naïve and natural effector populations were differentiated 
according to IgD+CD27-CD77- and IgD+CD27+IgM+ (138, 144) (154) expression 
respectively (Figure 12).  
 
 
 
 
Figure 12 – Gating strategy of CD19+CD38+IgD+CD27- naive and 
CD19+CD38+IgD+CD27+ natural effector (non-switched memory) B cells. Cells 
are first gated as in Fig. 6A, to include CD19+ B cells, then gated on CD38- to 
CD38+ population, followed by the use of IgD and CD27 antigens to identify naïve 
and natural effector (non-switched memory) cells. All final percentages were 
expressed as a percentage of total CD19+ B cells. 
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Switched memory B cells are most commonly described in the literature as 
CD19+CD38-CD27+IgD- (112) (138, 193). To begin quantifying switched memory B 
cells, CD38lo/- cells were first selected. From this population CD27+IgD- cells were 
subsequently gated to reveal the switched memory B cell subset percentage (Figure 
13). 
 
 
Figure 13 – Flow plots demonstrating the gating strategy of CD19+CD38-
CD27+IgD- switched memory B cells. Cells are first gated as in Fig. 6A, to include 
CD19+ B cells, then gated on CD38-/lo population, followed by the IgD-CD27+ 
population. All final percentages were expressed as a percentage of total CD19+ B 
cells. 
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Plasmablast and Plasma cells are identified as CD19+CD27hiCD38hi cells with 
plasma cells additionally expressing CD138 also known as syndecan-1 (138, 150, 
387). Firstly, B cells, which were CD38hi CD27hi, were gated. CD138 was then used 
as a marker to separate this gated population into plasmablasts and plasma cells 
(Figure 14). 
??
 
Figure 14 - Gating strategy of CD19+CD38hiCD138- plasmablasts and 
CD19+CD38hiCD138+ plasma cells. Cells are first gated as in Fig. 6A, to include 
CD19+ B cells, then gated on CD38hi population, followed by the use of CD138 
antigen to identify plasma cells from plasma blasts. All final percentages were 
expressed as a percentage of total CD19+ B cells. 
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B-1 cells, originally discovered in mice, derived from a distinct B cell lineage which 
differs functionally and anatomically from B-2 cells. Findings from a study by Griffin 
et al. 2011 identified a phenotype of human B-1-type cells based on sorting B cells 
according to their fundamental B-1 cell functions, including tonic intracellular 
signaling, T cell stimulation and most importantly, spontaneous IgM secretion (386). 
In humans, B-1-type cells were defined by this study as CD20+CD27+CD43+CD70- 
(386). I adopted the same gating strategy as this study to identify ‘B1-type’ cells, 
however replaced CD20 staining for CD19 to preserve consistency when identifying 
other B cell subsets. After selecting CD19+ B cells, the CD70- population was 
selected, followed by the selection of the CD43 and CD27 double positive 
populations (Figure 15).  
 
Figure 15 - Gating strategy of CD19+CD70-CD27+CD43+ ‘human B-1-type 
cells’. Cells are first gated as in Fig. 6A, to include CD19+ B cells, then gated on 
CD70- population, followed by the use of CD27 and CD43 antigens to identify double 
positive B-1-type cells in humans. All final percentages were expressed as a 
percentage of total CD19+ B cells. 
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CD77 was used as a primary marker in identifying the presence of centroblasts and 
centrocytes in hepatic tertiary lymphoid structures followed by the quantification of 
these subsets (138, 144, 388, 389). Literature states that GC dark zones are rich in 
proliferating centroblasts, whereas centrocytes in the light zone are CD38+IgD-
CD77- (138, 388). Consequently, centroblasts within the hepatic B cell compartment 
from liver explants were classified as CD19+CD77+ cells. In order to investigate 
centrocytes, CD19+CD77- B cell population was selected, followed by a CD38+IgD- 
population (Figure 16).  
?
???????????????????? ?
?
Figure 16 - Gating strategy of CD19+CD77+ centroblasts and CD19+CD77-
CD38hiIgD- centrocytes. Cells are first gated as in Fig. 6A, to include CD19+ B 
cells, then gated on CD77- or CD77+ population accordingly. Following selection of 
the CD77- population, centrocytes were as CD38hiIgD- B cells. All final percentages 
were expressed as a percentage of total CD19+ B cells. 
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Transitional B cells represent a population which has not yet fully matured from 
immature BM lineage cells to mature naïve B cells (45). They are identified as being 
CD38hiCD24hi B cells which produce IL-10, therefore possess a regulatory 
phenotype (45, 390). In mice, Breg cells (B10s) are identified as CD5+CD1dhi 
populations, and this gating strategy has also been used to identify a population of 
human Bregs (14, 93, 163). Both Transitional and human B10s were gated from 
CD19+ B cells using CD5+CD1dhi and CD38hiCD24hi gates respectively (Figure 
17).  
?
?
 
Figure 17 - Gating strategy of B10 cells (left) and Transitional Bregs (right). 
Cells are first gated as in Fig. 6A, to include CD19+ B cells. B10 cells are gated as 
CD1dhiCD5+ B cells. Transitional Bregs are gated as CD38hiCD24+ B cells. All final 
percentages were expressed as a percentage of total CD19+ B cells. 
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2.4. SPECIFIC TECHNIQUES 
?
?????? ?????????? ?????????????????????? ??????????????????????
?
Consented lymph nodes located within the mesentery of donor livers were weighed 
and finely macerated using scalpels on a petri dish. The macerated tissue was 
placed in a GentleMacs C tube (Miltenyi Biotec, UK 130-096-334) with 10ml RPMI 
(Supplemented with 10% FBS +1%PSG+1%NEAA+1%L-Glutamine). The C tube 
was placed in the gentleMACS tissue dissociator (Miltenyi Biotec, UK 130-093-235) 
on setting ‘spleen_01’. The lymph node-RPMI solution was then poured through a 
fine mesh beaker and washed through with sterile PBS. Filtrates were distributed 
into 50ml tubes (Corning incorporated, UK) prior to centrifugation for 5 minutes at 
750g. Pellets were pooled, washed and centrifuged several times until one 50ml 
tube remained. This final 50ml tube was washed once more and centrifuged for a 
further 5 minutes at 750g. The supernatant was disposed of and the pellet 
resuspended completely in >30ml PBS prior to being layered on 20ml of lympholyte 
cell separation media (Cedarlane, UK). This was centrifuged at 700g for 20 minutes 
with no brake. The mononuclear cell buffy coat layer was harvested and washed 
once with PBS prior to being resuspended in 1ml of FACS buffer (1% FBS diluted 
with sterile PBS) and counted using trypan blue (Sigma-Aldrich, UK).  
 
 
 
 
? ???
?????? ???????????????? ????????????????????????
?
BECs, HSEC and fibroblasts isolated from explanted diseased livers were cultured 
on rat-tail collagen (Sigma, UK) coated 24-well plates and incubated at 37°C in the 
relevant media (See Table 12) until confluent. LX2 cells (a hepatic myofibroblast cell 
line) were also seeded on a 24-well plate and incubated until confluent. PBMCs were 
isolated from healthy human blood on a lympholyte gradient. The PBMCs were then 
washed in PBS on a slow spin (200g, acc 7, brake 1 for 10 minutes) to deplete 
platelets, and were then resuspended in BEC/HSEC/fibroblast/LX2 cell media, at a 
concentration of 2x106  PBMCs/ml. 1ml of PBMCs were co-cultured with liver stromal 
cell lines for 1 hour and 24 hours, after which they were harvested and stained for 
CD19, CD38 and CD24 (See Table 6). 
 
?????????? Ingredients of media used to culture various liver cell lines / primary cells These 
cell lines were generated in house by Gill Muirhead. 
?
Cell line / Liver stromal cells? Culture medium?
LX2 cells? DMEM (Gibco, UK) +2% FBS (Gibco, UK) +1% Penicillin/Streptomycin  
(Gibco, UK)?
HSEC? 120ml Human Endothelial Serum Free Media (Gibco, 11-11-044, UK) +20ml 
human serum (HD Supplies, CS 300, UK) +20μl HGF at 100μg/ml  
(Peprotech, UK) +20μl VEGF at 100μg/ml (Peprotech, UK).?
BEC? 90ml Hams F12 media (Sigma, UK) +90ml DMEM +20ml human serum 
+20μl HGF at 100μg/ml (Peprotech, UK) +20μl EGF at 100μg/ml  
(Peprotech, UK)  + 2ml cholera toxin   (Sigma, UK, C8052) at 1μg/ml +2ml 
Hydrocortisone (QE pharmacy) at 2μg/ml +248μl Insulin (QE Pharmacy) 
+2ml of 0.2M Penicillin/Streptomycin +2ml Tri-ido-thyronine (T3 Sigma 
T5516)?
Fibroblasts? DMEM +20% FBS +1% Penicillin/Streptomycin +1% NEAA +1% L-Glutamine?
? ???
The purpose of this procedure was to assess whether co-culture with liver stromal 
cells induced downregulation of CD24 on PBMCs compared to controls at 0H, 1 hour 
and 24 hours in media alone. Stromal cells were also stained for P-selectin (CD24 
ligand), to detect whether any CD24 downmodulation may be due to a ligand specific 
mechanism. All samples were then fixed and data was collected using the Cyan flow 
cytometer (CyAn ADP Analyser, Beckman Coulter Inc., UK).  
?
?????? ???????????????? ????????????????????????
 
Healthy human blood was layered on lympholyte and left to spin for 20 minutes, 
acceleration 9, brake 0 at 700g. The PBMCs were harvested, counted and 
resuspended at a concentration of 1.5x106/100μl using RPMI. 100μl of PBMCs were 
added into the appropriate number of wells in two round bottom 96-well plates were 
labeled (1 hour and 24 hours). The plate was centrifuged for 5 minutes, acceleration 
9 brake 0 at 750g, and the media was flicked away to leave the pellet. Cytokines 
(Peprotech, UK) were diluted in RPMI+10% FBS +1%PSG+1%NEAA+1%L-
Glutamine (See Table 13), and each relevant cytokine was used to resuspend the 
PBMC pellets. The PBMCs were incubated for 1 hour and 24 hours respectively 
before being stained at room temperature in the dark for 20 minutes for CD19, CD38 
and CD24 (Concentrations as in Table 8). These samples were fixed and data was 
collected using the CyAn flow cytometer (CyAn ADP Analyser, Beckman Coulter 
Inc., UK), to assess whether different cytokines induced downmodulation of CD24 on 
B cells individually and in combination with other cytokines. 
 
 
? ???
????????????????????????????????? ??????????????? ???????????????????? ??????????????????
?????? ??????? ?????????? ???? used individually and in combination (pro-inflammatory & anti-
inflammatory), to assess whether cytokines which were present in the liver cause CD24 
downmodulation. All Cytokines were obtained from Peprotech, UK. 
 
Cytokine Dilution Catalogue 
No. 
Final Concentration 
IFN-γ 1/1000 300-02 100 ng/ml 
TNF-α 1/1000 300-01A 100 ng/ml 
Mixture TNF α & IFN γ 1/1000  100 ng/ml 
IL-1β 1/100 200-01B 100 ng/ml 
IL-6 1/1000 200-06 10 ng/ml 
IL-2 1/1000 200-02 50 ng/ml 
TGFβ1 1/1000 100-21 100 ng/ml 
IL-10 1/1000 200-10 100 ng/ml 
Proinflam mix: IL-6, IL-2, 
IL-1β, TNF-α & IFN-γ 
  
Anti-inflamm mix: TGFβ & 
IL-10 
  
 
?
?????? ???????????????????????????
?
An assay was developed to assess whether CD24 downmodulation on hepatic B 
cells was due to internalization (See Table 14 below). LIMCs were isolated from the 
liver as described in 2.3.1. and 7x106 LIMCs were used in this experiment. 1x106 
LIMCs were left unstained, 1x106 LIMCs were surface stained for CD19, CD24 and 
CD38 and 1x106 LIMCs were surface stained for the corresponding isotype matched 
controls (See 2.3.3. and Table 8). 
 
In parallel 2x106 LIMCs were surface stained for CD19 and CD38 alone and a 
further 2x106 LIMCs were surface stained with the corresponding isotype matched 
controls (Table 8). All seven samples were fixed in 100μl 1% PFA (Sigma-Aldrich, 
UK) for 15 minutes. Samples 1–3 were washed, resuspended in 200μl PBS and 
placed in the fridge. Samples 4 and 5 were resuspended in 150μl 0.1% saponin and 
? ???
samples 6 and 7 remained in fixing buffer. All remaining samples were incubated for 
20 minutes at room temperature. 
 
Following incubation samples were washed and 4 and 5 were resuspended in 100μl 
CD24 antibody and 100μl IgG1 APC diluted in saponin respectively (See Table 8). 
Samples 6 and 7 were resuspended in 100μl CD24 antibody and 100μl IgG1 APC 
diluted in FACS buffer respectively. All samples were incubated for 20 minutes at 
room temperature before being washed in PBS and resuspended in 300μl PBS (See 
Table 14 below for clarity on all seven samples and their respective treatments). 
Samples were then run through the Dako Cyan to assess what percentage of CD24 
was downmodulated from the surface compared to the percentage of CD24 which 
was present intracellularly. 
?
????????? Samples involved in CD24 internalisation assay and their respective surface and 
intracellular stains. All antibodies and dilutions were used as stated in Table 6.   
?
?
Sample 
number 
Sample Name Surface stain Intracellular Stain 
1 Unstained LIMCs None None 
2 Surface Stained only CD19-pecy5,  
CD38-pecy7, 
 CD24-APC 
None 
3 Surface stained IMC Mouse IgG1- PeCy5 
Mouse IgG1- APC 
Mouse IgG2B- PE VIO770 
None 
4 Surface and intracellular   
(Fix & perm) 
CD19-pecy5,  
CD38-pecy7, 
CD24-APC in 
saponin 
5 Surface and intracellular 
IMC   (Fix & perm) 
Mouse IgG1- PeCy5 
Mouse IgG2B- PE VIO770 
 
Mouse IgG1- APC 
In saponin 
6 Surface and intracellular   
(Fix NO perm) 
CD19-pecy5,  
CD38-pecy7, 
CD24-APC  
in FACs buffer 
7 Surface and intracellular 
IMC   (Fix NO perm) 
Mouse IgG1- PeCy5 
Mouse IgG2B- PE VIO770 
 
Mouse IgG1- APC 
In FACs buffer 
?
 
? ???
?????? ??? ?????????? ???????????????????????????????????????
?
In order to understand whether CD24- hepatic B cells were pro- inflammatory or anti-
inflammatory, an assay was developed to stimulate hepatic B cells and assess 
production of cytokine such as IFN-γ, TNF-α, IL-6 and IL-10 via intracellular cytokine 
staining. LIMCs were isolated from explanted human livers as described in 2.3.1. 
before being stimulated for 5 hours and 24 hours in CpG (Invivogen, ODN 2006 
(0DN 7909) used at 15.4μg/ml), PMA (Sigma Aldrich P1585, used at 50ng/ml) and 
Ionomycin (Sigma Aldrich I9657, used at 1μM) along with Brefeldin A (Sigma Aldrich 
B7651, used at 10μg/ml) all diluted in RPMI +10%FBS+1% GPS and plated in wells 
of a 96-well Falcon tissue culture plate (Fisher Scientific, 08772-3B). Controls 
included supplemented RPMI alone as well as CpG control (Invivogen, ODN 2006 
Control (ODN2137) and were also incubated with LIMCs in a 96-well plate for 5 and 
24 hours. 
 
Following stimulation, Cells were washed in 1ml FACs buffer, centrifuged and 
stained for surface CD19, CD24 and CD38 as described in 2.3.3. See Table 8. After 
staining, the FoxP3/Transcription Factor Staining Buffer Set (eBioscience, 00-5523) 
was used to fix LIMCs following surface staining by mixing 2ml of fix/perm 
concentrate (eBioscience, 00-5123) with 6ml of fix/perm diluent (eBioscience, 00-
5223), after which 500μl of fix buffer was added per sample, then left to incubate in 
the fridge for 30 minutes. The permeabilization buffer 10X (eBioscience, 00-8333) 
was made up to 1x using ddH20, and samples were washed in 2ml PBS and 
resuspended in 1ml of 1X permeabilization buffer prior to being immediately 
centrifuged again (750g, acc 9, brake 9, 5 minutes). 100μl cytokine antibody 
cocktails were added at their respective dilutions in 1x Permeabilisation buffer (Refer 
? ???
to Table 15) to LIMC samples and left to incubate at room temperature for 30 
minutes in the dark. They were washed in 500μl Permeabilization buffer and 
resuspended in PBS. Data was collected using the Dako CyAN. 
 
 
Table 15 – Antibodies used to form intracellular cytokine panel. This panel was used to define 
which hepatic CD24- B cells produced cytokines and whether this cytokine profile differed to CD24+ B 
cells. IMCs are used at the same concentration as their corresponding antibodies. All antibodies were 
diluted using the permeabilisation buffer as part of the FoxP3/ Transcription Factor Staining Buffer Set 
(eBioscience, 00-5523) 
 
 
Intracellular 
Cytokine antibody 
panel  
Catalogue 
number 
Working 
dilution 
Isotype Matched 
Control   (IMC) 
IMC catalogue 
number 
TNF-α APC/Cy7 
  (Biolegend, UK) 
 
502944 2/100 Mouse IgG1- APC/Cy7 
  (Biolegend, UK) 
 
400128 
 
IL-10 BV421 
  (Biolegend, UK) 
 
501421 
 
4/100 Rat IgG1 BV421 
  (Biolegend, UK) 
 
 
400430 
 
IL-6 PE 
  (Biolegend, UK) 
 
501107 
 
4/100 Rat IgG1 PE 
  (Biolegend, UK) 
 
400408 
 
IFNγ FITC 
  (Biolegend, UK) 
 
 
502506 
 
4/100 Mouse IgG1 FITC 
  (Biolegend, UK) 
  
400108 
 
 
 
Later experiments used additional TLR and BCR stimuli plus unstimulated cells to 
assess the effect of stimulation on B cell and B cell subset cytokine production using 
the same procedure outlined above. Cells were surface stained for CD19, CD38 and 
CD24 and intracellular stained for IL-6, IL-10, TNF-α and IFN-γ. Stimuli types and 
concentrations are outlined in detail in Table 16 below. 
 
 
 
 
 
? ???
Table 16– Combinations of stimuli and their working concentrations, used to induce cytokine 
production from hepatic B cells / various hepatic B cell subsets. All stimuli (including 
unstimulated sample 1) included use of Brefeldin A at 10μg/ml (Sigma Aldrich B7651), PMA 50ng/ml   
(Sigma Aldrich P1585) and Ionomycin 1μM (Sigma Aldrich I9657) 
 
 
 
Stimulation 
number 
Stimulations Working 
concentration 
Company 
1   
(Unstimulated) 
Brefeldin 10μg/ml 
 
Sigma Aldrich B7651 
2 CpG   
(TLR9) 
 
15.4μg/ml 
 
Invivogen, UK #tlrl-2006 
 
3 TLR7/8   
(R848) 
 
1μg/ml 
 
 
Invivogen, UK #tlrl-r848 
 
4 TLR4   (LPS) 1μg/ml Invivogen, UK #tlrl-eklps 
 
5 RP105 1μg/ml Biolegend, UK 312907 
6 CD40 
IgM/IgG 
 
1μg/ml 
1μg/ml 
 
Biolegend, UK, 334304 
eBioscience, UK #16-5099-
85 
 
7 CD40 
IgM/IgG 
LPS 
  
8 CD40 
IgM/IgG 
RP105 
  
9 CD40 
IgM/IgG 
R848 
  
10 CD40 
IgM/IgG 
CpG 
  
11 R848 
IFN-γ 
 
100 ng/ml 
 
Peprotech, UK, 300-02 
12 CD40 
IgM/IgG 
R848 
IFN-γ 
 
 
 
 
 
 
 
 
13 R848 
Il-21 
 
100ng/ml 
 
Biolegend, UK, #571204 
14 CD40 
IgM/IgG 
R848 
Il-21 
  
 
 
 
 
 
? ???
?????? ??????????????????? ???
?
Ki67 staining of LIMCs was performed in order to assess whether CD24- B cells 
proliferated more or less in comparison to CD24+ B cell subsets, therefore allowing 
further functional characterization of CD24- hepatic B cells. LIMCs were isolated 
from end stage diseased liver explants as described in 2.3.1. before being stimulated 
with PMA, ionomycin and CpG with brefeldin A as described in 2.4.8. Following 
stimulation, LIMCs were surface stained for CD19, CD24 and CD38 and their 
matching isotype controls as described in 3.3.3. Table 8. After staining, the 
FoxP3/Transcription Factor Staining Buffer Set was used to fix and permeabilise 
LIMCs using the same procedure as in 2.4.5. Intracellular staining this time was with 
Ki67 (Biolegend, Pacific Blue, 350512) (4/100) and its isotype matched control 
(2/100) (Biolegend, Mouse IgG1, Pacific Blue, 400151). 
?????? ???????????????????????????????????
 
In order to investigate whether activated B cells were more susceptible to losing 
CD24, PBMCs isolated from patient chronic diseased livers were stained at Day 0 to 
assess CD19, CD38 and CD24 surface expression (as described in 3.3.3.), as well 
as the naïve and memory B cell profiles within CD24- B cell populations using IgD 
and CD27. The remaining LIMCs were co-cultured in DMEM (Supplemented with 
10% FBS +1%PSG+1%NEAA+1%L-Glutamine) (Gibco Life Technologies, UK) with 
anti-CD40 (Biolegend, UK, 334304) and IgM/IgG (anti-BCR) (eBioscience, UK #16-
5099-85) both at 1μg/ml. This co-culture was left to incubate for 5 days at 37°C, 
before the blasts were harvested, washed, and stained for B cell panel 1 and 
corresponding isotype matched controls (as described in 2.3.3. and Table 8). 
? ???
Following staining, samples were run through the Dako CyAn and analysed via 
FlowJo software. 
2.5. LOCALISATION OF B CELLS IN HEPATIC DISEASE 
USING IMMUNOHISTOCHEMISTRY 
 
Immunohistochemistry (IHC) was used to detect the location of various B cell 
subsets in end stage chronic liver disease formalin-fixed sections. All end-stage liver 
disease samples were preserved in a fixative known as formalin. This formal saline 
solution preserved the tissue and its constituents by cross-linking hydroxyl (OH) 
groups with proteins in the tissue. Each sample was then embedded in paraffin wax 
which hardened each sample, allowing it to be sliced and placed onto ice to harden 
further. Each tissue section was then sliced further using a microtome (Pfm Rotary 
3003, pfmmedical, 030030) into 3μm sections. Tissue sections were then 
subsequently left floating in a water bath set at 30°C to allow the paraffin wax to 
expand therefore eliminating any creases in the tissue. Glass slides were used to 
collect individual sections, which were stored at 60°C for one hour to allow tissue to 
adhere sufficiently before proceeding with immunohistochemical stains. The 
reagents and antibodies used for the duration of IHC staining is shown in Table 17 
and 18 below respectively. 
 
 
 
 
 
 
? ???
Table 17 - Reagents used for the duration of all immunohistochemical techniques. All 
respective manufacturers and catalogue numbers are also displayed 
 
Reagent Manufacturer Catalogue Number 
High pH Antigen 
Unmasking Solution 
Vector H-3301 
Envision FLEX Wash 
Buffer   (20X)   (TBS) 
Dako SEA-1304-00A 
 
Casein   (10X Solution) Vector SP-5020 
 
Dako REAL Peroxidase 
Blocking Solution 
Dako S2023 
 
ImmPRESS Bloxall 
Blocking Solution 
Vector ZA0502 
 
ImmPACT DAB 
Chromagen 
Vector ZA0325 
 
Mayer’s Haematoxylin Pioneer Research 
Chemicals Ltd 
 
PRC/R/42 
 
Absolute Ethanol AnalaR 
NORMAPUR 
 
VWR Chemicals 
 
20821.330 
 
Xylene 
 
Pioneer Research 
Chemicals Ltd 
 
PRC/R/201 
 
Industrial Denatured 
Alcohol   (IDA) 99% 
 
Pioneer Research 
Chemicals Ltd 
 
PRC/R/101 
 
? ???
ImmPact NovaRED 
 
Vector SK-4805 
 
Mounting Media DPX 
 
CellPath 
 
SEA-1304-00A 
 
DAB Peroxidase   (HRP) 
Substrate Kit   (with 
Nickel), 3,3’-
diaminobenzidine 
Vector SK-4100 
ImmEdge Hydrophobic 
Barrier Pen   (Wax Pen) 
Vector H-4000 
ImmPRESS™-AP Anti-
Mouse IgG   (alkaline 
phosphatase) Polymer 
Detection Kit 
Vector MP-5402 
StayGreen/AP substrate   
(Alcohol and Xylene 
Substitute Compatible) 
Abcam Ab156428 
ClariTech XTF Mounting 
medium 
CellPath SEA-0404-00A 
ClariTech XTF Clearing 
Agent 
CellPath EBG-XXXX-00A 
 
 
 
 
 
 
 
 
? ???
Table 18 - Antibodies and isotype matched controls used for the duration of all 
immunohistochemical techniques. All respective manufacturers and catalogue numbers are also 
displayed. 
 
Antibody Manufacturer Catalogue Number Working 
Concentration   
(mg/ml) 
Monoclonal 
Rabbit CD79α 
Clone SP18 
Vector VPRM15 
 
2.5x10-3 
Monoclonal 
Mouse Anti-
Human CD19 
Clone LE-CD19 
Dako M7296 
 
Single: 
4.15x10-4 
Double: 
3.32x10-3 
 
Monoclonal 
Mouse Anti-
Human CD24 
Clone 8.B.76 
Abcam ab31622 
 
5x10-2 
Mouse Anti-
Human CD62P / P-
Selectin Antibody   
(AK-6) 
 
ThermoFisher 
Scientific 
MA5-16567 2x10-2 
Monoclonal 
Mouse Anti-
Human Ki-67 
Clone MIB-1 
Dako M7240 
 
6.9x10-3 
 
Monoclonal 
Mouse Anti-
Human CD31 
 
Clone JC70A 
 
Dako M0823 2x10-2 
FDC 
Clone CNA.42 
 
Monoclonal Mouse 
Anti-Human Follicular 
Dendritic Cell 
 
M7157 
 
2.48x10-3 
 
Mouse IgG1 
Isotype Control 
Clone G3A1 
Cell Signalling 
Technology 
 
5415 
 
5x10-2 
? ???
Rabbit IgG1 
Isotype Control 
Clone DA1E 
Cell Signalling 
Technology 
 
3900 
 
2.5x10-3 
Amplifier 
Antibody Anti- 
Mouse IgG 
 
Vector ZA0307 
 
N/A 
ImmPRESS 
Universal 
peroxidase 
reagent kit   (Anti- 
Mouse/ Rabbit) 
 
Vector MP-7500 
 
N/A 
Amplifier 
Antibody Anti- 
Rabbit IgG 
 
Vector  N/A 
ImmPRESS™ 
Excel Amplified 
HRP Polymer 
Staining Kit   
(Anti-Mouse IgG) 
Vector MP-7602 N/A 
ImmPRESS™ 
Excel Amplified 
HRP Polymer 
Staining Kit   
(Anti-Rabbit IgG) 
Vector MP-7601 N/A 
Monoclonal 
Mouse Anti-
Human CD20  
Clone L26 
Impath 45128 0.0578 
Polyclonal Rabbit 
Anti-Human CD3 
Dako A0452 3 
Monoclonal 
Mouse Anti-
human BCL-2 
Clone 124 
Dako M0887 3.02 
 
 
? ???
?????? ??????????????????????????????????? ????????????????????????????
?
All sections were prepared in the same way before being stained using specific 
techniques, which were previously optimized. Slides were labeled with the date and 
placed in a slide rack, then placed into 3 consecutive xylene baths to remove 
paraffin wax from the sample slides. Next, slides were exposed to 3 industrial 
denatured alcohol baths for 3 minutes each to remove excess xylene residue. In 
order to rehydrate the samples, slides were placed into water. 10ml of High pH 
Antigen Unmasking solution was placed into a plastic bucket with 1000ml of ddH20, 
and heated in the microwave for 10 minutes on high power. Slides were transferred 
into the preheated solution and placed back in the microwave for a further 20 
minutes on high power, which was followed by a 10 minute cooling incubation. This 
step was performed in order to expose antigens prior to antibody staining. Slides 
were transferred into the dehumidifier box where wax pen was used to enclose the 
tissue sample. Slides were then washed in Tris buffered saline, pH7.6 (TBS) for 5 
minutes before being ready to immunostain. 
 
?????? ? ????????????????????????????????????????????????????????????????
????????
?
In order to investigate the localization of liver-enriched CD19+CD24- B cells, double 
stains were performed on sections of liver from various end-stage hepatic diseases. 
All the reagents used are listed in Table 17 and 18. Following preparation as 
described in 2.5.1., 2 drops of Bloxall blocking solution was added to each slide and 
incubated for 10 minutes. Samples were washed in TBS for 5 minutes, followed by a 
10 minute incubation with 2% casein (diluted from a X10 solution). Following 
incubation, CD24 primary antibody was prepared to a concentration of 5 x 10
-2
mg/ml 
? ???
in PBS and 100μl was applied to each slide before being left for a 30 minute 
incubation. PBS diluent ensured antibody stabilization and ensured full coverage of 
the tissue section.  
Samples were washed twice in TBS for 5 minutes, before 2 drops of Amplifier 
Antibody (secondary antibody) was applied to each slide for 15 minutes, which 
increases sensitivity and specificity of antibody detection. Slides were then washed 
in TBS again for 5 minutes, following which ImmPRESS Excel Reagent (tertiary 
antibody) was applied and allowed to incubate for 30 minutes. The tertiary antibody 
is coupled to horseradish peroxidase micropolymers which binds to the secondary 
Amplifier Antibody. Another two 5 minute TBS washes were conducted to wash 
away unbound secondary antibody and to disrupt weak interactions to non-specific 
sites. ImmPACT DAB chromogen dye was then produced following the 
manufacturers guidelines, with the addition of nickel and applied to each slide for 5 
minutes. The slides were again washed twice in TBS for 5 minutes each time, before 
being incubated with the 2% casein solution for 10 minutes. The second primary 
antibody (anti-CD79α) was then prepared to a concentration of 2.5 x 10-3mg/ml, and 
100μl was applied for 1 hour. Subsequently, sample slides were washed with TBS 
for 5 minutes, followed by the addition of Amplifier Antibody for a further 15 minutes. 
The slides were again washed in TBS for 5 minutes, after which ImmPRESS Excel 
Reagent was applied and allowed to incubate for 30 minutes. Unbound secondary 
antibody was again washed off with two 5 minute TBS washes. ImmPACT NovaRED 
chromagen dye was prepared following manufacturers guidelines and applied to 
each slide for a further 5 minutes. The slides were again washed in TBS for 5 
minutes, before being dismounted from the sequenza and placed in a water filled 
coplin jar. The process was finalised as stated in section 2.5.5. 
? ???
?
?????? ? ????????????????????????????????????????α??????? ??????????
??????????????????????????????????
?
Triple staining was performed using the same slide preparation procedure as 
described in 2.5.1, with all reagents used listed in Table 17 and 18. Double staining 
to locate CD24- B cells was performed as in 2.5.2., however on this occasion both 
casein blocks were performed for 5 minutes, and primary antibodies were incubated 
for 30 minutes. After the ImmPACT NovaRED chromagen addition of the double 
stain, a 5 minute TBS wash was performed, followed by a 5 minute casein block. 
The third primary antibody (Ki67/CD31/P-selectin) was added to the slides at a 
dilution specified in Table 18. Subsequently, sample slides were washed with TBS 
for 5 minutes, followed by the 100μl addition of ImmPRESS-AP Anti-Mouse IgG 
(alkaline phosphatase) secondary antibody for a further 30 minutes. Another two 5 
minute TBS washes were conducted to wash away unbound secondary antibody. 
StayGreen Alkaline Phosphatase chromagen was then prepared and used according 
to the manufacturers instructions and applied to sample slides for 20 minutes. To 
finalise the triple immunostaining, slides were subjected to rapid dehydration in 
absolute ethanol twice for 30 seconds. Slides were then exposed to CellPath 
ClariTech XTF Clearing Agent for 5 minutes before being mounted using CellPath 
ClariTech XTF Mounting medium. These sections were left to dry overnight before 
being scanned via the Zeiss Axio Scanner and analysed via the Zen Blue software.  
 
 
 
 
? ???
?????? ? ?????????????????????????????????????????????????????????????????
??????
?
B cell aggregates were categorized according to their surface expression of 
surface markers into three groups: Lymphoid aggregates, B cell follicles and 
tertiary lymphoid structures. Lymphoid aggregates can be characterized as an 
aggregation containing both clustered B cells and a dense T cell population. B 
cell follicles are rich in B cells however lack substantial evidence to be 
characterized as a tertiary lymphoid structure. A tertiary lymphoid structure is a 
follicle, which has supporting evidence of an ongoing GC reaction. Single staining 
using Bcl-2, CD20 and CD3 primary antibodies were performed (See Table 18) 
on serial section slides from each patient and compared to staining from other 
hepatic diseases, as well as positive and negative controls. Interpretation of this 
staining into the three B cell aggregation phenotypes is demonstrated in Table 
19.   
?
Table 19 - Surface staining expression for identification of three B cell aggregate phenotypes. 
+: Moderate staining ++: Strong positive staining - :Absent staining  
 
 
 Lymphoid aggregate B cell follicle Tertiary lymphoid 
structure 
CD20 + ++ ++ 
CD3 ++ + + 
Bcl-2 +/++ +/++ - 
?
 
 
 
 
 
? ???
This phenotypic classification was used to quantify the distribution of B cell related 
aggregates from HCV, PBC, ALD and NASH patient cohorts with n=10 patients for 
each disease. B cell aggregates were enumerated manually using a clicker counter. 
Use of graphic labeling prevented recounting of the same aggregates. Numerical 
data was then converted into a ratio to the surface area of the entire tissue section 
image. Surface area was calculated using Zen graphics software, where careful free 
hand drawing was used to outline tissue borders, allowing the subsequent surface 
area to calculated by Zen. This same quantification method was applied throughout 
the investigation. Proportions of each B cell aggregate phenotype were calculated as 
a percentage of total B cell aggregate numbers for each tissue sample, to allow 
comparisons between and within hepatic diseases. 
?
???????? ? ???????????????????????????????????????????????????????????
????????????????????????
?
In order to investigate the localization of B cells and tertiary lymphoid structures in 
the liver, single stains were performed on serial sections of liver tissue from ALD, 
NASH, PBC and HCV end-stage hepatic disease sections. All the reagents used are 
listed in Table 17 and 18, following preparation as described in 2.5.1. 2 drops of 
Bloxall blocking solution was added to each slide and incubated for 10 minutes. 
Samples were washed in TBS for 5 minutes, followed by a 10 minute incubation with 
2% casein (diluted from a X10 solution). Following the casein block, 100μl of primary 
antibody diluted in PBS (CD20/CD3/Bcl-2) (See Table 18) was pipetted onto the 
tissue and incubated for 1 hour. Samples were subsequently washed twice in TBS 
for 5 minutes, before 2 drops of secondary Amplifier Antibody was applied to each 
slide for 15 minutes. Slides were then washed in TBS again for 5 minutes, following 
? ???
which the tertiary antibody, ImmPRESS Excel Reagent, was applied and allowed to 
incubate for 30 minutes. Another two 5 minute TBS washes were conducted to wash 
away unbound secondary antibody. Following the washes. ImmPACT DAB EqV was 
added, which is an equal part mixture of chromagen and buffer. 100μl was added to 
the tissue for 5 minutes to allow a sufficient staining intensity to develop. The slides 
were then prepared following this immunostaining to prepare the slides as described 
in 2.5.5. 
 
?????? ????????????????? ???????????????????????????
A series of steps need to be performed following immunostaining in order to 
complete the protocol and finalise the preparation. Following the water wash, 
Mayer’s Haemotoxylin was used to counterstain slides for 30 seconds. This stains 
the nucleus and acts as an aid for the interpretation of immunostaining. Following 
this, slides were immersed in cold water for 2 minutes followed by hot water for a 
further 2 minutes. Absolute ethanol was then added to the slides for 20 seconds 
before being poured off. This step was repeated again for 40 seconds. Finally, slides 
were placed into xylene for a further 3 minutes. A resin based mounting media, DPX 
was then added to the center of a coverslip which was placed over the top of each 
section to create a final preparation. These sections were left to dry overnight before 
being scanned via the Zeiss Axio Scanner and analysed using the Zen Blue 
software. 
 
 
?
? ???
?????? ?????????????????????????????????????
CD20 expression was investigated through DAB staining of paraffin embedded PBC, 
PSC, ALD, NASH and HCV liver specimens. Following slide scanning, computer 
assisted quantification of positively stained (brown) cells was performed through use 
of single colour threshold analysis using ImageJ software. Detection of a single 
colour on an image permitted the subsequent calculation of the percentage area of 
the entire image, which the positive stain occupies. This process was repeated 
across 10 fields of view to yield an average percentage area of CD20+ staining. 
Dimensions and colour thresholds of the images were kept consistent throughout. 
The overage percentage area of CD20+ staining in all patients was compared 
between diseases.  
?????? ????????????????????? ????????????????
Positive controls for primary antibodies were performed in tonsil sections due to this 
secondary lymphoid organ being enriched in B cells. Isotype-matched controls are 
negative controls which assist in detection of primary antibody background staining 
as a result of non-specific interaction between the primary antibody and Fc receptors 
in the tissue. Isotype control antibodies are matched to the species and antibody 
class of the primary antibodies used and therefore will stain non-specific Fc 
receptors for that class to highlight false positive staining. In this project, mouse and 
rabbit IgG isotype control antibodies were used to stain a representative proportion 
of tissue samples from the patient cohort. Concentration of isotype antibodies was 
calculated to match that of primary antibodies. 
? ???
?????? ?????????????????????????
The Zeiss Axio Scanner enabled entire sections of stained tissue to be scanned and 
photographed under a high power magnification (x20). Using this method meant that 
the entire tissue could be examined thoroughly in opposed to a small region of 
interest. After scanning the tissue, it was possible to zoom into the image at an even 
higher magnification which was essential in analyzing the localization of single cells 
which were either total B cells (CD79α+) or CD79α+CD24- with a high degree of 
accuracy.  
?
?
?
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2.6. STATISTICAL ANALYSIS 
?
?
Statistical analysis was conducted using GraphPad Prism software. Non-parametric 
statistical tests were performed in cases where when assumptions of a normal or 
Gaussian distribution could not be tested, permitting the calculation of statistical 
significance without assuming normal distribution of data. This included all B cell 
phenotype assays including the quantification of total B cells, B cell subsets, 
cytokine producing B cells and ABCs. It also included CD20+ IHC staining. Due to 
the donor liver not being completely representative of a ‘healthy liver’, significant 
differences in B cell numbers or percentages were analysed in all experiments 
across end stage liver diseases using a non-parametric One-way ANOVA test 
(Kruskal-Wallis test). This is with the exception of where two specific data sets were 
being compared, in which case an unpaired non-parametric t-test was used with a 
Mann-Whitney test. Data are shown as the mean ± standard deviation % unless 
otherwise stated. 
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3.1. INTRODUCTION 
?
?
Although data suggests that 5–10% of lymphocytes in the human liver are B cells (5) 
(391, 392), the exact phenotype and role of intrahepatic B cells and B cell subsets 
still remains to be thoroughly elucidated.  
 
The significance of human liver B cells in the presence and absence of hepatic 
disease is so far uncharted, however, B cells in mice have been found to contribute 
to liver inflammation and fibrosis. B cell depletion has been found to effectively 
promote the remission of liver inflammation in a mouse model of type 2 autoimmune 
hepatitis (58). Furthermore, depletion of B cells in a mouse model of CCl4-induced 
liver injury demonstrated significantly reduced collagen deposition in comparison to 
non-B cell depleted mice suffering from hepatic fibrosis over a 6-week period (282). 
Further findings demonstrated that the potential B cell contribution to fibrosis is 
antibody and T cell-independent, causing further speculation that other factors such 
as cytokines could be involved (282). However, no studies since have supported 
these results. Another mouse study indicated that HSCs initiate an immune 
regulatory role by influencing B cells to become pro-fibrogenic via retinoic acid 
signaling (393). CD40 induced B cell activation has also been identified as key in 
promoting a necro-inflammatory response in murine livers through IFN-γ and TNF-α 
dependent mechanisms (394).  
In recent years various studies have implicated B cells in the pathogeneses and 
subsequent development of specific human chronic liver diseases. A recent patient 
study showed that quantities of intrahepatic CD20+ B cells positively correlated with 
ALT, AST, ALP and GGT levels, as well as with increased liver inflammatory grades 
? ???
(287). This emphasised that B cells may play a pathological role in hepatic 
inflammation across chronic liver diseases. However, the proportion of B cells found 
in liver inflammation were found to bear no association with increased liver fibrosis 
(287).  
Other studies have highlighted that B cells play a role in viral hepatitis. Conflicting 
immunohistochemical findings from another human study, showed a positive 
correlation between intrahepatic IgD+ B cells and the degree of liver fibrosis in HBV 
patients (296). This correlation could be explained by B cells producing the 
profibrotic cytokine IL-6, which may contribute to fibrosis by enhancing HSC 
differentiation and collagen synthesis In HBV patients (395). Naïve B cells have 
been shown to take up Hepatitis B core antigen (HBcAg) and present them to T 
helper cells whilst simultaneously expressing co-stimulatory molecules CD80 and 
CD86 (395). HBcAg has also been found to promote IgM antibody production by B 
cells via a T cell-independent mechanism (396, 397). Conversely, clinical studies 
indicate that B cell depletion via rituximab in HBV infection resulted in latent HBV 
reactivation in a cohort of patients suffering from B cell lymphoma (398). Disease 
flares and poor CD8+ T cell responses have been associated with an enriched 
population of IL-10 producing B cells. It is possible that this correlation causes the 
suppression of anti-HBV CD4+ T helper cells and CD8+ T cells (399). HCV infection 
has been found to cause B cell activation and B cell subset bias (400). A risk factor 
for lymphomas, lymphoproliferative disorders and B cell dysregulation, HCV also has 
the capacity to infect B cells directly, permitting viral replication within and evasion of 
antiviral interferon responses (401). The virus enters the B cells through interactions 
? ???
with the HCV E2 envelope protein and B cell CD81, which subsequently leads to 
hepatocyte transinfection with boosted infectivity (402).  
B cell participation in autoimmune disease has been evidential. As well as the 
involvement of B cells in antigen presentation to autoreactive T cells, autoreactive B 
cells are central to the pathogenesis of PBC through the production of anti-
mitochondrial antibodies (AMAs). Murine study findings have linked high frequencies 
of plasma cells in portal aggregates with autoimmune inflammatory diseases such as 
PBC (225, 403). Supporting findings show that genetically, B cell deficient mouse 
models of autoimmune cholangitis demonstrate reduced biliary cystic changes and 
hepatic inflammation compared to controls (404). In AIH and PBC patients, B cell 
depletion with rituximab treatment resulted in improved outcomes (30, 31). One AIH 
mouse model demonstrated reduced liver inflammation and improved liver function 
following treatment with a single dose of anti-CD20 antibody (58). As AIH is a 
primarily T cell-mediated disease, this effect was speculated to be due to the 
consequential reduction in T cell populations and activation in the liver. 
Despite previous studies highlighting B cell contributions to autoimmune liver 
diseases, one study involving B cell depletion via anti-CD79α and anti-CD20 in mice 
with PBC, produced conflicting results. Depletion of B cells in this study was 
associated with the release of superoxides (IL-6), TNF-α production, enhanced T cell 
liver infiltration and disease exacerbation compared to controls (405).  
 
Collectively, these murine and human studies indicate that hepatic B cells may play 
a role across end stage liver disease and may possibly have different characteristics 
to B cells elsewhere in the body. Establishing whether specific human B cell subsets 
? ???
contribute to, or prevent defined hepatic diseases, could lead to therapeutic targeting 
of B cells in the future to treat liver disease. I hypothesize that the human liver 
contains a range of defined B cell subsets, and that distinct disease across liver 
conditions possess unique B cell signatures reflecting relevant populations in the 
liver. 
 
Chapter objectives.  
To understand the role of B cells and B cell subsets in chronic liver disease, I 
designed experiments: 
1. To isolate and quantify total B cells and B cell subsets from human livers and 
compare to the B cell compartment in blood and SLO using flow cytometry. 
2. To establish B cell subset bias by quantifying B cell subsets across end stage 
hepatic disease livers. 
3. To investigate and characterize B cell aggregates in the liver using 
immunohistochemistry. 
 
 
 
 
 
 
 
 
 
?
? ???
3.2. RESULTS 
?????? ??????????????????????????????????????????????????????????????
?
Little is known regarding the human liver B cell subset composition. I first asked 
whether the B cell subset profile in the liver differed in comparison to blood, as 
strong differences between liver and blood may further highlight the functional role of 
B cells in the liver. I aimed to obtain livers from patients suffering from a range of 
chronic end stage hepatic diseases (See Table 20) from The Queen Elizabeth 
Hospital Birmingham, and isolate LIMCs. Isolation of LIMCs aided in my 
investigation on hepatic B cells in vivo, allowing me to stain for B cell subset markers 
to make quantitative comparisons across chronic liver diseases. Occasionally donor 
liver tissue was also donated for research purposes. However these tissues were 
usually rejected for transplant due to the presence of underlying disease aetiologies 
and normal healthy tissue was only obtained in rare cases of surplus tissue to 
requirements at the time of transplantation. PBMCs were isolated from matched 
patient blood on a density gradient using the method outlined in 2.3.2. Following 
PBMC and LIMC isolation from blood and liver respectively, B cells were surface 
stained for three eight-colour panels of phenotypic markers, to identify and quantify 
11 B cell subsets, allowing comparisons of the B cell subset profiles to be made 
between blood and liver. Obvious differences in B cell profiles between liver 
diseases and patient blood could highlight biological markers uniquely found on 
hepatic B cells, aiding in the deployment of new diagnostic measures in the future. 
Furthermore, identifying whether some B cell subsets are present in liver tissue 
within certain hepatic diseases and absent in others, or whether some B cell subsets 
may be enriched or reduced in specific hepatic diseases, would hint towards a 
possible role of B cells in disease progression or prevention.  
? ???
?
?Table 20 - The main disease aetiologies of liver explants and their respective abbreviations. 
Explants were obtained and used routinely to isolate B cells in this study at the Centre for 
Liver Research, University of Birmingham. 
 
Abbreviation  Disease 
ALD Alcoholic Liver Disease 
NASH Non-alcoholic Steatohepatitis 
NAFLD Non-alcoholic fatty liver disease 
PBC Primary Biliary Cirrhosis 
PSC Primary Sclerosing Cholangitis 
Donor Tissue from rejected donor liver  
HCC Hepatocellular carcinoma 
HCV Hepatitis C Virus 
HBV Hepatitis B Virus 
Other Genetic disorders (e.g. polycystic liver 
disease) and enzyme deficiencies (e.g. α1 
anti-trypsin. 
?
?
?
?
?
?
?
?
?
?
?
?
?
?
? ???
Comparing B cell profiles highlighted differences in the proportions of specific 
subsets present between the blood and liver (Fig. 18). In particular, double negative 
memory B cell populations were found to be significantly enriched in the liver 
compared to matched patient blood, (double negative memory: 27.0±14.7%, double 
negative memory blood: 8.5±5.1%, where p=0.008). Conversely, naïve B cell 
populations were more significantly enriched in the blood compared to in the liver 
(naïve liver: 38.2±13.8% and naïve blood: 62.0±11.1% where p=0.003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
? ???
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Figure 18 – The B cell subset profile in patient blood differs to that of matched 
liver from chronic end-stage liver disease patients. (A) Subset profiles of naïve 
(CD19+CD27-IgD+), switched memory (CD19+CD27+IgD-), non-switched memory 
(CD19+CD27+IgD+) and double negative memory (CD19+IgD-CD27-) B cell 
populations in matched blood and liver from patients suffering from chronic liver 
disease. Data is representative of n=7. (B) Subset profile of Transitional/Breg 
(CD19+CD24hiCD38hi), B10-type (CD19+CD1dhiCD5+), plasmablasts 
(CD19+CD38hiCD27+CD138-), and plasma cells (CD19+CD38hiCD27+CD138+) 
where data is representative of n=7, as well as  ‘human B1-type’ (CD19+CD70-
CD43+CD27+), centroblasts (CD19+CD77+) and centrocytes (CD19+CD77-
CD38+IgD-) where data represents n=4 independent repeats. Data is expressed as 
a percentage of total CD19+ B cells. Statistical comparison was executed to 
compare blood and liver groups using multiple t tests correcting for multiple 
comparisons using the Holm-Sidak method in (A) and non-parametric Mann-Whitney 
t tests in (B). Significant differences between blood and liver are highlighted by the p 
values on the graphs, where P<0.05. 
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After observing that some B cell subset profiles differed in proportions between 
matched blood and liver samples, I then sought to identify whether blood and liver B 
cells were qualitatively different. To address this question I investigated surface 
immunoglobulin expression in memory B cells. Memory B cells (CD19+CD27+IgD-) 
contained different isotype distributions in matched patient blood and liver (Fig.19). 
For this approach, LIMCs and PBMCs isolated from the liver and blood respectively 
were surface stained for the B cell marker CD19, along with memory markers  
(CD27+IgD-) and isotype markers (IgA/IgG/IgM). Data was collected by running 
stained B cells through the flow cytometer, after which it was analysed using FlowJo 
software. All isotype staining was expressed as a percentage of memory B cells.  
 
The percentage of IgA+ memory B cells was significantly enriched in the blood 
compared to the matched liver samples (blood: 46.8±16.5% and liver: 10.8±4.3% 
where p=0.005), and that the liver contained a significantly higher percentage of 
IgG+ memory B cells compared to matched blood (liver: 16.3±10.4% and blood: 
2.0±1.3% where p=0.03). This demonstrated that the memory B cell compartment in 
liver differed to that of blood, and further highlighted the overall difference in the B 
cell compartment between the two. 
 
 
?
? ???
????????????????????? ?
?
Figure 19 – Switched memory B cells in liver have a different isotype 
distribution to those in blood. Percentages (%) of IgA+, IgG+, and IgM+ 
CD19+IgD-CD27+ memory B cell populations in the total CD19+ subset of matched 
blood and chronic diseased liver patient samples. Data is representative as n=4, 
except in the case of IgM where n=7. Statistical comparison was executed to 
compare blood and liver groups using multiple t tests correcting for multiple 
comparisons using the Holm-Sidak method. Significant differences between blood 
and liver are highlighted where p<0.05. 
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In order to further understand the human hepatic B cell compartment, hepatic B cell 
subsets were compared to those present in the blood and secondary lymphoid 
organs (SLOs) such as hepatic mesenteric lymph nodes. To perform this 
investigation PBMCs and LIMCs from blood and liver were stained for total B cells, 
naïve mature B cells (CD19+CD27-IgD+) and memory B cells (CD19+IgD-CD27+) 
(Fig. 20). Mononuclear cells were extracted from SLOs via mechanical digestion 
using the GentleMACs as described in 2.4.1. prior to being stained using the same 
technique.  
 
Findings from this experiment indicated that the frequencies of CD19+ B cells in the 
liver were comparable to the total percentage of CD19+ B cells located in the blood 
(Fig. 20A). However, comparisons in the subset composition of the B cell 
compartment between blood, liver and secondary lymphoid tissues demonstrated 
that the subset composition of hepatic B cells (naïve and memory) were qualitatively 
more similar to SLOs, as both groups contained a higher proportion of memory B 
cells and a lower proportion of naïve B cells compared to blood (Fig. 20B & C). 
 
 
                         
? ???
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 – The composition of B cells in the liver was more similar to that of 
secondary lymphoid organs (SLO) compared to human blood. (A) CD19+ B 
cells as a percentage of total mononuclear cells, (B) percentage of naïve (CD27-
IgD+) CD19+ B cells and   (C) percentage of memory (CD27+IgD-) CD19+ B cells in 
Blood, SLO and liver respectively. Blood was represented by healthy donors, 
haemochromatosis patients and chronic liver disease patients (CLD) where n=4, n=8 
and n=16 respectively. Liver was represented by donor livers and CLD patients 
where n=9 and n=75. Liver and blood samples in this data set are unmatched. 
Whiskers are representative of min and max values.   
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Following the understanding that the hepatic B cell compartment bears some 
similarities with B cells in SLOs, the next question was whether the B cell 
compartment differed between patient livers with various aetiologies. Answering this 
question could also be pivotal in establishing whether B cells may have a role in 
specific end stage hepatic diseases. To address this, LIMCs were isolated from 
various end stage chronic diseased livers and surface stained with a total of 18 
surface markers to allow the phenotypic characterization and the subsequent 
quantification of 11 B cell subsets as in the first figure of this chapter (Fig. 18A & B).  
 
PBC liver explants contained a higher number and percentage of total B cells 
compared to donor livers and end stage liver diseases (Fig. 21A). All other diseases 
were comparable to donor livers. Results indicated that B cell subsets in liver 
diseases of various aetiologies were similar in proportions and absolute numbers 
(Fig 21B & C). This is with the exception of the proportion of naïve mature B cells 
per gram of tissue, which were significantly higher in PBC liver explants compared to 
donor livers (PBC: 10365±9419% and donor: 1358±1253% where p=0.02) (Fig. 
21C). 
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Figure 21 – B cell subsets are similar in proportions and absolute numbers 
across chronic liver diseases, with the exception of naïve B cells in PBC. (A) 
The percentages (%) and the absolute number of total CD19+ B cells across chronic 
hepatic diseases and (B) The percentages (%) of B cell subsets across Donor, PBC, 
PSC, NASH, ALD, Viral and Other livers (n=9, 12, 17, 12, 27, 10 and 13 
respectively), except for centroblasts, centrocytes and b1-types (n=7, 9, 10, 9, 16, 7 
and 6 respectively). (C) The absolute number of B cell subsets across in Donor, 
PBC, PSC, NASH, ALD, Viral and Other livers (n=8, 9, 13, 9, 19, 9 and 6 
respectively), except in the case of centroblasts, centrocytes and b1-types (n=6, 8, 
9, 8, 16, 7 and 6 respectively). Error bars represent the mean and standard 
deviation. A one-way non-parametric ANOVA (Kruskal-Wallis test) was conducted to 
compare the means across hepatic diseases. Significant differences are displayed 
where p<0.05.  
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3.2.3. ???????????????????????????????????????????????????????????????? 
 
To assess the distribution of B cells within the liver architecture, IHC stains were 
performed on human liver sections from end stage hepatic disease patients using 
anti-CD20 (as described in 2.5.) (Fig.22A-G). Use of anti-CD20 resulted in detection 
of all B cells with the exception of plasmablasts and plasma cells, where the CD20 
marker is downmodulated. Following the staining procedure, the sections were 
scanned and 10 random pictures were taken per field of view. The percentage area 
of CD20+ DAB stain was calculated before values for each hepatic disease (ALD, 
NASH, PBC, PSC, HCV) were averaged and plotted (Fig.22G). To confirm the 
validity of the B cell stains, human tonsil was used as a positive control and isotype 
matched controls used as negative controls on human liver tissue sections (Fig. 
22E&F).  
 
Results from B cell IHC quantification corroborated findings from the flow data, 
demonstrating that total B cells were elevated in PBC (Fig.22G & 22A). IHC staining 
further highlighted that the proportion of CD20+ B cells in PBC were significantly 
higher compared to those present in PSC (PBC: 1.72±1.46% and PSC: 0.2±0.18% 
where p= 0.014) (Fig. 22G). 
? ???
 
 
?
Figure 22 – B cells localize across the liver architecture and are enriched in 
PBC. IHC staining demonstrating the presence of CD20+ B cells (A) aggregating 
around bile ducts (PBC), (B) around portal veins (PBC), (C) in lobular areas (HCV) 
and (D) within the fibrotic septa (HCV). All images with taken at 10x magnification 
with 44%, 16%, 10%, 15%, 17% and 10% zoom respectively. (E) CD20+ staining 
control in human tonsil (F) CD20 isotype matched control (negative control) in 
human PBC liver section (G) The enumeration of total B cells in liver diseases of 
various aetiologies. CD20+ stains are represented as a percentage (%) of the total 
area. Patient sample values are additionally plotted with error bars representing the 
mean and standard deviation, where n=10. All statistics were performed as a one-
way non-parametric ANOVA (Kruskal-Wallis test) comparing the mean of each 
hepatic disease with the mean of every other hepatic disease. Significant differences 
are displayed on the graphs where p<0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
PB
C
PS
C
AL
D
NA
SH HC
V
0
2
4
6
%
 A
re
a 
of
 C
D
20
+ 
p=0.014
? ?
? ?
????? ????
???? ????
?
????
?
????
? ???
B cell aggregates have previously been reported and characterised to a great extent 
in HCV patients, however there are no qualitative or quantitative comparative data 
across liver diseases. To further investigate the frequency of B cell aggregates in 
end stage hepatic diseases, IHC stains were performed on liver sections from 
chronic liver disease patients using CD79α, which is a pan-B cell marker and is 
associated with the surface BCR. B cell aggregates were quantified in a cohort of 
n=77 patients comprising of 67 patients with end stage chronic liver disease (ALD, 
NASH, PBC, PSC, AIH, HCV and HBV) and 10 donor liver samples. This method of 
quantification is outlined in 2.5.4.1.  
On average, patients suffering from chronic HCV demonstrated the highest 
frequency of aggregates per unit area of tissue, followed closely by PBC (Fig. 23B). 
Statistical comparisons of the data highlighted that PBC liver sections contained a 
significantly higher frequency of B cell aggregates in comparison to NASH and donor 
livers (PBC: 3.236e-008±2.098e-008%, NASH: 4.734e-010±1.497e-009% and 
donor: 3.873e-009±1.068e-008%, where p=0.007 and p=0.03 respectively), which 
was also true for HCV livers compared to NASH and donor patients (HCV: 6.653e-
008±5.006e-008% where p=0.0001 and p=0.0009 respectively). This data 
highlighted variation in B cell aggregate frequencies across patients suffering from 
different end-stage chronic liver diseases.  
 
 
? ???
 
 
 
Figure 23 – Proportions of B cell aggregates vary between end stage hepatic 
diseases. (A) x10 magnification of a HCV liver demonstrating the presence of 
several B cell aggregates in the liver. CD79α+ B cells were visualised by DAB 
staining shown in brown and highlighted by the arrowheads. (B) Quantification of B 
cell aggregates identified by CD79α IHC staining across liver diseases of various 
aetiologies n=77. Error bars are representative of the standard deviation and mean. 
Significant differences are represented as P<0.05*, P<0.01**, P<0.001*** 
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To investigate the presence of tertiary lymphoid structures beyond autoimmune and 
viral hepatitis, serial sections from an ALD liver were stained with tertiary lymphoid 
markers for CD19 (B cells), CNA42 (FDC marker) and a marker of proliferation 
(Ki67) (Fig. 24). This work was performed by Rebecca Smith (BMedSci) in our 
laboratory.  
 
Results from this stain indicated that certain lymphoid aggregates presented 
characteristics similar to that of a tertiary lymphoid structure. As well at the entire 
follicle staining positive for the presence of CD19+ B cells, the presence of FDCs 
and high endothelial venule-like structures (HEV) were also detected. The positive 
staining for Ki67 on half of the follicle also demonstrated the presence of 
proliferation, highlighting a possible light and dark zone within the aggregate.  
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Figure 24 – GC-like structure in an Alcoholic Liver Disease (ALD) patient. 
Immunohistochemical staining of a hepatic follicle with evidence of a GC-like 
structure (a tertiary lymphoid structure) in a patient with ALD. CD19; B cell marker, 
FDC: FDC marker; CNA42, Ki67; dark zone proliferation marker. DZ: Dark Zone, LZ: 
Light Zone. Figure from Rebecca Smith (BMedSci). 
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The phenotypic characterization of B cell aggregates involves categorization into 
three distinct groups: lymphoid aggregates, B cell follicles and tertiary lymphoid 
structures. Distinctions between these groups were predominantly defined by three 
antigens: the B cell antigen CD20, the T cell antigen CD3 and the anti-apoptotic 
protein Bcl-2 (Fig. 25). Bcl-2 is an anti-apoptotic protein, and their absences is 
important in the identification of GC-like structures, as GC B cells downregulate the 
expression of Bcl-2 protein and are therefore more prone to apoptosis in order to 
eliminate autoreactive and low-affinity B cells (110).  
Lymphoid aggregates contain a mixed population of T and B cells and consequently 
are known to present with high levels of CD3+ staining within the aggregate, with low 
to moderate staining for CD20 and Bcl-2. B cell follicles present with a more dense 
aggregation of B cells, and contain fewer T cells than a lymphoid aggregate (Fig. 
25B). These follicles resemble primary follicles usually located in SLOs, and are rich 
in CD20 and Bcl-2 positive cells with a low to moderate positivity of CD3 staining, 
making these structures distinct from GC structures (Fig. 25C). Tertiary lymphoid 
structures bear close resemblance to organized GC-like structures. Their phenotype 
can be described as rich in CD20, with moderate to low aggregates of CD3. Unlike in 
lymphoid aggregates and B cell follicles, GC B cells (tertiary lymphoid structures) 
lack Bcl-2 expression, which is otherwise located on other B and T cell subsets. 
Therefore, tertiary lymphoid structures contain a significant proportion of clustered 
Bcl-2 negative cells. Positive staining for Ki67 represents the presence of 
proliferation and is therefore also indicative of a GC-like follicle (Fig. 25D).  
 
 
? ???
To investigate the distribution of B cell aggregates in end stage chronic liver 
diseases, phenotypic and quantitative analysis was performed on B cell aggregates 
in HCV, PBC, ALD and NASH livers (n=10 per disease). The IHC staining system for 
identifying the three B cell aggregate subgroups (described above) permitted the 
identification and subsequent quantification of B cell aggregates into lymphoid 
aggregates, B cell follicles and tertiary lymphoid structures. Percentages of lymphoid 
aggregates, B cell follicles and tertiary lymphoid structures out of total B cell 
aggregates were then normalized to surface area prior to investigating and 
calculating differences in these three aggregates between diseases.  
Results demonstrated that between liver diseases, lymphoid aggregates in ALD and 
NASH suffers demonstrated the highest mean percentages of approximately 77% 
and 73% respectively in comparison to HCV and PBC (55% each) (Fig. 25E). 
Similarly, the mean percentage scores for the presence of B cell follicles in PBC and 
HCV were 44% and 42% respectively, in comparison to 22% and 27% respectively 
in ALD and NASH patients (Fig. 25F). PBC suffers demonstrated the highest mean 
percentage for tertiary lymphoid structures (4%), compared to ALD (3%), HCV (2%) 
and NASH (0.5%) patients (Fig. 25G). All these differences however, did not present 
with statistical significance, thereby denoting any obvious similarities between these 
diseases. 
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Figure 25 – Lymphoid aggregates, B cell follicles and tertiary lymphoid 
structures exist in liver. (A) Positive control staining in human tonsil where CD20 
staining depicts a germinal center, CD3 staining of a T cell area within a follicle and 
Bcl-2 staining in extrafollicular areas surrounding a germinal center follicle. 
Remaining IHC staining highlights examples of (B) lymphoid aggregates, (C) B cell 
follicles (D) tertiary lymphoid structure through CD20, CD3 and Bcl-2 staining. Each 
row is representative of the same aggregate from serial sections of a tissue sample 
from a single patient. Successful Ki-67 staining was demonstrated within the dark 
zone of a tertiary lymphoid in one patient. Lymphoid aggregates were identified as 
rich CD3 positivity relative to CD20, with Bcl-2 positivity. B cell follicles were 
identified as rich CD20 and Bcl-2 positivity relative to moderate or low CD3 positivity. 
Tertiary lymphoid structures were identified as an aggregate rich in CD20 positivity 
over a corresponding clustered area of Bcl-2 negativity, whilst CD3 staining may be 
variable. Images were taken at x5 magnification and scanned from a Zeiss Axio slide 
scanner. Figure from Bardia Guevel (BMedSci). Percentages (%) of (E) lymphoid 
aggregate, (F) B cell follicle and (G) tertiary lymphoid structures of total B cell 
aggregates per m2 for n=10 of HCV, PBC, ALD and NASH. Error bars represent the 
mean and standard deviation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
??? ??? ???
HCV PBC ALD NASH
0
20
40
60
80
100
HCV PBC ALD NASH
0
20
40
60
80
100
HCV PBC ALD NASH
0
20
40
60
80
100
??
???
??
???
???
???
??
???
?
???
??
?
??
???
???
???
????
???
???
??
?
??
??
???
???
???
??
???
?
???
??
???
???
??
??
? ???
3.3. DISCUSSION 
?
The B cell compartment in the human liver has never been characterised or 
quantified in depth. However B cells have actively been found to play a role in 
hepatic disease, such as in autoimmune mediated diseases like PBC and viral 
mediated diseases like HCV. This highlights the necessity to investigate the B cell 
compartment in human liver further, as enrichment of specific B cell subsets in the 
presence of defined chronic liver disease could be an indicative of B cell mediated 
pathogenesis or B cell mediated protective responses in the liver. Furthermore, 
identifying the role of B cells in the liver could highlight a target, which could be 
manipulated therapeutically in the future to prevent hepatic disease progression. 
Numerous B cell subtypes have previously been characterized in human peripheral 
blood. In this chapter, I sought to identify B cell subsets in human blood before 
confirming whether the same subsets were present in human livers.  
Formerly, human B cells were characterized in tonsil using the Bm1-Bm5 
classification system using CD19, IgD, CD38 and CD27 antigens. These markers 
were used to identify naïve cells (Bm1: IgD +CD38−); activated naïve cells (Bm2: 
IgD+CD38lo); pre-GC cells (Bm2′: IgD+CD38++); GC cells (Bm3-centroblasts), 
centrocytes: (Bm4-IgD-CD38++); and memory cells (Bm5: IgD-CD38+/−) (140) (144) 
(138). More recently, alternative marker combinations have been used to phenotype 
B cell subsets in human tonsil and blood (139, 406). These include: Bregs 
(Transitional/B10) (93), switched memory B cells (IgD-CD27+) (407) naïve B cells 
(IgD+CD27-) (139) and less well described subsets such as marginal zone B cells 
(non-switched memory) (IgD+CD27+) (195) and human ‘B1-type’ cells 
(CD20+CD70-CD43+CD27+) (386). Human B cell characterisation is less well 
? ???
established compared to murine B cell subsets, therefore it is unsurprising that 
conflicting views exist on how to definitively phenotype B cell subsets in humans. 
The first part of this chapter involved the consolidation of findings from existing 
studies, to organise three eight-colour flow cytometry panels to identify over 11 B cell 
subsets in human peripheral blood. The presence of all 11 B cell subsets were 
confirmed in peripheral blood, after which the same panels were used to confirm the 
presence of these B cell subsets in human liver. Direct comparisons were then made 
in B cell subsets within human peripheral blood vs. human liver using matched 
patient samples.  
Data from Figure 18 demonstrates that all B cell subsets located in human 
peripheral blood were also present in the liver. It is also clear that the profile of these 
B cell subsets vary between the two, with peripheral blood containing a higher 
percentage of naïve B cells, and the liver containing a significantly higher percentage 
of the double negative memory and centroblast B cell compartment. This difference 
in profile suggests that either B cells home to the liver following circulation (possibly 
through blood from the gut) where they are activated, or that the liver harbours its 
own distinct tissue resident memory B cell population. Considering that the liver 
tissue experiences several thorough washes during LIMC isolation to remove 
contaminating blood lymphocytes, it is fair to speculate that the latter explanation is 
more than plausible.  
In order to further compare the memory B cell compartment in blood and liver, 
surface isotype staining for IgM, IgG and IgA was performed on memory B cells 
isolated from matched blood and liver (Figure 19). Unfortunately, due to difficulty 
obtaining a high yield of PBMCs from precious blood samples, and the lack of space 
? ???
on our B cell panels, I was unable to assess the IgE surface expression on memory 
B cells at this point. Interestingly, memory B cells were found to have significantly 
higher surface expression of IgA in peripheral blood compared to matched chronic 
diseased livers, whereas IgM surface expression was significantly higher on hepatic 
memory B cells. This result was surprising, as impaired hepatic clearance of 
circulating IgA immune complexes has previously been reported in liver disease 
patients, and a high incidence of IgA nephropathy has been previously discovered in 
patients with liver cirrhosis (408, 409). Furthermore, as IgA is a mucosal antibody, it 
is rarely found to be enriched in the blood, however has been previously been found 
to be enriched in human hepatic bile (410). These data show that when assaying 
memory B cell function from patients with liver disease, data from peripheral blood 
may be misleading. 
I set out to establish if the hepatic B cell compartment resembled the frequency and 
composition of B cells in peripheral blood, or in SLOs (Figure 20). Mononuclear cells 
isolated from spleen and lymph nodes harvested from the mesentery of donor 
explants were surface stained for the B cell panel as previously performed on blood 
and liver. Results showed that liver B cells may be similar in total numbers to blood, 
but in composition were similar to SLOs, with naïve B cells being reduced in liver 
and SLOs, and the memory subset being enriched in liver and SLOs compared to 
blood. These data further implied that the liver may harbor more activated, antigen 
experienced B cells in comparison to blood and that memory B cells specifically 
were sequestered or expanded in the liver. Previous studies have described what is 
now known as the ‘liver graveyard theory’. This “graveyard theory” suggested that 
the liver was able to exclusively eliminate activated antigen specific CD8+ T cells, 
? ???
programmed to undergo apoptosis (411, 412). In this way, the liver was able to 
actively contribute to the hepatic tolerance effect. As is the case for CD8+ T cells, it 
is possible that memory B cells are also sequestered and cleared in the liver via 
apoptosis, adding further speculation to the ‘liver graveyard theory’ (411, 413).  
To elucidate the role of B cells in chronic liver diseases, a recent study investigated 
the infiltration of B cells in human liver tissues of chronic liver disease patients by 
immunohistochemistry. They found that chronic liver disease patients with higher 
inflammatory grades had significantly more CD20+ B cell infiltration in their livers 
compared to those with lower grades. However, intrahepatic CD20+ B cells were not 
positively associated with liver fibrosis stages in these patients (287).  
Considering a diverse spectrum of end stage hepatic disease exists, I also wanted to 
investigate differences within the B cell compartment between chronic liver disease 
types. These disease types included dietary injury (ALD, NASH), autoimmune (PBC, 
PSC), viral (HCV/HCC) and genetic/enzyme deficiencies (other). Whereas the 
previous study used IHC to enumerate B cells in hepatic disease, I primarily used 
flow cytometry to elucidate the role of B cells in chronic liver diseases, where results 
highlighted that an increased quantity of CD19+ B cells existed in PBC compared to 
other hepatic conditions, although these results were not statistically significant (Fig. 
21A). These findings were supported with immunohistochemistry, where 
quantification of CD20+ stains were performed on AIH, PBC, PSC, NASH, ALD and 
HCV liver tissue sections, and demonstrated that a significantly higher quantity of 
CD20+ B cells existed in PBC compared to PSC (p=0.014) (Fig. 22G). This result 
was corroborated by recent data which detected significantly fewer CD20+ B cells 
surrounding portal tracts and bile ducts in PSC compared to PBC using 
? ???
immunohistochemistry and flow cytometry (286, 287). It is possible that thorough 
washes performed on liver tissue to remove circulating blood B cells during the LIMC 
isolation process consequently leads to a loss in hepatic B cells. This would make us 
unable to always highlight significant differences between hepatic subsets using flow 
cytometric quantification. I therefore support that histology is a more reliable method 
to estimate liver B cell quantities in various liver diseases. Furthermore, I was able to 
score AIH sections by histology, as they were available in our tissue collection, 
whereas AIH explants were rarely available in our clinic. 
Immunohistochemical staining of liver tissue sections demonstrated that CD20+ B 
cells localised to parenchymal and fibrotic areas within the liver architecture, with B 
cells predominantly localising around portal veins and bile ducts (Fig. 22 A–D). 
Aggregates of B cells around bile ducts and portal veins were frequently observed in 
HCV and PBC livers (Fig. 23B), an observation which is supported by another 
recent study by Takahashi et al, (224). This study found that in PBC patients, CD20+ 
B cells aggregated in a follicle-like fashion around inflamed portal tracts, and where 
intrahepatic bile ducts were usually located (224). Other studies characterising B cell 
aggregates in the liver however, have been defined best in HCV patients in 
particular, further supporting that B cell aggregates in the liver may be disease 
specific (414-416). 
With the exception of mature naïve B cells being enriched in PBC, unlike total B cell 
numbers, B cell subsets in liver diseases of various aetiologies were similar in 
proportions and absolute numbers (Fig. 21B). This may be due to the similar 
hallmarks expressed in all end stage liver diseases, such as fibrosis and cirrhosis of 
tissue. Excess scar tissue and inflammation could mean that detectable differences 
? ???
in B cell populations in early-mid stage hepatic disease were undetectable in end 
stage hepatic disease. Alternatively, the excess fibrosis in end stage liver explants 
may result in difficulty isolating all B cells from liver tissue, resulting in insignificant 
differences between hepatic diseases when analysing B cell subsets. Research has 
highlighted a possible role of B cells in PBC, where B cell depletion with Rituximab 
results in reduced autoantibody production and improved symptoms in PBC patients 
(30, 417). Furthermore, it is known that liver infiltrating lymphocytes, including 
CD19+ B cells, are recruited around bile ducts through the constitutive expression of 
chemokine CXCL12 (stromal cell-derived factor 1 - SDF-1) where they participate in 
the destruction process of targeted bile ducts through AMA production (224). Our 
data shows a significant increase in the proportion of naïve mature B cells in PBC 
compared to donor livers (p = 0.02). It is possible that these naïve B cells are 
recruited to the liver as a consequence of the autoimmune inflammatory response, 
however further investigations would need to be performed in order to determine 
whether this is the case. 
 It is likely that expansion in subsets yet to be identified and missed by our antigen 
combination schemes could explain this increase of B cell numbers in PBC patient 
livers. 
Given that many characteristics of chronic liver diseases are similar as a 
consequence of common liver pathology, histological variation in B aggregate 
presence in chronic liver diseases could be of use diagnostically. With this in mind, it 
was important to investigate the quantitative differences in B cell aggregates across 
various hepatic aetiologies. To quantify differences in B cell aggregation numbers 
between chronic liver diseases, B cells were stained with CD79α, which is a pan-B 
? ???
cell marker and forms part of the BCR with CD79b. Following staining, aggregates of 
these B cells were visualized (Fig. 23A). ImageJ software analysis was then used to 
quantify these aggregates across end stage hepatic disease. Results concluded that 
HCV and PBC livers had a significant enrichment of B cell aggregates compared to 
NASH (p=0.0001 and p=0.007) and Donor (p=0.0009 and p=0.03) patients. (Fig. 
23B). This finding replicates data for HCV (362) and PBC where B cell rich lymphoid 
aggregation has been frequently mentioned in biopsy reporting’s (224, 418). 
Additionally, results showed B cell aggregates to mostly be a phenomenon of 
diseased and not donor liver. This is with the exception of a few samples in our 
donor cohort, which may be a result of disease occurrences in rejected donor 
samples (e.g. excess fat content) and other such case reports. 
Centroblasts are a proliferative B cell type involved in the GC reaction, which were 
found to be enriched in human liver compared to matched peripheral blood samples 
(Fig. 18B). Investigations by a BMedSci student in our lab located a GC-like 
structure in an ALD patient with a dark and light zone, which contained B cells (Fig. 
24). Small structures resembling HEV were also identified, which are indicative of 
GC-like structures. One observation was that within the follicle, FDCs were identified 
in the dark zone, whereas GCs are described with FDCs being present in the light 
zone.  A previous investigation by Mosnier et al and Murukami et al. supports the 
theory of the presence of GC-like structures in liver. Using IHC staining, they found a 
proportion of liver B cell aggregates (ectopic lymphoid structures) in HCV patients 
which expressed markers comparable to those located in GCs of typical secondary 
lymphoid tissues (lymph nodes or tonsils) (419) (362). These data in conjunction with 
our findings highlight similarities between the liver and secondary lymphoid tissue, at 
? ???
least in HCV infection. Even this study however, indicated that GC-like B cell follicles 
were not universal in HCV patients, and the presence of FDCs in the dark zone 
raises some doubt as to whether these structures can definitively be identified as 
GCs, provoking further questions into why and if GCs are present in certain patients 
and what the distribution of other types of B cell aggregates may be (362, 420). To 
confirm the presence of GCs across human liver disease, future work could involve 
investigation of further markers indicative of a GC reaction, such as Activation-
Induced (Cytidine) Deaminase (AID), as AID is the principal enzyme responsible for 
class switch recombination in the GC light zone. 
As well as forming associations with HCV, studies have demonstrated that ectopic 
lymphoid structures can also be found in patients and in mouse models with chronic 
liver diseases such as HBV and PBC, where increased numbers of such aggregates 
have been associated with poor prognosis (223). It has also been proposed that the 
B and T cells present in ectopic lymphoid structures, create a pro-inflammatory, 
cytokine-rich environment, and that this environment in conjunction with surrounding 
hepatocytes supports the growth of hepatocellular carcinoma progenitor cells within 
the aggregate, thereby promoting de novo hepatocarcinogenesis (421, 422). With 
this in mind, targeting the cells in ectopic lymphoid structures might provide 
therapeutic benefit for end stage chronic liver disease patients. Quantifying the 
distribution of types of B cell aggregates across hepatic diseases would not only 
confirm previous findings, but would also assist in identifying immunopathological 
differences between hepatic diseases, thereby aiding in diagnostics and 
understanding of pathophysiology.  
To perform this characterization, a panel of antibodies was used which were chosen 
? ???
and optimized by our intercalating medical student Bardia Guevel. These markers 
included CD20 (pan B cell), CD3 (pan T cell) and Bcl-2 (GC-negative B cells, T 
cells), which allowed robust categorisation of B cell aggregates based on phenotype. 
By means of immunohistochemistry, varying patterns of staining intensity described 
in 2.5.4. permitted the classification of B cell aggregates into lymphoid aggregates, B 
cell follicles or tertiary lymphoid structures. (Fig. 25 E–G) presents the quantification 
of B cell aggregate types across end stage hepatic disease, where no statistical 
differences between the percentages of lymphoid aggregates, B cell follicles or 
tertiary lymphoid structures were identified between hepatic diseases. This is likely 
due to high variation between livers, therefore would require an increased cohort 
size to confirm these results.  
In summary, I have established a reliable technique to characterise 11 B cell subsets 
across end stage hepatic diseases through flow cytometry, the results of which have 
been confirmed by immunohistochemistry. Data from over seventy livers supports 
that proportions of hepatic B cell subsets did not vary significantly between hepatic 
liver diseases with the exception of the naïve mature B cell compartment. This may 
be due to the fact that there are few differences in overall hallmarks of end stage 
hepatic disease, with all livers eventually experiencing fibrosis, cirrhosis and 
inflammation. Supportive of the initial hypothesis that the B cell compartment varies 
according to disease specificity, PBC patients presented with a higher overall 
proportion of B cells, and contained a higher proportion of B cell aggregates 
compared to dietary injury livers. These aggregates were predominantly located 
around portal veins as well as bile ducts, which are known to be targeted by 
autoantibodies during disease, further indicating the possible pathogenic role of B 
? ???
cells in PBC. It is important to understand which B cells subsets are specifically 
expanded to account for the increase in PBC B cell numbers in the liver, as this 
information may indicate which cells are involved in disease pathogenesis and 
therefore can be targeted therapeutically going forward. 
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4.1. INTRODUCTION 
?
While performing phenotypic analyses to compare matched blood and liver for B cell 
subset distributions, I noticed that CD24- B cells were enriched in the human liver 
compared to matched blood. This instigated a series of investigations to characterise 
CD24- B cells in donor livers and in liver inflammation. This chapter will focus on 
CD24- B cells in the liver.  
?????? ?????
?
CD24 is a mature sialoglycoprotein (423) and is expressed on the surface of 
haematopoietic cells such as B cells (423-426), some T cells (427-429), neutrophils 
(429, 430), eosinophils (431), DCs (432, 433) and macrophages (434). It is also 
found on non-haematopoietic cells such as neural cells (435, 436), ganglion cells 
(437, 438), epithelia (439, 440), keratinocytes (441), pancreas (442), and muscle 
cells (443). CD24 is known to be overexpressed on many types of cancers, and is 
recognised as an important diagnostic and prognostic marker (444). Loss of CD24 
expression on tumour cells has been associated with inhibited invasive growth, 
apoptosis and decreased proliferation (445). 
The wide distribution of CD24 in conjunction with its variable glycosylation, means 
that it has many ligands and so numerous unrelated functions have been associated 
with this glycoprotein (446). Studies have definitively shown that CD24 is able to 
bind P-selectin on human tumour cells, endothelium and activated platelets, and that 
this interaction can be blocked by soluble anti-CD24 (447). CD24 found on immune 
cells such as B cells, some T cells and neutrophils, could possibly interact with P-
selectin on platelets and endothelium, although these interactions have yet to be 
investigated. Other CD24 ligands include CD171 in the brain, TAG-1 and contactin 
? ???
(448-450), which are all involved in mediating CD24-induced inhibition of neural cell 
growth. CD24 plays a role in inflammation by binding DAMPs such as high mobility 
group box protein 1 (HMGB-1), Heat-shock protein and nucleolins along with Siglec-
10 to selectively repress the host response to tissue injury (451). 
?
?????? ?????????????????????????
?
Although various immunological functions have been associated with CD24, due to 
its variable glycosylation the true function of CD24 remains an enigma for most cell 
types. CD24 is however, known to mediate signal transduction through the 
recruitment of Src family protein tyrosine kinases (PTKs) via membrane rafts, and 
activates the mitogen-activated protein kinase pathway (MAPK), which triggers B 
and T cell development and apoptosis, cell binding and granulocyte oxidative burst 
(452-456). Furthermore, the mouse equivalent to CD24, known as heat stable 
antigen (HSA), has been implicated in cellular adhesion (457) and lymphocyte 
activation (458-460). 
Expression of CD24 is high on B cell progenitors and mature resting B cells but not 
on terminally differentiated plasma cells (461). It influences B cell growth and 
activation responses through a calcium-mobilising signal transduction pathway (424, 
462) and mediates cell-cell adhesion on naive B cells in mice (463). Previous studies 
also show that this gradual loss of CD24 expression on maturing B cells is 
necessary for a commitment to differentiation (464, 465) (466). One study further 
highlighted the importance of CD24 in early B cell development, by characterising 
mice lacking a functional HSA gene, constructed by homologous recombination in 
embryonic stem cells. Results proved that while T cell and myeloid development 
? ???
appeared normal, HSA knockout mice presented with a leaky block in B cell 
development and a reduction in late pre-B and immature B cell populations in the 
bone marrow (463). On the other hand, data also shows that transgenic mice that 
overexpress HSA experience a significant reduction in pro-B and pre-B lymphocytes 
(467). As HSA performs as an adhesion molecule for P-selectin to facilitate the 
homing and stabilization of B cell precursors to the bone marrow, HSA 
overexpression is thought to retain B cell precursors on the bone marrow stroma, 
thereby preventing further maturation (468). HSA has since been implicated as a 
potent negative regulator of B cell development and activation, where another study 
reported that cross-linking HSA with the M1/69 monoclonal antibody induced the 
apoptosis of cultured B cell precursors in a stromal cell and cytokine-independent 
manner and that sensitivity to HSA-mediated cell death increased with 
developmental maturity. This study went on to prove that cross-linking of HSA did 
not induce apoptosis in mature splenic B cells, but instead inhibited their ability to 
proliferate in response to anti-CD40 + IL-4 (469).  
CD24 expression is also linked to increased vulnerability to autoimmune disease 
development (470), where CD24 deficiency causes deletion of autoreactive T cells 
that normally escape negative selection, and abrogates the development of EAE in 
transgenic mice with a TCR specific for a pathogenic autoantigen (471). 
Furthermore, CD24 polymorphisms have been identified as an important genetic 
factor in regulating susceptibility to autoimmune diseases, including multiple 
sclerosis (472, 473) and ulcerative colitis in humans (474) (475). 
 
? ???
?????? ???????????????????????????????????????????????
?
A newer flow cytometric approach has emerged over recent years to distinguish 
human memory B cells from naïve B cells, using B cell antigens CD19 with CD24 
and CD38. These three antigens allowed the characterization and quantification of 
memory B cells (CD19+CD24+CD38-), Transitional/Breg type cells 
(CD19+CD24hiCD38hi) and mature naïve B cells (CD19+CD24intCD38int) (93) 
(476). One study used this gating strategy to investigate B cell subsets in the 
peripheral blood of the elderly, and discovered the presence of a new ‘memory B 
cell’ subset identified as CD19+CD24-CD38- B cells.  This CD24- B cell population 
was enriched in the elderly compared to younger controls and was found to produce 
TNF-α following stimulation with CpG, thereby leading to a hypothesis that this 
expanded population may contribute to the increased inflammatory status in the 
elderly known as ‘inflamm-aging’ (477). The CD19+CD38-CD24- B cell population 
has also been found to be significantly enriched in the blood of atopic dermatitis 
patients compared to healthy control and psoriasis patients. This correlated with 
higher chronic activation amongst these patients, further supporting the hypothesis 
that CD24- B cells may contribute an inflammatory phenotype (478).  
 
In addition to the Buffa study, there have been numerous reports on ‘age-associated 
B cells’ (ABCs) (479, 480). ABCs are defined as an antigen-experienced population, 
which process and present antigen, and accumulate with age (479, 480). Although 
this subset shares many phenotypic characteristics with exhausted memory B cells 
(481), ABCs lack CD21 and CD23 expression (479), express high levels of the 
transcription factor T-bet (482), and respond poorly to BCR engagement (483) (See 
Table 19). Following TLR stimulation in vitro however, ABCs have been found to 
? ???
class switch (480, 482), produce antibodies and secrete a spectrum of 
immunomodulatory cytokines such as IFN-γ and IL-10 (483). Further in vivo studies 
demonstrated that ABCs were also producers of pro-inflammatory cytokine TNF-α 
(484), and that the sustained accumulation of ABCs could lead to autoinflammatory 
and autoimmune pathologies (480, 482).  
 
Overall, although previous studies have implied CD24- B cells may contribute to 
inflammation, the function of CD24- B cells and their role in inflammation still 
remains to be thoroughly elucidated. 
Chapter objectives.  
To understand the phenotype of CD24- B cells across end-stage liver disease, I 
designed experiments: 
1. To compare proportions of CD24-CD38- and CD24-CD38int B cells in human 
diseased liver and matched blood using flow cytometry. 
2. To quantify CD24-CD38- and CD24-CD38int B cells across end stage hepatic 
diseases. 
3. To investigate the phenotype of the CD24- B cell population by flow cytometry 
by characterizing their expression of B cell subset markers, activation 
antigenic markers and age-associated B cell markers. 
4. To understand how expression of the CD24 glycoprotein is lost from B cells 
using co-culture assays. 
 
 
 
 
? ???
Table 21 – Surface marker expression used to define human and mouse ABCs and human 
exhausted B cells (483). Expression markers of human and mouse antigens defining ABC and 
exhausted B cell phenotypes are shown as high, positive (+), intermediate (int), negative (-) or N/A 
(unknown). The first three columns compare expression of surface markers of mouse and human 
ABCs reported by Hao et al. in mice, and Rubtsov et al. in mice and humans respectively. The last 
column characterises exhausted human B cells. 
?
?
?
?
?
?
?
?
??????????????????? ????????????????????????
???????
?????????????????
????????????????
?????????
? ???
4.2. RESULTS 
?????? ??????????????????? ?????????????????????????????????????? ???????
??????????????
 
CD24- B cells were found to be present in the liver, which could be further separated 
into CD24-CD38- and CD24-CD38int subsets (Fig. 26A). Given that CD24 is 
involved in cell migration, B and T cell activation, signaling, and autoimmune 
disease, I sought to determine if liver B cells expressed a greater proportion of 
CD24- B cells in comparison to matched and unmatched blood samples.  
 
In order to investigate the presence of CD19+CD24-CD38- and CD19+CD24-
CD38int populations in the liver, I stained PBMCs from matched patient blood and 
LIMCs from liver for CD19, CD24 and CD38 antigens. I observed an enrichment of 
CD19+CD24-CD38- populations in 6 out of 7 diseased livers (where the fold change 
for NASH1, NASH2, ALD1, ALD3, PSC and PBC was 1.9, 1, 0.6, 0.6, 10.2 and 12.7 
respectively), and enrichment of CD19+CD24-CD38int in 7 out of 7 livers compared 
to matched blood (where the fold change for NASH1, NASH2, ALD1, ALD2, ALD3, 
PSC and PBC was 2.2, 2.1, 1.1, 0.32, 1.35, 11.8 and 25.8 respectively) (Figure 26 
A & B). Of these matched blood and liver donors, autoimmune patients 
demonstrated the greater fold increase of CD24- B cell subsets compared to 
matched blood, whereas the fold change between matched blood and metabolic liver 
disease demonstrated a lower fold change. 
 
To establish whether CD24- B cells were enriched in SLOs or were specific to the 
liver, the percentages of CD24-CD38- and CD24-CD38int subsets per gram of tissue 
in donor and diseased livers were compared to perihepatic lymph nodes and donor 
? ???
spleens. Results demonstrated that the percentage of CD24-CD38int B cells were 
significantly enriched in healthy livers (6.4±8.2%) compared to perihepatic lymph 
nodes (4.0±4.4%) and spleen (2.7±2.28%) (where p=0.018 and 0.014 respectively). 
However, there were no significant differences between hepatic CD24-CD38- B cell 
proportions (healthy 6.4±8.2% and chronic liver disease 14.13±15.34%) compared to 
secondary lymphoid tissues (lymph node 4.0±4.43% and spleen 2.7±2.28%) (Fig. 
26C). Taken together, these results indicate that CD24- B cells are specifically 
enriched in liver when compared to matched and unmatched blood and SLO 
samples. 
? ???
. ????????  
Figure 26 – CD24- B cells are enriched in liver compared to matched blood and 
SLO samples. (A) Gating strategy for CD24-CD38- and CD24-CD38int B cells, and 
other subsets in a matched PBC liver and blood sample. (B) Fold change increase of 
CD24- B cells within liver samples compared to matched blood (n=7) from patients 
with different chronic liver diseases. (C) Percentage (%) of CD24-CD38- and CD24-
CD38int B cells present per gram of tissue in SLO (perihepatic LN and spleen), 
donor and chronic diseased livers. All statistics were performed as a one-way non-
parametric ANOVA (Kruskal-Wallis test) comparing the mean of each tissue cohort 
with the mean of every other tissue cohort. Significant differences are displayed on 
the graphs where *p<0.05. 
 
 
 
?
0 102 103 104
0
102
103
104
0 102 103 104
0
102
103
104
C
D
24
 
CD38 
Blood Liver 
1.  Memory 
2.  Naive 
3.  Transitional/Breg 
4.  CD24- CD38-  B cells 
5.  CD24- CD38int B cells 
6.  Plasmablasts 
??
?? ??
??
??
??
??
?? ?? ??
??
??
??
??
???
??
??
???
????
???
????
???
???
?
????
???
???
??? ???
?
???
????
???
???
?
????
???
???
??? ???
?
??
0
20
40
60
80
100
C
D
24
-C
D
38
- B
 c
el
ls
(%
 o
f C
D
19
+)
SLO Liver
0
20
40
60
80
100
CD
24
-C
D3
8i
nt
 B
 c
el
ls
(%
 o
f C
D1
9+
)
LiverSLO
*
*
0.1
1
10
100
CD24-CD38- CD24-CD38int 
???
???
???
???
??
???
???
???
??
???
??
??
???
???
???
??
???
????????????????????
?????????????????????
? ???
?????? ????????????????????????????????????????????????????????????????????
?
?
I wanted to establish whether CD24-CD38- and CD24-CD38int B cell populations in 
liver and blood were heterogeneous, and if so, whether they were similar to naïve or 
memory B cells. To investigate this, I used CD27 and IgD antigens to quantify the 
percentage of naïve mature, switched memory, non-switched memory and double 
negative B cells within the CD24-CD38- and CD24-CD38int B cell subsets (Fig. 27).  
 
Experiments revealed that in donor livers, the phenotype of CD24-CD38- B cells 
were mainly naïve, and harbored a significantly higher proportion of naïve B cells 
(41.5±21.0%) compared to non-switched memory B cells (‘marginal zone-like’ cells) 
(11.5±15.9%) where p=0.03. Conversely, CD24-CD38int B cells in donor livers did 
not contain significant enrichment of any B cell phenotype  (Fig 27B).  
 
In diseased livers, the CD24-CD38- population also contained a significantly higher 
proportion of naïve B cells (where 46±21.0%) compared to non-switched memory 
(10±10%), switched memory (16±13%) and double negative B cells (28±17%), 
where p=0.0001, p=0.0001 and p=0.006 respectively. The hepatic CD24-CD38int 
population contained B cells with a significantly higher naive phenotype compared to 
switched memory and double negative memory (naïve: 34±25%, switched mem: 
13±13%, double negative mem: 11±9%), where p=0.0001 and 0.001 respectively. 
This population also contained a significantly higher proportion of non-switched 
memory B cells compared to switched memory and double negative memory B cells 
(non-switched memory: 43±26%), where p=0.0001 and p=0.0001 respectively (Fig 
27B). Interestingly, the trend in terms of proportions of B cell subsets within the 
? ???
CD24-CD38int B cell compartment was similar between human blood and diseased 
liver samples. 
 
In healthy blood, the phenotypic profile of CD24- B cells differed to that found in 
donor and diseased livers, as both CD24-CD38- and CD24-CD38int groups 
contained a significantly high non-switched memory B cell compartment (CD24-
CD38-: 46.8±12.6% and CD24-CD38int: 64.6±11.2%, p=0.0001) compared to 
double negative memory B cells (CD24-CD38-: 3.8±2.7% and CD24-CD38int: 
1.8±1.4%, p<0.0001) (Fig 27B). CD24-CD38int B cells in blood also contained a 
significantly higher proportion of naïve cells compared to switched memory (where 
naïve: 21.5±6.7% and switched memory: 27.95±11.7% and p=0.03), and 
significantly enriched non-switched B cells compared to switched memory (where 
non-switched: 46.75±12.6% and switched: 27.95±11.7% and p=0.03). These data 
show that CD24-CD38- and CD24-CD38int B cells are phenotypically distinct in the 
liver and their subset composition may differ between anatomical locations.  
? ???
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 - Liver and blood CD27 and IgD expression of CD24-CD38- and 
CD24-CD38int B cells reveals phenotype in blood and liver. (A) Flow cytometry 
plots highlight differences between naïve mature, non-switched memory, switched 
memory and double negative B cells (as gated in Fig. 18A) within the CD19+CD24-
CD38- and CD19+CD24-CD38int compartment in diseased liver and healthy donor 
blood. (B) The percentage (%) of naïve mature, non-switched memory, switched 
memory and double negative B cells present in the CD19+CD24-CD38- and 
CD19+CD24-CD38int compartment of healthy donor blood, donor liver and diseased 
liver. Error bars represent the mean and standard deviation, where n=6 for healthy 
bloods, n=7 for donors and n=57 for diseases livers. Statistical differences were 
calculated with a non-parametric one-way ANOVA (Kruskal-Wallis test), corrected 
for multiple comparisons (Dunn’s). Statistical differences were represented when 
p<0.05*, p<0.005** and p<0.0005****. 
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To test if CD24- B cells in the liver were more phenotypically comparable to blood or 
LN from the same donor, I compared matched tissues from three end stage liver 
disease donors with PBC, ALD and NASH (matched blood and liver) and two donor 
livers (matched liver and LN) (Fig. 28). These experiments showed that the 
proportion of naïve and memory B cells within the CD24- compartment were different 
between the liver and the periphery, and between the liver and perihepatic lymph 
nodes in every individual patient. 
 
 
 
? ???
 
 
 
Figure 28 – The composition of CD24- B cells differs between matched blood 
and liver and between different individuals. The proportions of naïve, non-
switched memory, switched memory and double negative B cells within the CD24- B 
cell compartment in (A) matched blood and liver patients, and (B) matched lymph 
node and liver. Each row is representative of an individual donor. 
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To help establish whether the absolute number of CD24-CD38- and CD24-CD38int 
B cells varied proportionally between end stage chronic hepatic disease, I stained 
LIMCs isolated from end stage hepatic liver disease explants (viral, autoimmune and 
dietary injury) with CD19, CD38 and CD24. Secondly, I phenotypically characterised 
the CD24- B cell compartments further, by staining these cells to quantify 
proportions of naïve mature (IgD+CD27), non-switched memory (IgD+CD27+), 
switched memory (IgD-CD27+) and double negative B cells (IgD-CD27-).  
 
Fig. 29A demonstrates that the number of CD24-CD38- B cells per gram of tissue 
was significantly enriched in PBC livers compared to donor livers (PBC: 
6541±7681% and donor: 274±338% where p=0.02). The number of CD24-CD38int B 
cells per gram of tissue was not increased in PBC (Fig. 30A) compared to other 
chronic liver diseases. The proportions of naïve, non-switched memory, switched 
memory and double negative B cells also did not vary significantly between end 
stage hepatic diseases within both CD24-CD38- and CD24-CD38int B cell 
compartments (Fig. 29B & 30B).  
 
In order to further characterize the CD24- B cell populations, surface antigens were 
quantified for B cell activation (CD69), antigen presentation (CD1d) and class-
switched B cells (IgG & IgA) (Fig. 29B & 30B). Within the CD24-CD38- B cell 
compartment, the percentage of CD1d expression was significantly increased within 
donor patient livers compared to dietary liver disease patients (donor: 10.6±4.2%, 
and ALD: 2.13±2.36% NASH: 0.66±0.8% where p=0.03 and, p=0.0007 respectively). 
This result was also true within the CD24-CD38int B cells compartment, where CD1d 
expression was significantly increased within donor patient livers in comparison to 
? ???
NASH liver patient livers, (donor: 14.8±8.1% and NASH: 3.11±5.64% where 
p=0.019). PSC patient livers demonstrated a significantly higher proportion of IgG 
class switched CD24-CD38- B cells compared to viral livers (PSC: 5.05±6.7% viral: 
2.65±3.35% where p=0.037) (Fig. 29B), however no such difference was 
demonstrated within the CD19+CD24-CD38int compartment (Fig. 30B). 
 
 
 
? ???
 
Figure 29 – The percentage of CD24-CD38- B cells varied phenotypically 
across end-stage liver diseases. n=7,9,9,9,16 and 7 for donor, PBC, PSC, NASH, 
ALD and Viral livers respectively. (A) Proportions of CD24-CD38- B cells across end 
stage hepatic diseases per gram of tissue. (B) Percentages (%) of naïve mature, 
non-switched memory, switched memory, double negative, CD69+, CD1d+, IgG+ 
and IgA+ cells within the CD19+CD24-CD38- B cell compartment. Error bars 
represent the mean and standard deviation. Statistical differences were calculated 
with a non-parametric one-way ANOVA (Kruskal-Wallis test), corrected for multiple 
comparisons (Dunn’s). Statistical differences were represented when p<0.05*, 
p<0.005** and p<0.0005***, or with the original p value. 
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Figure 30 – The percentage of CD24-CD38int B cells varied phenotypically 
across end-stage liver diseases. n =7,9,9,9,16 and 7 for donor, PBC, PSC, NASH, 
ALD and Viral livers respectively. (A) Proportions of CD24-CD38int B cells across 
end stage hepatic diseases per gram of tissue. (B) Percentages of naïve mature, 
non-switched memory, switched memory, double negative, CD69+, CD1d+, IgG+ 
and IgA+ cells within the CD19+CD24-CD38int B cell compartment. Error bars 
represent the mean and standard deviation. Statistical differences were calculated 
with a non-parametric one-way ANOVA (Kruskal-Wallis test), corrected for multiple 
comparisons (Dunn’s). Statistical differences were represented where p<0.05*. 
r C C H D l
0
5000
10000
15000
20000
25000
N
o.
 o
f C
D
19
+C
D
24
-C
D
38
in
t
 B
 c
el
ls
 /g
 ti
ss
ue
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
r C C H D l
0
20
40
60
80
100
*
0
20
40
60
80
100
0
20
40
60
80
100
???
??? ???
? ???
?
???
?? ???
?
????
??
???
??? ???
? ???
?
???
?? ???
?
????
??
???
??? ???
? ???
?
???
?? ???
?
????
??
%
 C
D
19
+C
D
24
-C
D
38
in
t B
 c
el
ls
 
N
ai
ve
 
M
em
or
y 
(N
S
) 
M
em
or
y 
(S
) 
D
N
 
C
D
69
+ 
C
D
1d
+ 
Ig
G
+ 
Ig
A
+ 
??
??
? ???
?????? ????????????????????????????? ??????????????????????????????????
 
Buffa et al. showed that the proportion of CD24-CD38- B cells was increased in the 
blood of the elderly (477). I wanted to assess whether an age correlation existed 
between our CD19+CD24-CD38- and CD19+CD24-CD38int hepatic B cells and 
patient age. Age data was obtained for patient livers used in our cohort, from a range 
of hepatic diseases. This data was then analysed for the correlation between patient 
age and the number of CD24-CD38- and CD24-CD38int B cells obtained per gram 
of liver tissue.  
 
Fig. 31 demonstrates an inverse correlation exists between increased patient age 
and the number of CD24-CD38- and CD24-CD38int B cells per gram of tissue. Older 
patients with end stage chronic hepatic disease had reduced numbers of CD24-
CD38- and CD24-CD38int B cells, where r=-0.27 and -0.35, and p=0.02 and 0.004 
respectively. Furthermore, no correlation was observed between types of hepatic 
disease, age, and the number of CD24- B cells/g of tissue.  
Figure 31 – The number of CD24-CD38- and CD24-CD38int B cells in human 
chronic diseased livers decrease with age. Scatter graph demonstrating the linear 
regression between the number of CD24-CD38 and CD24-CD38int B cells per gram 
of human chronic liver diseased tissue with age. Each dot is representative of a 
different disease as indicated by the key. The ‘other’ cohort is representative of 
patients with enzyme deficiencies or polycystic liver disease. Correlations between 
the variables were assessed by calculating Pearson correlation coefficients (two-
tailed) with 95% confidence intervals, where n=64. 
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The Buffa study initiated our interest in age-associated B cell populations. ABCs are 
a specific B cell subset found to be enriched in peripheral blood in the elderly. These 
cells have phenotypically been described in the literature as 
CD19+CD11c+CD80/86hiT-bet+CD21-CD23-IgD- (483). Furthermore, a recent 
study discovered CD21- ABCs in human blood to contain a CD38-CD24low 
population of B cells (485). ABCs have been proven to play a role in autoimmune 
disease (480, 482), and my data shows that CD24-CD38- B cells were enriched in 
PBC. For these reasons, I was driven to investigate whether the phenotype of 
exhausted and ABCs correlated with our hepatic CD19+CD24-CD38- and 
CD19+CD24-CD38int B cell population, to further understand the function of these 
CD24- liver B cells. To address these points, LIMCs were stained for CD19+ B cells, 
CD38 and CD24 antigen markers and ABC markers across three panels: (1) CD21, 
IgD, CD11c, T-bet (2) CD23, T-bet and (3) CD80, T-bet respectively (see methods 
2.3.3.1). Stained LIMCs were run through the flow cytometer. The gating strategy of 
the three ABC antigen panels using total hepatic CD19+ B cells is outlined in Fig. 
32A.  
 
Fig. 32B demonstrates that when ABCs (antigen combination staining panels 1, 2 
and 3) (blue) were overlaid onto total CD19+ B cells in the liver (red), the majority 
mapped onto the CD24-CD38int population, indicating that a large amount of ABCs 
located in the liver may be contained within the CD24-CD38int population. In panels 
1 and 2, a few ABC-like cells were also found to map within the memory B cell 
compartment (CD19+CD38-CD24+). ABCs are known to lack CD23 expression but 
? ???
exhausted B cells are CD23+. I decided to investigate whether hepatic B cell 
populations contained exhausted B cell markers. Fig. 33 shows that like ABC-like 
cells, exhausted-like B cells (CD19+CD21lowCD23+CD11c+IgD-CD80hi) were also 
mainly contained within the CD24-CD38int population. 
 
? ???
 
 
Figure 32 – ABCs were contained within the CD24-CD38int hepatic B cell 
compartment. (A) Sequential gating strategy of ABCs across three panels (CD21-
IgD-CD11C+Tbet+, CD80hiTbet+ and CD23+Tbet+) after first gating on total CD19+ 
B cells from a PSC liver sample. (B) ABCs identified in panel 1, 2 and 3 (blue) were 
overlayed onto total CD19+ B cells from the PSC liver (red) to highlight ABCs within 
the total B cell population. 
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Figure 33 – Exhausted B cells were contained within the CD24-CD38int hepatic 
B cell compartment. (A) Sequential gating strategy of exhausted B cells across 
three panels (CD21lowIgD-CD11C+, CD80hi and CD23+) after first gating on total 
CD19+ B cells from a PSC liver sample. (B) ABCs identified in panel 1, 2 and 3 
(blue) were overlayed onto total CD19+ B cells from the PSC liver (red) to highlight 
exhausted B cells within the total B cell population. 
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Following the indication that ABCs may be contained within the CD24-CD38int B cell 
subset, I decided to perform a quantitative analysis of ABCs within B cell subsets in 
the liver. LIMCs were stained from chronic liver disease tissue and PBMCs from 
healthy donor blood with the three ABC panels to allow comparisons of ABC-like 
cells within B cell subsets between the liver and blood (Fig. 34).  
 
Results indicate that ABCs may be enriched within the CD24-CD38- B cell 
compartment in healthy blood, as the percentage of CD21-CD11c+Tbet+ and CD23-
Tbet+ cells was significantly higher in the CD24-CD38- B cell compartment 
compared to the naïve and transitional B cell subsets (CD24-CD38-: 3.3±2%, and 
naïve: 0.9±0.22% transitional: 0.06±0.04%, where p=0.0125 and p=0.0005 
respectively). Furthermore, the percentage of CD23-Tbet+ cells was also 
significantly higher in the CD24-CD38- B cell compartment compared to the naïve 
and transitional B cell subsets (CD24-CD38-: 5.96±3.49% and naïve: 0.53±0.21% 
transitional: 0.88±0.29%, where p=0.0006 and p=0.02 respectively). In agreement 
with Fig. 32B, Fig. 34 demonstrates that unlike in blood, ABCs may be contained in 
the hepatic CD24-CD38int compartment in end stage liver disease. Quantitative 
analysis of ABC markers in B cell subsets in the liver showed that the percentage of 
CD21-CD11c+Tbet+ was significantly increased within the CD24-CD38int B cell 
compartment compared to transitional B cells (CD24-CD38int:  10.15±7.09% an 
transitional: 1.01±1.79% where p=0.008**), and that the percentage of CD80+T-bet+ 
B cells were also significantly higher in the CD24-CD38int compartment compared to 
the transitional and memory B cell subset (CD24-CD38int: 15.28±10.54% and 
transitional: 2.28±5.54%, memory: 0.1±0.14% where p=0.02* and p=0.02* 
respectively). 
? ???
 
A similar analysis to detect exhausted B cell markers in the liver (Fig. 32 & 33) 
showed that showed that like ABCs, exhausted B cell markers CD21lowCD11c+ were 
significantly higher in CD24-CD38int B cells compared to transitional (CD24-
CD38int: 21.74±21.66% and transitional: 0.75±1.17% where p=0.04), and CD80hi 
were significantly higher in CD24-CD38int B cells compared to transitional and naïve 
B cells, (CD24-CD38int: 16.63±15.04% and transitional: 0.00±0.00% naïve: 
0.002±0.004%, where p=0.004 and p=0.01 respectively) (Fig. 35). In blood, panel 1 
showed that peripheral CD24-CD38- B cells had a significantly higher proportion of 
exhausted markers (CD21lowCD11c+IgD-) compared to transitional B cells (CD24-
CD38-: 2.87±1.18% and transitional: 0.09±0.06% where p=0.004). Conversely, 
panel 3 in blood demonstrated that it was the CD24-CD38int B cell subset which 
contained a significantly high proportion of CD23+ B cells compared to memory B 
cells (CD24-CD38int: 68.5±9.04% and memory: 19.82±6.58% where p=0.0001). 
Panel 2 showed that the exhaustion marker CD80hi did not vary significantly 
between B cell subsets in blood. 
 
? ???
 
 
 
Figure 34 – ABCs appear enriched in the CD24-CD38- B cell compartment of 
healthy blood, and the CD24-CD38int compartment in end stage disease liver. 
The percentages (%) of transitional, naïve, memory, plasmablast/plasma cells, 
CD24-CD38- and CD24-CD38int B cells expressing ABC markers (labeled panels 1, 
2 and 3). Error bars represent the mean and standard deviation, where n=6 for blood 
and liver. Statistical differences were calculated with a non-parametric one-way 
ANOVA (Kruskal-Wallis test), corrected for multiple comparisons (Dunn’s). Statistical 
differences were represented where p<0.05*, p<0.005** or p<0.0005***. 
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Figure 35 – Exhausted B cells may be enriched in the CD24-CD38int 
compartment in end stage disease livers. The percentages (%) of transitional, 
naïve, memory, plasmablast/plasma cells, CD24-CD38- and CD24-CD38int B cells 
expressing exhausted B cell markers (labeled panels 1, 2 and 3). Error bars 
represent the mean and standard deviation, where n=6 for blood and liver. Statistical 
differences were calculated with a non-parametric one-way ANOVA (Kruskal-Wallis 
test), corrected for multiple comparisons (Dunn’s). Statistical differences were 
represented where p<0.05*, p<0.005**, p<0.0005*** or p<0.0001****. 
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Figure 36 demonstrates that supportive of Fig. 34, B cells expressing ABC markers 
(CD11c+CD21-T-bet+ B cells) resided mainly in the CD24-CD38- compartment of 
healthy blood donors. In non-inflamed livers the expression of ABCs markers were 
split between the CD24-CD38- and CD24-CD38int compartment. In immune-
mediated liver inflammation such as PBC, PSC and ALD, B cells expressing 
CD11c+CD21-T-bet+ were mainly confined to CD24-CD38int B cells, suggesting 
that ABCs were probably enriched in this compartment. This supports previous 
studies, which have found that ABCs have played a role in autoimmune disease 
(486) (480, 482, 483). 
 
CD21low exhausted-type B cells in healthy donor blood were variably distributed 
between B cell subsets, however in non-inflamed livers they were enriched within the 
naïve B cell population, eluding to the fact that exhausted B cells may be enriched 
the naïve compartment. In PSC patients in particular, the exhausted B cell marker 
CD21low was enriched in the CD24-CD38int B cell compartment. This implies that 
CD24-CD38int B cells may also be representative of an exhausted population, which 
may have associations with liver disease pathogenesis (Fig. 36).  
  
 
 
 
? ???
         
 
 
Figure 36 – ABC markers are mainly found on CD24-CD38int B cells within 
inflamed liver diseases – Bars representing total CD19+ B cells and the 
percentage proportion of ABCs and exhausted B cell markers contained within B cell 
subsets in healthy blood and diseased liver. Each bar is representative of a separate 
donor, where liver disease of each donor is indicated. B cell subsets displayed are 
Transitional, naïve, memory, plasmablast/plasma cells, CD24-CD38- and CD24-
CD38int B cells from top to bottom respectively.  
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?
I demonstrated that CD24- B cells were enriched in human liver compared to blood 
(Figure 26B) To explore how CD24 was lost on hepatic B cells, and whether CD24 
loss was induced by the hepatic environment, co-cultures between blood B cells and 
liver stromal cells, or blood B cells and cytokines, were performed. PBMCs from HFE 
patients were isolated and co-cultured for 1 hour and 24 hours in the presence of 
liver stromal cells (LX2, HSEC, BECs & Fibroblasts) (See method 2.4.2). Following 
co-culture with liver stromal cells, PBMCs were ‘rested’ in media alone for an hour to 
assess if any loss of CD24 on B cells could be regained. PBMCs were stained prior 
to and following co-culture to assess whether CD24 surface expression had been 
downmodulated.  
 
Results from Fig. 37 demonstrate that B cells did not lose CD24 expression after 1h 
and 24-hour co-culture with liver stromal cells. This was true for all liver stromal cells 
including BEC, LX2 cells, fibroblasts and HSEC. In all experiments, there were no 
significant differences in the percentage of CD24-CD38- and CD24-CD38int B cells 
post isolation compared to co-cultures, cultures in media alone, or cultures in media 
alone following co-cultures with liver stromal cells.  
?
? ???
               
 
Figure 37 – CD24 expression on peripheral blood B cells is unaffected 
following co-culture with liver stromal cells. CD19+CD24-CD38- and 
CD19+CD24-CD38int expression on B cells in blood directly ex vivo (0h) and 
following co-culture with BEC, LX2 cells, fibroblasts or HSEC for 1h and 24h.  
PBMCs cultured in media alone for 1h or 24h were used as a control. After 1h and 
24h co-cultures, PBMC were placed in media alone to be ‘rested’ (R=recovery) for 
1h (1hR) to assess whether CD24 expression was further lost or regained. Error 
bars display the mean and SD where n=3 for all co-cultures. Statistical analysis was 
performed using a one-way ANOVA, where all treatments were compared to the 0h 
controls, and corrected for multiple comparisons (Dunn’s). 
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The inflamed liver is a hub for growth factors, chemokines and cytokine activity, 
which affects many cells within the liver including Kupffer cells and hepatocytes 
(301, 304). In order to investigate whether the cytokine microenvironment present in 
the liver induced CD24 downmodulation on hepatic B cells, PBMCs isolation from 
HFE donors were co-cultured in media with an array of cytokines for 1 hour and 24 
hours (See method 2.4.3.). Percentage CD24 expression on these cells were 
assessed at 0h as well as 1 and 24 hours following co-culture, to determine whether 
CD24 expression was affected by cytokines present in the liver microenvironment.  
 
Fig. 38 shows that neither pro-inflammatory or anti-inflammatory cytokine treatments 
induced an increased percentage in CD24-CD38- and CD24-CD38int B cell 
populations. All 1 hour and 24 hour treatments were compared to the percentage of 
CD24-CD38- and CD24-CD38int B cell populations at 0h (immediately post 
isolation).  
 
 
 
 
? ???
 
 
           
Figure 38 – CD24 expression on B cells is not affected by cytokines present in 
the liver. The percentage (%) of CD24-CD38- and CD24-CD38int B cells before and 
after 1h and 24h co-culture with pro-inflammatory (TNF-α, IFN-γ, IL-6, IL-2, IL-1β) 
and anti-inflammatory (IL-10 and TGFβ) cytokine treatment. Error bars indicate the 
mean and SD where n=3 for all co-cultures. Statistical analysis was performed using 
a one-way ANOVA, where all treatments were compared to the 0h controls, and 
were corrected for multiple comparisons (Dunn’s). 
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To determine whether loss of CD24 on hepatic B cells was due to internalization 
rather than being shed from hepatic B cells, B cells were isolated from human end 
stage diseased livers, permeabilised and stained as stated in 2.4.5. Once prepared, 
samples were run through the flow cytometer to assess intracellular and surface 
expression of CD24. 
 
Fig 39. Demonstrates that the % of CD24 stain on the surface and within hepatic B 
cells does not equate to 100% in all three experiments. This indicates that CD24 is 
not internalized on hepatic B cells following the loss of surface expression, and may 
instead be lost via a ligand dependent mechanism. 
 
 
 
 
Figure 39 – CD24 molecule is not internalized on hepatic B cells. Bar graph 
demonstrating the percentage of CD24+ B cells where B cells were stained for 
surface markers alone (CD19, CD24 & CD38) and surface with intracellular staining 
(CD19 & CD38 surface, CD24 intracellular). N=3 where each experiment is 
separated into 1, 2 and 3.  
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4.3. DISCUSSION  
?
A large population of CD24- B cells were present in the liver. Upon further 
investigation I found that the CD24- B cell population could be further categorized 
into CD24-CD38- and CD24-CD38int subsets (Fig. 26A). When compared to 
matched blood, it was found that both these CD24- B cell populations were enriched 
in human liver B cells compared to peripheral blood (Fig. 26B). Of these matched 
blood and liver donors, autoimmune patients demonstrated a greater fold increase of 
CD24- B cell subsets compared to matched blood, whereas the fold change between 
matched blood and dietary liver disease consistently demonstrated a lower fold 
change, highlighting that the proportion of CD24- B cells demonstrate a possible 
disease bias in autoimmune livers. Loss of CD24 expression on MDA-MB-231 breast 
cancer cells and mouse pre-B cells lines has been found to increase SDF-1-
mediated cell migration and signaling via CXCR4, which correlated with enhanced 
tumour formation in NOD/SCID mice compared with cells overexpressing CD24 
(487). Given that CD24 is expressed on B cells prior to differentiation, the loss of 
CD24 on hepatic B cells could mean that B cells migrate into the liver, resulting in a 
reduced population of CD24- B cells in the blood (461).  
 
The percentage of CD24-CD38- and CD24-CD38int subsets in donor and diseased 
livers was compared to SLOs such as perihepatic lymph nodes and donor spleens. 
Although the proportion of CD24-CD38- B cells did not differ significantly between 
liver and SLO populations, healthy livers contained a significantly higher percentage 
of CD24-CD38int B cells compared to perihepatic lymph node and spleen samples, 
indicating that this population is enriched in the liver compared to secondary 
? ???
lymphoid tissues. B cell progenitors and mature resting B cells are known to express 
high levels of CD24, but this expression is absent on terminally differentiated cells 
such as plasma cells (461). Another study has shown that activation of naïve human 
tonsillar B cells through CD44 co-ligation causes progression towards a GC B cell 
phenotype, involving an upregulation of GC markers and a downregulation of CD24 
(488). These findings suggest that the high proportion of CD24-CD38int B cells in 
the liver may be indicative of an activated B cell population, possibly even GC-like B 
cells. It is anticipated that an activated immune population would exist in the healthy 
liver given that the liver is a tolerogenic organ, and given that it encounters a 
constant influx of antigen-rich blood from the gut (489, 490).   
 
I next wanted to identify whether these CD24-CD38- and CD24-CD38int populations 
were homogenous, and if they were similar to naïve or memory B cells. This was 
performed by gating on CD24-CD38- and CD24-CD38int populations and separating 
them into naïve, switched memory, non-switched memory and double negative B 
cells using CD27 and IgD expression markers (Fig. 27). Results showed that both 
CD24- B cell populations were heterogeneous in the diseased and donor livers. The 
CD24-CD38- population in diseased and donor livers contained significantly more 
naïve (IgD+CD27-) cells and the CD24-CD38int population in diseased livers 
contained significantly more naïve and non-switched ‘MZ-like’ memory (IgD+CD27+) 
cells. The profile of hepatic CD24-CD38- B cells differed to blood and harbored a 
significantly higher proportion of non-switched memory cells compared to other 
subsets. This phenotypic variation in the CD24-CD38- B cell compartment between 
blood and liver further highlights that functionally, the B cell compartment may also 
differ between the two. Interestingly, although differences existed between liver and 
? ???
blood with regards to the CD24-CD38- B cell populations, the general trend of MZ-
like and naïve B cells being enriched in the CD24-CD38int B cell compartment was 
replicated in both diseased liver and blood samples.  
 
Results from Fig. 28 demonstrated that matched blood and liver from individual 
patients suffering from chronic liver disease contained variable proportions of B cell 
subtypes within the CD24- B cell population, highlighting further that the B cell 
compartment in the blood and liver are heterogeneous. These differences were also 
observed between matched perihepatic lymph nodes and liver patients, which 
indicates that in order to study the effect of CD24- B cells on chronic liver disease in 
detail, B cells isolated directly from the liver tissue should be investigated as the 
impact of these cells within the liver tissue may be different to those in the blood. 
The difference in B cell profile between chronic liver diseases further indicates that 
the role of CD24- B cells in the liver compartment in particular may be disease 
relevant, and therefore this B cell population within specific chronic liver diseases 
should be further investigated. 
 
Fig. 29A & 30A helped to establish whether the absolute number of CD24-CD38- 
and CD24-CD38int B cells varied significantly between end stage hepatic diseases. 
Whereas the proportion of CD24-CD38int B cells did not vary significantly between 
end stage liver diseases, the number of CD24-CD38- was significantly enriched in 
PBC livers compared to donor livers per gram of tissue. On the contrary, CD24 
deficiency has previously been associated with an increased efficiency in clonal 
deletion, and in mice, with higher resistance to autoimmune disease (470, 471). 
Furthermore, murine studies have shown that HSA cDNA from activated B cells 
? ???
encode CD80/CD86 which are important in inducing CD4+ T cell activation and 
clonal expansion in mice (427, 459). With this in mind, one would expect a lack of 
CD24 on B cells to result in reduced inflammation, which contradicts the high levels 
of inflammation found in a chronic autoimmune disease like PBC. Nonetheless, 
enrichment of CD24-CD38- B cells in PBC in this case alludes to a potential role of 
this subset in disease pathogenesis. However the positive or negative role this 
population remains to be determined. 
 
CD1d expression was significantly decreased on CD24-CD38- hepatic B cells in 
ALD and NASH patients and on CD24-CD38int hepatic B cells in NASH patients 
compared to donor livers (Fig. 29B). These differences were not observed for 
CD24+ B cell populations, which is indicative of this marker having a possible role in 
CD24- B cells in dietary injury. CD1d is involved in the presentation of lipid antigens 
to NKT cells, which leads to their activation and subsequent secretion of Th1/Th2 
cytokines such as IFN-γ and IL-4 (266, 491). In the case where CD1d expression is 
downregulated in dietary injured livers, it is possible that fewer NKT cells are 
activated. Studies have shown that NKT cells play an important role in immune 
regulation, and that dysfunction of deficiency of NKT cells leads to development of 
autoimmune diseases or cancer (492, 493), highlighting a possible susceptibility in 
ALD and NASH patients. These findings contradict those from other studies that find 
that cellular and molecular mechanisms underlying ALD are known to involve 
complex interactions between innate immune cells such as NKT cells, parenchymal 
cells (hepatocytes) and non-parenchymal cells (HSEC, Kupffer cells, HSCs and 
DCs). Furthermore, murine models of chronic plus binge ethanol feeding, and 
models of mice, which are fed alcohol via an intragastric tube, have demonstrated an 
? ???
increased number of activated type I NKT cells (494-496). Jα18−/− mice (which are 
deficient in type I NKT cells) and CD1d−/− mice (which are deficient in both NKT cell 
subsets) have also demonstrated protection against liver injury after alcohol intake 
(495).  
 
A publication by Buffa et al. 2013, has been the only study to date known to identify 
a CD24-CD38- B cell population enriched in the blood of elderly patients (477). 
Furthermore, a recent study by Thorarinsdottir and colleagues, discovered that 
CD21- ABCs in human blood contained a CD38-CD24low population of B cells 
(485). In order to assess whether an age correlation existed within CD19+CD24-
CD38- and CD19+CD24-CD38int hepatic B cell populations, I obtained age 
information from the majority of livers used in our cohort from a range of hepatic 
diseases. Results showed that contrary to the Buffa study where CD24- B cells 
increased with age in healthy blood, our CD19+CD24-CD38- and CD19+CD24-
CD38int hepatic B cells significantly decreased with age, demonstrating an inverse 
correlation (Fig. 31). This difference in observation could be due to the fact that 
unlike in the Buffa study, the ages of the patients in this cohort study do not exceed 
aged 80, and only four patients in this study cohort representative of ‘younger 
donors’ below the age of 30.  In the future, it would be interesting to see if separating 
this cohort into separate diseases would highlight any correlation between age and 
CD24- B cell proportions. 
 
Nonetheless, this Buffa study sparked our interest in ABC populations. Since then, 
there have been numerous reports on ABCs, which have no reference to CD24 
expression. Although ABCs were discovered in aging, they can also be found in the 
? ???
young (479). They respond poorly to BCR and CD40 ligation and are instead 
stimulated by TLR ligation (479). As well as also accumulating with age, they have a 
unique phenotype in humans (CD19+CD11c+CD80/86hiT-bet+CD21-CD23-IgD-), 
and are mainly characterized by their high T-bet expression, which in B cells has 
recently been discovered as being pivotal in controlling chronic viral infection (479, 
480) (497). 
 
 ABCs are not to be confused with ‘exhausted B cells’. A large proportion of the 
published CD21low B cells which are postulated to be exhausted B cells, have been 
shown to contain a CD24-CD38- B cell population (485). This prompted our 
investigation into determining whether the phenotype of exhausted and ABCs 
correlated with our CD19+CD24-CD38- and CD19+CD24-CD38int liver enriched B 
cell population. Our results showed that B cells isolated from chronic liver disease 
patients contained the ABC phenotype across three antigen stain panels 
combination, which all mostly mapped onto the CD24-CD38int B cell population (Fig. 
32B). This was assessed further quantitatively, where the percentage of ABCs 
across B cell subsets was analysed in diseased liver and healthy blood samples (Fig 
34). B cells with the markers CD21-CD11c+Tbet+ were enriched in hepatic CD24-
CD38int and CD24-CD38- B cells compared to transitional B cells, and hepatic and 
CD80+Tbet+ markers were enriched significantly on CD24-CD38int B cells 
compared to transitional and memory B cells. This data implied that ABCs were 
enriched in the CD24-CD38int subset. Conversely, it seemed that ABCs in blood 
were enriched in the CD24-CD38- populations, where the percentage of CD21-
CD11c+Tbet+ and CD23-Tbet+ B cells were significantly enriched in CD24-CD38- 
? ???
populations compared to both naïve and transitional subsets (Fig. 34). This further 
highlights the differences in the B cell compartment between blood and liver.  
 
Besides previous studies showing that exhausted human B cells and ABCs share 
many antigen markers, the two can be differentiated as exhausted human B cells are 
CD23+ and ABCs contain positive to high T-bet expression (483). Figure 33 shows 
that B cells with exhausted B cell markers also appear to be present in the CD24-
CD38int B cell compartment, suggesting that this subset contains a mixed population 
of B cells which represents both exhausted and age associated B cells. 
Quantitatively speaking, the main markers for B cell exhaustion 
(CD21lowCD11c+IgD-) replicate the findings of ABC enrichment within the CD24-
CD38int compartment. This was further confirmed by the significantly higher 
percentage of CD80hi B cells, another B cell exhaustion marker enriched within the 
CD24-CD38int hepatic B cell subset compared to naïve and transitional B cells (Fig. 
35). In healthy blood, the confinement of exhausted B cells to a particular B cell 
subset is unclear, with exhaustion markers showing significant enrichment in CD24-
CD38-, CD24-CD38int and plasmablast/plasma cell subsets.  
 
Figure 36 assisted in mapping exhausted B cells and ABCs to a particular subset 
within blood and liver, whilst also highlighting any possible associations of these 
populations with disease pathogenesis. A large proportion of ABCs were contained 
in the CD24- B cell compartment and this distribution differed between blood and 
liver. Differences in the ABC profile were also apparent between the four chronic 
immune-mediated damage livers (PBC/ALD, ALD/HCC and 2 PSC’s) and two non-
inflamed livers (seronegative hepatitis and non-cirrhotic portal hypertension), where 
? ???
those patients with more inflammation demonstrated a high ABC marker profile 
within the CD24-CD38int B cell population. In 2/3 patients suffering from non-
immune-mediated disease, ABC markers were enriched in the CD24-CD38- B cell 
population. In the case of exhausted CD21low B cells, the profile of these cells 
varied across B cell subsets in healthy donor blood. However, in PSC patients 
specifically, an enrichment of CD21low B cells was found within the hepatic CD24-
CD38int subset, suggesting again that B cell exhaustion of CD24-CD38int B cells 
may be contributing to disease. Whether this contribution is protective or related to 
pathogenesis still remains to be elucidated, as previous studies have shown B cells 
to have both a pathogenic and inflammation dampening role in liver disease (399, 
405, 498). Although our data shows that the quality of the exhausted B cell and ABC 
compartment differs between blood and liver, as well as between disease status, 
additional time would have allowed me to correlate both exhausted B cells and ABCs 
with disease severity. The collection of further patient numbers would help to 
address this.  
 
In order to investigate how CD24 was lost on hepatic B cells, and whether CD24 was 
lost due to the hepatic environment, co-culture assays were performed using PBMCs 
with liver stromal cells and cytokines. Results showed no downmodulation of CD24 
on blood B cells following co-culture with stroma cells in vitro (Fig. 37 & 38). It is 
possible that functional differences exist between blood and liver CD24- B cells, 
thereby making it harder to induce CD24 loss from blood B cells. Future work could 
involve repeating these experiments with hepatic B cells. Furthermore, as the liver 
microenvironment is extremely complex, it is possible that another factor other than 
liver stromal cells and cytokines are inducing this downmodulation. Results from a 
? ???
further experiment showed that CD24 is not internalized on hepatic B cells when its 
expression is downmodulated, as similar percentages of B cells expressed CD24 on 
the surface and intracellularly in total compared to the surface expressed antigen 
alone (Fig. 39). Since a known ligand for CD24 is P-selectin, it also is possible that 
CD24 is lost through ligand binding with P-selectin on platelets or liver vascular 
endothelium. Preliminary data from our lab shows CD24+CD79α B cells within blood 
vessels, with CD79αCD24- B cells surrounding the vessels on the other side (Data 
not shown). Going forward, future experiments could involve investigating loss of 
CD24 from B cells through platelet / primary liver endothelial cell transwell assays.  
 
Overall two CD24- B cell populations have been identified, which were enriched in 
human liver compared to blood. These CD19+CD24-CD38- and CD19+CD24-CD38- 
populations were heterogeneous and differed phenotypically from blood. 
Furthermore, these populations were found to differ phenotypically between end 
stage liver diseases. CD24-CD38- B cells were the only subset significantly 
increased in patients with PBC, both in absolute numbers and in proportions within 
the B cell compartment. Conversely, CD24-CD38int B cells were not increased in 
end stage disease compared to donor livers. Although not enriched in the livers of 
elderly patients, hepatic CD24-CD38int B cells were enriched with ABC and 
exhausted B cell markers. The role of both these CD24- B cell populations in liver 
inflammation remains to be defined.  
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5.1. INTRODUCTION 
?
In Chapter 4, a greater proportion of CD24-CD38- and CD24-CD38int B cells were 
detected in livers compared to peripheral blood (Fig. 26A&B). Phenotyping of CD24- 
B cells has shown that liver CD24- B cell populations contained different frequencies 
of naïve and memory markers compared to matched blood and lymph nodes (Fig. 
27B & 28). The localization of CD24- B cells in the liver remains to be elucidated, 
and would provide insights into the potential role of CD24-B cells in liver 
inflammation. 
 
Little is known about the functional role of CD24- B cells in liver, however past 
studies have shown that CD24-CD38- B cells were enriched in the blood of aged 
patients and were pro-inflammatory, as they produced high levels of TNF-α but not 
IL-6 or IL-10 (477). I found that CD24- B cells in the liver may be representative of a 
disease-relevant population, as their numbers were significantly enriched in end-
stage PBC explants compared to liver samples from other disease aetiologies and 
healthy donors (Fig. 29A). 
 
Previous studies in mice have shown that B cells were able to regulate inflammation 
in the inflamed gut via the release of IL-10 (72), and that TNF-α and IL-6-producing 
B cells could exacerbate inflammatory conditions and autoimmune pathologies, 
including rheumatoid arthritis and inflammatory bowel disease (499-501). 
Furthermore, it has recently been shown in mice that activated B cell-mediated 
inflammatory responses had pathogenic consequences for the liver, through the 
induction of inflammatory cytokines such as IFN-γ and TNF-α (394). However, it has 
not been reported if liver CD24- B cells specifically secrete TNF-α and IL-6 and it is 
? ???
unknown if CD24- B cells are important in promoting or alleviating chronic liver 
injury. 
 
I therefore wanted to assess the cytokine production of CD24-CD38- and CD24-
CD38int B cells in end stage liver diseases, by measuring the production of 
immunomodulatory cytokines TNF-α, IFN-γ and IL-6 and IL-10 following stimulation. 
Cytokine production from stimulated B cells was compared to unstimulated CD24- B 
cells isolated directly ex-vivo from the liver, CD24+ hepatic B cell subsets 
(transitional, naïve and memory B cells), as well as CD24- B cells in the blood. This 
line of investigation aimed to establish whether our CD24- hepatic B cells also 
contribute to the regulation of inflammation in the liver. 
 
I wanted to address the above points to understand B cell activation and function in 
the liver, by defining how liver B cell subsets respond to stimulation.? Cytokine 
production is a valid readout for B cell stimulation and would provide information on 
the ability of liver B cells to regulate the immune response. Studies indicate that B 
cells produce immunomodulatory cytokines depending on their environment and 
method of stimulation (See 1.3.) (80, 502-504). For example, the presence of 
cytokines such as IL-2, IL-4, IL-10, IL-21, are critical in different types of human B 
cell activation and differentiation (504-507). In addition to cytokines, engagement of 
CD40 and the BCR on B cells by CD40L and the TCR expressed by activated CD4+ 
T cells is essential for B cell stimulation, resulting in TNF-α and IL-6 production from 
memory B cells, and IL-10 production from naïve B cells (508). As well as being 
activated through the conventional methods of CD40/BCR ligation, B cells can also 
be activated via TLRs (54, 63, 75, 86, 284). Both methods are known to induce B 
? ???
cell cytokine production. However, B cell cytokine secretion differs according to the 
type of TLR stimulation. For example, TLR9 stimulation can specifically activate 
naïve B cells to produce IL-10 (54, 92), and engagement of TLR4 on B cells can 
cause decreased IL-10 production in inflammatory disease patients coupled with 
increases in pro-inflammatory cytokine production (67, 509). The study on CD21-/lo 
ABCs in human blood highlighted that CD24-/lo cells within this population couldn’t 
be stimulated by just BCR/CD40, but also required IL-2 and TLR7/8 to proliferate 
and differentiate into plasma calls in vitro, although cytokine production was not 
detected in this study (485). 
?
Little is known regarding the role of B cells in the modulation of liver inflammation. I 
decided to characterize the effects of TLR4, TLR7, TLR9, RP105 and CD40/BCR 
stimulations on cytokine production from hepatic B cell subsets in vitro, with a focus 
on CD24- B cells. Detailed information of hepatic B cell activation via TLRs may lead 
to a better understanding of B cell involvement in chronic liver disease. Furthermore, 
understanding the effects of TLR stimulation on hepatic B cells would further 
highlight if they differ functionally to blood, and whether they contribute to a pro-
inflammatory hepatic environment. This would also help to address our knowledge 
on whether B cell responses are dampened in the liver.  
 
Chapter objectives.  
To understand the function and role of CD24- B cells in liver disease pathobiology, I 
designed experiments: 
1. To map the localization of CD24- B cells in human end stage diseases using 
immunohistochemistry 
? ???
2. To isolate CD24- B cells from blood and liver and establish their cytokine 
production profiles ex vivo by intracellular flow cytometry 
3. To investigate the cytokine expression profiles of CD24- B cells from blood 
and liver following in vitro stimulations with BCR+CD40L, TLR4, TLR7 and 
TLR9 (with and without BCR stimulation). 
5.2. RESULTS 
?
?????? ???????????????????????????????????????????
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I wanted to assess where CD24- B cells localised within the architecture of inflamed 
livers using immunohistochemical staining, as this could be indicative of a possible 
pathogenic role in end stage hepatic disease. In particular, this would indicate if 
CD24- B cells plays a role in liver damage in PBC, where bile ducts are damaged. 
Double IHC staining was used against the pan B cell marker (CD79α) and CD24 (as 
described in 2.5.2.), on sections of human liver tissue obtained from patients 
suffering from end stage liver diseases.  
 
Results in Fig. 40 demonstrated that CD24- B cells were located throughout the liver 
architecture in end stage chronic liver disease patient tissue. CD24- B cells were 
found within the fibrotic scar tissue and surrounding bile ducts in PBC patients in the 
examples shown, suggesting that CD24- B cells may play a role in disease 
pathogenesis of PBC.  
?
? ???
?
 
Figure 40 – CD24- B cells were located throughout the liver architecture. IHC 
images from patients suffering from end stage liver diseases. CD24- B cells were 
located amongst (A) hepatocytes (PSC), in the (B) fibrotic septa (PBC) and 
surrounding (C) bile ducts (PBC) and (D) portal veins (PBC). B cells were stained 
with pan B cell marker CD79α (red/brown) and with CD24 (black). Full tissue slides 
were then scanned using the ZEISS Axio scanner using a X20 objective. B cells with 
CD79α brown stain alone represents the CD24- B cell population highlighted by 
white arrowheads CD24+ B cells are highlighted by the black arrowheads.  
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In order to assess whether the distribution and proportion of CD24- B cells correlated 
with disease specificity, the frequency of CD79α+CD24- B cells was scored semi-
quantitatively throughout the liver architecture (Fig. 41). All liver sections were 
stained using anti-CD24 and anti-CD79α mAb, (as described in 2.5.2.), following 
which all sections were scanned using the ZEISS Axio slide scanner using a x20 
objective. CD79α+CD24- B cells were scored using semi-quantitative analysis 
ranging from “not found” (NF) to “+++++” (5+), with higher scoring values indicating 
that a more enriched population of CD79α+CD24- B cells were located within that 
region of the liver section. 
 
Results from Fig. 41 demonstrated that all liver disease cohorts contained patients 
with CD79α+CD24- B cell populations within portal areas and around vessels. It was 
also apparent that in inflammatory liver diseases (excluding donor livers), 
CD79α+CD24- B cells were frequently identified along the fibrotic septa. 
In support of our flow cytometry findings (Fig. 29 & 30), PBC patients scored the 
highest for the presence of CD24- B cells, which were relatively equal in distribution 
across portal, fibrotic, lobular and vesicular areas within the liver. HCV, and ALD 
patients additionally contained a large but homogenous distribution of 
CD79α+CD24- B cells compared to other liver diseases. Conversely, it was the 
donor and HBV livers that demonstrated a more heterogeneous distribution of the 
CD24- B cell population, as most of these patients had a single location in the liver 
where CD79α+CD24- B cells were enriched (50% or more). For example, 50% of 
donor livers displayed positive expression of CD79α+CD24- B cells located around 
portal areas. PBC, HCV and ALD patient cohorts were consistently the most plentiful 
? ???
in CD24- B cells throughout their livers, whereas few NASH patients showed 
incidence of CD24- B cells.  These data indicate that the distribution of CD24- B cells 
may vary with liver disease aetiology.  
 
   
 
Figure 41 – Patient variation exists in the distribution of CD79α+CD24- B cells 
across various liver diseases. Cumulative percentages (%) of patients positive 
CD79α+CD24- B cells found in the fibrotic septa (blue), B cell aggregates (red), 
portal areas (green), near vessels (purple) or within liver lobules (teal) in the liver 
diseases indicated. n=10 patients per disease, apart from PBC n=9 and AIH and 
HBV where n=8. All liver sections were stained using anti-CD24 and anti- CD79α, 
using the optimised double IHC protocol (2.5.2.). All 3uM thick sections were 
scanned using the ZEISS Axio slide scanner using a x20 objective. CD79α+CD24- B 
cells were scored using semi-quantitative analysis from “not found” (NF) to “+++++” 
(5+), with a higher scoring value indicative of a higher population of CD79α+CD24- B 
cells located within that region of the liver section.  
?
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Fig. 41 demonstrated that CD24- B cells were located in various anatomical sites in 
end stage liver disease. However, in order to establish the specific localization of 
CD24-CD38- or CD24-CD38int, a triple stain was performed with the assistance of 
experienced immunohistochemist Dr. Gary Reynolds (Fig. 42).   
 
CD24-CD38- B cells localized preferentially in B cell aggregates, sometimes in the 
region of hepatic bile ducts. Literature has previously described GC B cells as CD24-
CD38int (488, 510). However, here we show that the hepatic CD24-CD38+ B cell 
populations are not GC B cells as they are excluded from the CD24-CD38- B cell 
aggregates. Instead, CD24-CD38+ B cells were tightly associated with the biliary 
epithelia, and within the fibrotic tracts of end stage liver diseases, and were excluded 
from these aggregates. The close association of CD24- B cell subsets with damaged 
bile ducts and B cell aggregates may indicate a role in liver disease pathogenesis.  
                                                                    
? ???
                                              
 
 
Figure 42 – CD24-CD38+ B cells were located around liver bile ducts and along 
the fibrotic tracts, however CD24-CD38- B cells were found within aggregates 
in PBC. Triple IHC staining to locate CD24-CD38- (white arrows – brown cells) and 
CD24-CD38+ B cells (black arrows – brown and green cells) in end stage liver 
disease (PBC). Anti-CD20+ B cells (red/brown), CD24 (black), CD38 (green). 
Location of CD24-CD38+ and CD24-CD38- B cells (A) in the region of bile ducts (x5) 
(B) around bile ducts and within aggregates and (x10) (C) in aggregates and fibrotic 
tracts (x5) in end stage hepatic disease livers.  
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CD24 downmodulation is known to occur on activated B cells, such as those 
undergoing the GC reaction marker (488). I wanted to establish whether CD24- B 
cells located within the liver were similar to activated CD24- GC blast B cells. In 
order to investigate the aggregate distribution of these cells, I performed a double 
IHC stain (as described previously in 2.5.2.) in human tonsil tissue and human 
chronic liver diseased tissue. Fig. 43 shows that CD24- B cell aggregate in chronic 
liver disease were surrounded by CD24+ B cells. The CD24- B cell aggregates in 
liver is similar in appearance to those found in the GCs of human tonsil, where 
CD24- B cells, representative GC B cells, were surrounded by CD24+ B cells.  
 
 
 
 
? ???
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Figure 43 – Diseased liver contains CD24- B cell aggregates surrounded by 
CD24+ B cells, which appear to look similar to those aggregates located in 
human tonsil. B cells in human tonsil and diseased (PSC) liver were double stained 
with pan B cell marker CD79α (brown) and with CD24 (black). CD24- B cells are 
highlighted by white arrowheads, whereas CD24+ B cells are highlighted by black 
arrowheads. Populations of B cells within the dotted gate represents where the 
majority of CD24- B cells aggregate. Full tissue slides were then scanned using the 
ZEISS Axio scanner using a X20 objective. Cells with the CD79α brown stain alone 
represents the CD24- B cell population. 
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Next, I wanted to assess whether CD24-CD38- and CD24-CD38int B cells 
proliferated more or less than other B cell subsets upon activation. To do this I 
stimulated hepatic B cells for 5h with CpG, PMA and ionomycin, and stained for the 
nuclear protein Ki67, which is a known cell proliferation marker (511) (as described 
in 2.4.6). To confirm whether CD24- B cells proliferated in the liver, an IHC triple 
stain was also performed on human chronic diseased liver tissue sections for CD79α 
(red), Ki67 (green) and CD24 (black) as described in 2.5.3. 
 
Results from Fig. 44A demonstrated that stimulation with CpG/PMA/Ionomycin did 
not increase proliferation in B cell subsets beyond in vivo levels. In both stimulated 
and unstimulated treatment groups, plasmablast/plasma cells (stimulated: 
48.8±28.8% unstimulated: 30.9±22.9%) demonstrated the highest proliferation, 
which was significantly higher than memory B cells (stimulated: 3.5±2.3%  
unstimulated: 1.1±1.5%, where p=0.0007 and p=0.005 respectively). Furthermore, 
stimulated plasmablast/plasma cells were also found to proliferate at a significantly 
higher level than naïve B cells (naive: 1.9±1.5% where p=0.02). CD24-CD38int B 
cells demonstrated the next highest percentage of proliferation, presenting 
significantly higher percentages of Ki67 compared to memory B cells in both 
unstimulated and stimulated groups, (CD24-CD38int stimulated: 27.3±12.1% and 
CD24-CD38int unstimulated: 16.6±11.7% where p=0.04 and p=0.02 respectively). 
These data were corroborated by IHC staining for Ki67. Fig. 44B, demonstrates that 
CD24- B cells in chronic liver disease showed evidence of Ki67+ proliferating cells. 
The frequencies of Ki67+ cells were not as high as described for GC centroblasts 
(Figure 24 with ALD GC B cells).  
? ???
 
?
Figure 44 – Hepatic CD24-CD38int B cells proliferate significantly more than 
memory B cells before and following stimulation. (A) Percentage (%) Ki67 
expression in unstimulated and stimulated (5h, CpG/PMA/Ionomycin) hepatic B cell 
subsets. Error bars represent the mean and standard deviation, where n=6. 
Statistical differences were calculated with a Kruskal-Wallis test, corrected for 
multiple comparisons (Dunn’s), where p<0.05*, p<0.005**, p<0.001***. (B) Triple IHC 
stain performed on chronic diseased liver to demonstrate the proliferation of CD24-B 
cells. Cells were stained with CD79α (red), Ki67 (green) and CD24 (black) as 
described in 2.5.3. White arrowheads demonstrate proliferating CD24+ B cells 
(CD79α +CD24+Ki67+ - red, black & green) and black arrowheads demonstrate the 
proliferating CD24- B cells (CD79α +CD24-Ki67+ - Red & green) 
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I wanted to investigate whether CD24- B cells could be generated in vitro, and if so, 
whether blood B cells generated would resemble liver CD24-B cells. Blood B cells 
from healthy donors were stimulated for 5 days with CD40L and anti-BCR and 
stained at Day 0 and Day 5 post-stimulation for CD19, CD24, CD38, CD27, IgD and 
IgM as described in 2.4.7.  
 
Figure 45A shows that when blood B cells were stimulated for 5 days through CD40 
and the BCR, they became activated blasts and therefore lost expression of CD24. 
Fig. 45B further demonstrates that even following stimulation, these activated blood 
CD24- B cells contained both memory and naive populations, of which the naïve 
population was significantly larger (CD24-CD38- naive: 44.7±10.3 CD24-CD38- 
memory: 10.4±3.0 where p=0.0007 and CD24-CD38int naive: 66.7±24.3 CD24-
CD38int memory: 6.9±6.3 where p=0.003). These CD24- B cells do not change 
profile upon stimulation, and on day 5, the percentage of memory and naïve B cells 
remain similar to unstimulated CD24-CD38- and CD24-CD38int B cells on day 0. 
Conversely, Fig. 45C demonstrates that hepatic CD24- B cells (from PBC) differed 
from both naïve and memory B cells, where CD24-CD38- B cells contained fewer 
IgM+IgD+ B cells than naive and more than memory, and CD24-CD38int B cells 
generally contain more IgM+IgD+ B cells than both naïve and memory B cells from 
the same patient. This indicates that activated CD24- blood B cells generated in vitro 
differ from hepatic CD24- B cells isolated directly ex vivo. 
  
 
? ???
         
 
?Figure 45 – CD24- B cells can be generated in vitro, however they did not 
resemble hepatic CD24- B cells regarding CD27 and IgD expression. (A) Flow 
plots demonstrating increased downmodulation of CD24 on blood B cells following 5-
day stimulation with anti-CD40 and anti-BCR (IgM/IgD) in culture. (B) Bar graph 
demonstrating the phenotypic profile (naïve or memory) of CD24- B cells before and 
after 5 day stimulations in culture (n=4). One t test per row was performed to assess 
significant differences between the proportion of naïve and memory subsets in 
CD24- B cells within each treatment group, where p<0.05*. (C) The phenotypic 
profile of hepatic CD24-CD38- and CD24-CD38int B cells compared to naïve and 
memory subsets in the same livers. All donors were PBC suffers (n=8).?
??????????
????????
???????? ????????
????????
0 101 102 103
0
102
103
104
0 101 102 103
0
102
103
104
1.  CD24- CD38-  B cells 
2.  CD24- CD38int B cells 
???????? ?????
????????????????? ???????????????????
e s y
0
20
40
60
80
%
 Ig
D
+I
gM
+ 
ce
lls
e s y
0
20
40
60
80
100
%
 Ig
D
+I
gM
+ 
ce
lls
C
D
24
 
CD38 
???
???
???
???
???
??
??
??
???
???
???
???
???
???
????
??
??
???
A 
B 
C 
Un
tre
ate
d (
D0
)
CD
40
L+
αB
CR
 (D
5)
0
20
40
60
80
100
%
 C
D
24
-C
D
38
- B
 c
el
ls
*
*
Un
tre
ate
d (
D0
)
CD
40
L+
αB
CR
 (D
5)
0
20
40
60
80
100
%
 C
D
24
-C
D
38
in
t B
 c
el
ls * * Naive (IgM+IgD+)
Memory (CD27+IgD-)
????????????????? ???????????????????
? ???
?????? ????????????????????????????????????????????????????????? ????????
?
 
Understanding the cytokine production of CD24- B cells will give us a further 
indication as to whether this B cell subset may contribute to chronic disease and 
damage in the liver. To investigate this, I measured cytokine production of hepatic B 
cell subsets following stimulation with CpG, PMA and Ionomycin for 5 hours (See 
methods 2.4.5). This method has been used by several previous studies to activate 
B cells, in particular by Buffa et al. to stimulate CD24-CD38- B cells to induce 
cytokine production (72, 477). I hypothesized that CD24- B cells are pro-
inflammatory and that activated B cells such as memory and plasma cells would also 
produce high levels of inflammatory cytokines compared to naïve subsets.  
 
Cytokine production of stimulated hepatic B cell subsets from LIMCs were compared 
to unstimulated hepatic B cell subsets post isolation. These experiments were also 
compared to stimulated and unstimulated peripheral blood B cells, to assess 
whether the functional characteristics of CD24- B cells differed between the liver and 
blood. 
 
Results in Fig. 46B indicate that both stimulated and unstimulated healthy blood B 
cell subsets did not produce large amounts of cytokines. In matched blood from 
chronic liver disease patients however, (Fig. 46C), peripheral blood B cells could be 
stimulated to produce higher levels of TNF-α across most B cell subsets.  
 
Hepatic CD24-CD38int B cells were found to demonstrate an inflammatory 
phenotype following stimulation (Fig. 46A&B). Although TNF-α percentages in 
? ???
unstimulated and stimulated CD24-CD38int B cells were not significantly increased 
compared to other subsets, CD24-CD38int B cells produced significantly higher 
levels of IFN-γ compared to transitional, naïve and memory subsets, in stimulated 
and unstimulated samples respectively (CD24-CD38int: 35.6±28.6%, transitional: 
0.8±0.9%, naïve: 2.9±3.7% and memory: 2.8±5.8%, where p=0003, 0.03 and 0.002 
respectively) (CD24-CD38int: 16.0±13.9%, transitional: 0.8±1.0%, naïve: 1.8±2.5% 
and memory: 0.7±1.2%, where p=002, 0.005 and 0.0004 respectively).  
 
Production of IL-10 also significantly increased following stimulation from CD24-
CD38int B cells compared to naïve and memory B cells, (CD24-CD38int B cells: 
11.7±9.2%, naïve: 2.6±3.6% and memory: 1.8±2.2% where p=0.01 and 0.01 
respectively), indicating that these cells may be also be involved in immune 
regulation. Of note, IL-10 producing cells co-expressed IL-6 and IFN-gamma, 
however they did not co-express TNF-alpha (data not shown). 
 
Fig. 46B also demonstrates that CD24-CD38- B cells in blood and liver produce very 
little TNF-α following stimulation by CpG, PMA and ionomycin compared to other B 
cell subsets, however in both liver and blood, TNF-α production is increased 
compared to unstimulated B cells. 
 
Fig. 46C demonstrates that CD24-CD38- B cells in matched blood and liver samples 
produced similar proportions of IL-6, IL-10, IFN-γ and TNF-α when stimulated and 
unstimulated. This pattern was replicated in the case of CD24-CD38int B cells in 
liver and blood, except for in the case of IFN-γ, where unstimulated and stimulated 
? ???
hepatic CD24-CD38int B cells produced more IFN-γ compared to CD24-CD38int B 
cells in matched disease patient blood.  
? ???
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Fig. 46B demonstrated that CpG (TLR9), PMA and ionomycin was effective at 
stimulating CD24-CD38- B cells to produce significantly higher percentages of TNF-
α from liver and blood (where unstimulated CD24-CD38- B cells in liver: 2.4±4.5% 
and stimulated CD24-CD38- B cells in liver: 22.7±14.9%, p=0.007) (unstimulated 
CD24-CD38- B cells in blood: 2.4±4.5% and stimulated CD24-CD38- B cells in 
blood: 22.7±14.9%, p=0.03). The nature of TLR-activating stimuli on B cells 
dramatically influences B cell cytokine production (77, 92, 93). Understanding which 
methods of stimulation induce cytokine secretion from CD24- B cells and other major 
B cell subsets would assist in further establishing the significance, function and 
activation of B cells within the hepatic environment. Consequently, I wanted to 
investigate the effects of TLR stimulation on cytokine production of human hepatic B 
cell subsets, with particular focus on defining which stimuli were pivotal in the 
activation of CD24-CD38- B cells in blood and liver. Fig. 46D demonstrated that 
hepatic CD24-CD38int B cells contain a population, which secrete IFN-γ and IL-6 
pro-inflammatory cytokines simulataneously. This effect is observed both directly ex-
vivo and following stimulation (unstimulated: 55%, stimulated: 42%). This population 
is almost absent from CD24-CD38int B cells in matched patient blood (unstimulated: 
1%, stimulated: 3%). Both stimulated and unstimulated B cells from matched patient 
liver and blood also contained a small percentage of cells which were able to 
simultaneously produce both pro- and anti-inflammatory cytokines IFN-γ and IL-10 
(stimulated blood CD24-CD38-: 1%, stimulated blood CD24-CD38int: 3%, stimulated 
liver CD24-CD38-: 1%, stimulated liver CD24-CD38int: 3%) (Fig. 42D).  
 
 
? ???
Fig. 47 demonstrated that cytokine production between blood and liver B cell 
subsets were different following stimulation with the same TLRs. For example, Fig. 
47A demonstrated that TLR9 stimulation of hepatic naïve and memory B cells 
induced significantly higher TNF-α production compared to unstimulated naïve and 
memory B cells (stimulated naive 52.7±17.3% unstimulated naive: 9.8±6.3% where 
p=0.01 and stimulated memory: 68.4±6.1% unstimulated memory: 10.0±7.8% where 
p=0.001). Furthermore, TLR9 stimulation of CD24-CD38- and CD24-CD38int B cells 
also induced significantly higher TNF-α production compared to unstimulated B cells 
belonging to the same subsets (stimulated CD24-CD38-: 57.7±16.7% unstimulated 
CD24-CD38-: 7.6±4.1% where p=0.01 and stimulated CD24-CD38int: 37.7±18.3% 
unstimulated CD24-CD38int: 9.9±3.9% where p=0.04). In blood, although TLR7 and 
TLR9 induced slightly higher TNF-α production as a trend across B cell subsets, no 
significant differences were found. Fig. 47 demonstrated that hepatic CD24-CD38- B 
cells were most responsive to TLR7 and TLR9 stimulation in regards to TNF-α 
production.  
 
TLR9 stimulation of memory and CD24-CD38- B cells in blood, induced a 
significantly higher production of IL-6 compared to unstimulated memory and CD24-
CD38- peripheral blood B cells (Fig. 47C), further highlighting that hepatic and blood 
B cells may require different stimuli to induce cytokine production. IFN-γ and IL-10 
(Fig. 47B & D) production does not differ significantly within B cell subsets following 
different TLR stimulations in comparison to unstimulated B cells, except for in the 
case of TLR9, which induced significantly higher IL-10 production from memory 
hepatic B cells compared to unstimulated (stimulated memory: 2.2±1.9% 
unstimulated memory: 0.25±0.32% where p=0.04), and TLR4 which also induced 
? ???
significantly higher IL-10 production from naïve hepatic B cells subsets compared to 
unstimulated (stimulated naive: 6.4±7.9% unstimulated naive: 1.0±0.6% where 
p=0.02).  
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Figure 47 – TLR9 stimulates significantly higher TNF-α production compared 
to unstimulated B cells across naïve, memory, CD24-CD38- and CD24-CD38int 
hepatic B cell subsets. Percentage (%) of (A) TNF-α, (B) IFN-γ, (C) IL-6 and (D) IL-
10 production from peripheral blood and hepatic B cell naïve, memory, 
plasmablast/plasma cell, CD24-CD38- and CD24-CD38int B cell subsets stimulated 
with BCR + CD40L, LPS, R848 (TLR7 ligand), CpG (TLR9 ligand) and RP105 (TLR 
homologue). Untreated samples contained brefeldin alone, and all treated cells were 
stimulated for 5h with PMA, ionomycin and brefeldin. Error bars represent the mean 
and standard deviation, where n=5 for liver and n=4 for healthy blood. Statistical 
differences were calculated with a non-parametric one-way ANOVA (Kruskal-Wallis 
test), corrected for multiple comparisons (Dunn’s). 
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Fig. 47 demonstrated the effects of TLR stimulations on individual B cell subsets in 
the liver. However, the data was replotted so that direct comparisons between 
hepatic and peripheral B cell subsets could be made (Fig. 48). Presenting the data 
this way would specifically allow us to compare cytokine secretion of blood and liver 
CD24- B cells following TLR stimulation compared to other activated and naïve B 
cells. 
 
Certainly, most hepatic and peripheral B cells contained populations capable of 
producing TNF-α following stimulation (Fig. 48A), providing a valuable internal 
control that B cell stimulations are effective and capable of inducing higher levels of 
cytokine production from B cell subsets compared to unstimulated subsets. In 
peripheral blood, TNF-α production increased following stimulation and was higher 
across B cell subsets stimulated with TLR9. TNF-α production did not vary 
significantly between hepatic B cell subsets following stimulation, and appeared to 
be relatively comparable to that from blood B cells stimulated in the same manner. 
 
Unstimulated CD24-CD38int and plasmablast/plasma cells produced significantly 
higher IFN-γ levels compared to memory B cells (CD24CD38int: 19.7±12.1%, 
plasmablast/plasma cells: 31.7±31.6% and memory: 0.7±0.7% where p=0.03 & 0.04 
respectively). Following all stimulations except TLR9, IFN-γ production from hepatic 
plasmablast/plasma cells increased significantly compared to hepatic memory cells 
(plasmablast/plasma cells: 54.3±33.2%, 58.9±31.0%, 55.5±28.3%, and 54.5±28.6, 
memory: 4.9±5.4%, 6.1±6.8%, 4.6±4.5%, and 3.2±4.8% where p= 0.03, p=0.03, 
p=0.02, and p=0.003 for BCR/CD40, TLR4, TL7, TLR9 and RP105 respectively) 
(Fig. 48B). This was not the case for peripheral blood B cells, where IFN-γ 
? ???
production was not significantly enriched in any subsets with or without BCR/TLR 
stimulation, highlighting that pro-inflammatory plasma cells / plasmablasts were 
present in the liver but absent from the blood. 
 
Both CD24-CD38- and CD24-CD38int hepatic B cells produced significantly higher 
levels of IL-6 compared to transitional B cells prior to stimulation (CD24-CD38-: 
7.0±4.6%, CD24-CD38int: 50.3±30.0 and transitional: 0.03±0.06%, where p=0.04 
and p=0.001 respectively) (Fig. 48C). Following stimulation via TLR4, TLR7 and 
TLR9, CD24-CD38int hepatic B cells alone produced a significantly higher 
percentage of IL-6 compared to transitional B cells (CD24-CD38int: 63.0±33.9%, 
60.8±32.8%, 63.0±31.0% transitional: 2.5±2.2%, 3.6±6.1%, 3.8±4.4% and p=0.02 for 
TLR4, TLR7 and TLR9 respectively), highlighting that CD24-CD38int hepatic B cells 
may possess an inflammatory phenotype, which is another trend absent from blood 
CD24-CD38int B cells (Fig. 48C). 
 
As well as demonstrating pro-inflammatory qualities compared to some other hepatic 
B cell subsets, CD24-CD38int B cells were also found to produce significantly higher 
percentages of IL-10 following anti-BCR+CD40L, TLR7, TLR9 and RP105 
stimulation compared to memory populations, (CD24-CD38int: 23.9±14.2%, 
24.7±13.0%, 21.4±10.0% and 23.1±12.3% memory: 1.3±0.5%, 2.3±3.2%, 2.2±1.9% 
and 0.9±0.5% where p=0.008, 0.02, 0.01 and 0.002 for anti-BCR+CD40L, TLR7, 
TLR9 and RP105 respectively). This was also the case for activated 
plasmablast/plasma cell hepatic B cells, (plasmablast/plasma cells: 20.9±10.4%, 
30.0±16.8%, 29.0±24.5% and 24.0±13.3%, where p=0.007, 0.02, 0.03 and 0.001 for 
anti-BCR+CD40L, TLR7, TLR9 and RP105 respectively). In blood, CD24-CD38int B 
? ???
cells did not produce significantly higher levels of IL-10 following stimulation 
compared to other B cell subsets. Hepatic CD24-CD38int B cells therefore may be 
more responsive to stimulation compared to blood CD24-CD38int B cells (Fig. 48D). 
 
 
? ???
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Figure 48 – Hepatic CD24-CD38int B cells produced significantly higher levels 
of IL-6 compared to transitional B cells following TLR stimulation. Percentage 
(%) of (A) TNF-α, (B) IFN-γ, (C) IL-6 and (D) IL-10 production from peripheral blood 
and hepatic B cell subsets stimulated with BCR + CD40L, LPS, R848 (TLR7 ligand), 
CpG (TLR9 ligand) and RP105 (TLR homologue). Untreated samples contained 
brefeldin, and treated cells were stimulated for 5h (contained PMA, ionomycin and 
brefeldin). Error bars represent the mean and standard deviation, where n=5 for liver 
and n=4 for healthy blood. Statistical differences were calculated with a non-
parametric one-way ANOVA (Kruskal-Wallis test), corrected for multiple 
comparisons (Dunn’s).  
 
??????
???
???
???
???
??
???
???
????
???
?
??
???
???
???
?
??
??
???
??
?
???
???
???
??
???
???
??
??
??
???
???
??
???
??
??
??
???
???
???
???
???
???
???
????
?
??
??
???
???
???
???
????
???
??
???
???
? ??????
???
???
???
???
???
???
???
????
?
??
??
???
???
???
???
????
???
??
???
???
0
20
40
60
80
100
C t
0
20
40
60
80
100
C t
0
20
40
60
80
100
l e y C t
0
20
40
60
80
100
l C t
0
20
40
60
80
100
0
20
40
60
80
100
p
l y C t
0
20
40
60
80
100
0
20
40
60
80
100
p
**
**
0
20
40
60
80
100
p
l C t
0
20
40
60
80
100
*
*
l C t
0
20
40
60
80
100
*
*
0
20
40
60
80
100
**
**
D 
? ???
 
Fig. 32 & 34 indicated that CD24-CD38int B cells may contain ABC type B cells. In 
line with the possibility that CD24- hepatic B cells could contain a majority age- 
associated B cell population, I decided to stimulate hepatic B cells with TLR7 
stimulation ±IL-21, IFN-γ and ±anti-CD40/BCR. These are the proposed methods of 
ABC generation according to the literature (479, 512). To assess activation of these 
B cell subsets, particularly CD24-CD38int B cells, I measured the percentage of IL-
10, IL-6, TNF-α and IFN-γ cytokine produced (Fig. 49). 
 
Fig. 49 showed that none of the hepatic B cell subsets demonstrated significantly 
different cytokine production with TLR7, TLR7+IL-21 or TLR7+IFN-γ stimulation in 
the presence or absence of CD40/BCR stimulation.  Additionally, in terms of IL-6, IL-
10 and IFN-γ (Fig. 49 B–D) cytokine production, blood plasmablasts/plasma cells 
were more unresponsive to TLR7, TLR7+IL-21 and TLR7+IFN-γ compared to 
hepatic B cells. Similarly, hepatic CD24-CD38int B cells showed higher IL-6 
production (Fig. 49C) in the presence and absence of TLR7, TLR7+IL-21 and 
TLR7+IFN-γ stimulation compared to blood CD24-CD38int B cells, as well as other 
liver B cell subsets. Although this increased IL-6 production was not found to be 
stimulation specific, these data highlighted the pro-inflammatory capacity of this 
subset in the liver, which was absent from blood. 
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Figure 49 – TLR7 did not induce increased cytokine production from hepatic 
CD24- B cells ±IL-21, IFN-γ or ±BCR/CD40 stimulation compared to 
unstimulated B cells. Percentage (%) of (A) TNF-α, (B) IFN-γ, (C) IL-6 and (D) IL-
10 production from peripheral blood and hepatic B cell subsets stimulated with 
TLR7, TLR7+IL-21 and TLR7+IFN-γ in the presence and absence of CD40/BCR 
stimulation. Untreated samples contained brefeldin alone. All treated cells were 
stimulated for 5h and also contained PMA, ionomycin and brefeldin. Error bars 
represent the mean and standard deviation, where n=5 for liver and n=4 for healthy 
blood. Statistical differences were calculated with multiple t tests.  
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5.3. DISCUSSION 
 
CD24-CD38- and CD24-CD38int B cell subsets were identified in the liver during 
phenotypic characterization of hepatic B cells. The next step was to functionally 
elucidate these populations to identify the potential role of these subsets in chronic 
liver disease. Mouse studies have shown that T cell responses are dampened in the 
liver (273, 274), which I hypothesise may also be the case for hepatic B cells. To 
address these points, I set out to characterize the localization and cytokine 
production of major B cell subsets in the liver, including the CD24- B cell population. 
?
To investigate the significance of CD24- B cells in liver disease pathogenesis, I 
stained for CD24- B cells (CD79α+CD24-) to establish where they localized within 
the liver architecture (Fig. 40). CD24- B cells were found throughout the liver, 
surrounding bile ducts and portal veins, and within the fibrotic scar tissue of 
chronically diseased livers, including PBC. It is possible that the aggregation of 
CD24- B cells around bile ducts and within fibrotic septa was an indication of their 
role in PBC, especially since the main hallmark of PBC is bile duct damage caused 
by inflammation (345, 513). Given that CD24-CD38- B cells were significantly 
elevated in PBC livers (Fig. 29), it was important to establish the specific localization 
of CD24-CD38- and CD24-CD38int B cells in the liver, to further elucidate their 
functional role. A preliminary triple stain was performed with the help of Gary 
Reynolds (Fig. 42), which showed that CD24-CD38- B cells aggregated in the region 
of bile ducts and fibrotic tracts (Fig 42B & C), excluding the CD24-CD38+ B cell 
population. Literature states that ABCs lack CXCR5, the chemokine receptor 
involved in B cell aggregation (479). The lack of aggregation found within the hepatic 
? ???
CD24-CD38+ B cell population, further adds to the possibility that CD24-CD38int 
population could be an ABC-like population.  
 
The localization of CD24-CD38- B cells in the region of bile ducts and fibrotic tracts 
implies that this population may be representative of a more activated population in 
inflamed livers. Figure 29B in Chapter 4 supports this by highlighting that CD24-
CD38- B cells contain a significantly higher proportion of IgG class switched cells in 
PSC livers compared to viral livers. The triple stain also revealed that CD24-CD38+ 
B cells aggregated around bile ducts and within the fibrotic tracts in PBC livers. 
AMAs are known to be involved in bile duct damage in PBC (345, 349); therefore it is 
possible that this CD24-CD38int B cell subset in the liver may be involved in PBC 
disease pathogenesis.  
 
To further investigate whether distribution of CD24- B cells in the liver correlated with 
disease specificity, the frequency of CD24- B cells throughout the liver architecture 
were semi-quantitatively scored (Fig. 41). Results corroborated previous flow data in 
Chapter 4, demonstrating that PBC patients contained a higher frequency of CD24- 
B cells compared to other hepatic diseases, and that this B cell population was 
distributed relatively equally in PBC across fibrotic septa, portal areas, vessels and 
within lymphoid aggregates. Lymphoid aggregates have previously been found to be 
enriched in PBC (514), which was also supported by our aggregate data in Fig. 23, 
where their role remains uncertain. It is speculated that similar to tertiary lymphoid 
follicles in rheumatoid arthritis, lymphoid aggregates might provide an environment in 
which self-antigens can be presented and antigen-specific T cells can be activated, 
enabling the propagation of autoimmunity (223). Given that CD24- B cells are 
? ???
present in lymphoid aggregates in PBC (Fig. 41), it is possible that they may 
somehow contribute to this proposed function. How the composition of lymphoid 
aggregates in the context of PBC differs from ectopic lymphoid structures found in 
chronic HCV infection where CD24- B cells are also found to be present, and how 
this affects the lymphoid structure function is not clear. It is also possible that CD24-
CD38+ B cells are involved in PBC disease pathogenesis directly via cytokine/Ab 
production or indirectly by attracting other immune cells to cause damage.? PBC 
patients harbored over twice as many CD24- B cells in the liver compared to the 
other autoimmune disease cohort of AIH patients, which had similar CD24- B cell 
percentages to donor livers (Fig. 41). It is possible that the addition of more patient 
numbers to this study may highlight further differences between these disease 
cohorts, giving further indication to the role of CD24- B cells within the liver in the 
presence of chronic disease. 
 
Studies have shown that early ontogeny B cells express high levels of CD24, a 
marker whose expression precedes that of the pan B cell marker CD19 (462, 515). 
As these B cells leave the bone marrow as transitional B cells, their development 
into naïve B cells and consequent antigen-induced activation into GC blasts, 
correlates with downregulation of surface CD24 expression (455, 488, 516). In order 
to investigate whether CD24- hepatic B cells resembled activated GC B cells, human 
tonsil and liver sections were stained and compared for pan B cell markers CD79α 
and CD24. Results from Fig. 41 demonstrated that in both liver and tonsil, CD24- B 
cells aggregated, and in both cases were surrounded by what appeared to be a 
‘halo’ of CD24+ B cells, indicating a possible GC in both the liver and tonsil. For 
? ???
confirmation that CD24- B cells were an actively proliferating population, I stained for 
the proliferation marker Ki67 following 5 hour stimulation of B cells with anti-
BCR/CD40L (Fig. 44A). Our experiments showed that both before and following 
stimulation, CD24-CD38int B cells, proliferated significantly more that memory B 
cells, but less than plasmablast/plasma cell populations, and that proliferation 
increased slightly across all B cell subsets following activation into blasts. These 
data was again indicative that this particular CD24- population might be a GC 
subset. CD24-CD38- B cells showed little if any proliferation following B activation at 
5 hours, further implying that this subset is different to the CD24-CD38int B cell 
population, is harder to stimulate and most likely is not comparable to the CD24- B 
cells that were observed in human tonsil. I was able to corroborate my CD24-
CD38int B cell data using IHC (Fig. 44B), which showed that some CD24- B cells 
also co-expressed the proliferation marker Ki67.  
 
In order to understand whether CD24- B cells could be generated in vitro, and 
whether CD24- B cells generated in vitro are comparable to liver CD24- B cells, 
blood B cells were assessed for CD24- B cell expression at day 0, then activated 
into B cell blasts as described in 2.4.7. Fig. 45 demonstrated that although CD24 
downmodulation of blood B cells could be induced following stimulation, the 
phenotypic profile of both CD24-CD38- and CD24-CD38int blood B cells did not shift 
to show a more activated memory phenotype prior to or following stimulation, and 
instead remained mainly naive. This result differed to what is reflected in the hepatic 
environment, where CD24-CD38- liver B cells ex vivo had an intermediate 
phenotype between naïve and memory cells, and CD24-CD38int B cells presented 
with a higher proportion of IgM+IgD+ B cells compared to memory cells. This did not 
? ???
only contradict recent literature describing blood CD24- B cells in general as a type 
of ‘memory’ B cell population (477), but also confirmed that CD24- B cells could not 
be generated from blood to represent hepatic CD24- B cells in our experiments, as 
these differ in IgD/CD27 expression. 
 
B cells have previously been found to contribute to hepatic diseases such as PSC 
and PBC (30, 417) (225, 517) (355, 378), where B cells have been found to have an 
autoimmune function and secrete autoantibodies. B cells have also been implicated 
in viral infections such as HBV and HCV (292, 400), where B cell markers have been 
associated with levels of fibrosis and B cells have served as a reservoir for persistent 
hepatitis C virus infection. In such cases, treatments such as rituximab have been 
used, resulting in a knock out of total B cells using anti-CD20 monoclonal antibodies 
(401). By characterizing the contribution of B cell subsets to end stage hepatic 
disease, I will be able to effectively target the knock out of specific B cell subsets, 
which contribute to immune inflammation and disease pathogenesis within the liver. I 
decided to investigate the function of major B cell subsets in the liver, by identifying 
their cytokine secretion profiles. This will indicate how B cells may exacerbate or 
dampen hepatic immune responses.  
 
The Buffa study (2013) identified a population of CD24-CD38- B cells expanded in 
chronic stimulation states and enriched in the blood of elderly patients. This 
population was labeled as a ‘new memory B cell population’ (477), which secreted 
significantly higher TNF-α compared to unstimulated B cells following stimulation 
with CpG/PMA. This study suggested that CD24-CD38- B cells played an 
inflammatory role in aged patient blood. However this study did not go on to define 
? ???
TNF-α, IFN-γ, IL-6 and IL-10 production from major B cell subsets or demonstrate 
any comparative data. I found that memory B cells in the blood differ to hepatic 
memory B cells (Fig. 19), and reports show that specific B cell subsets are 
susceptible to variable forms of stimulation (80, 81, 394). Studies have also shown 
that T cell responses are dampened in the liver (273, 274), which may also be the 
case for hepatic B cells, given that that the liver is a tolerogenic organ. More 
recently, the frequencies of CD19+CD24-CD38- B cells were found to be 
significantly enriched in atopic dermatitis patients compared to psoriasis patients and 
healthy individuals, suggesting that these B cells may play an important role in 
promoting inflammation, although these frequencies did not correlate with disease 
severity (478).  
 
I wanted to assess whether the hepatic CD24-CD38- and CD24-CD38int B cell 
populations, which I identified, were similar to the CD24- B cells described in the 
Buffa paper. Furthermore, I wanted to compare cytokine production of B cell subsets 
across hepatic diseases following B cell stimulation via BCR/CD40 and TLRs. 
Several TLRs have been reported to be present in B cells (518) which trigger 
cytokine stimulation upon ligation (519). Cognasse et al. previously reported 
secretion of IL-6 by TLR9 expressing memory B cells (520). Additionally, Buffa et al. 
stimulated B cells using CpG/PMA to induce TNF-α production from CD24-CD38- B 
cells (477). I decided to use the same method to investigate hepatic B cell activation 
and cytokine production of IL-6, TNF-α, IL-10 and IFN-γ via flow cytometry. Fig. 46B 
demonstrates that stimulation with CpG/PMA was effective at stimulating hepatic B 
cell subsets, as TNF-α production was higher from B cells post-stimulation. 
Supportive of the Buffa findings, directly ex-vivo, CD24-CD38int hepatic B cells 
? ???
demonstrated an inflammatory phenotype which was increased upon stimulation, 
where this population produced significantly higher levels of IFN-γ compared to most 
other B cell subsets and significantly higher levels of IL-6 compared to naïve and 
memory subsets. Considering I showed that CD24-CD38+ B cells cluster around bile 
ducts in PBC, it is possible that this B cell population causes immune damage by 
contributing to elevated inflammatory responses in PBC patients, or by propagating 
direct or indirect inflammatory-mediated destruction of bile ducts by attracting other 
immune cells, further driving the characteristic bile duct damage seen in PBC. CD24-
CD38int B cells from the liver also demonstrated anti-inflammatory properties, by 
producing significantly higher levels of IL-10 compared to transitional and memory B 
cells directly ex vivo when unstimulated. This increase in IFN-γ, IL-6 and IL-10 
cytokine production from hepatic CD24-CD38int B cells following stimulation was not 
observed in healthy blood, where all B cell subsets maintained low cytokine 
production both prior to and following stimulation. This contradicts previous studies, 
where peripheral blood B cells stimulated by CpG produced IL-10 levels between 
12–20% (69, 93). This is with the exception of TNF-α, which increased across 
peripheral B cell subsets following stimulation. Previous studies showed that MZ B 
cells secreted IL-10 in response to LPS (TLR4) and CpG (TLR9) (77). Since the 
hepatic CD24-CD38int B cell population contains a human MZ population (Fig. 27), 
it is possible that this B cell subset was activated in the same way to modulate 
immune responses in the liver. Duddy et al., using the BCR and CD40 signaling 
system, showed that memory B cells produce TNF-α and lymphotoxin (TNF-β) (508), 
so it is also possible that hepatic CD24- B cells are activated by T cell-dependent 
mechanisms. Fig. 46D demonstrated dual pro-inflammatory cytokine production 
from stimulated (CpG/PMA/Iono) and unstimulated CD24- B cells in a matched liver 
? ???
and blood sample from an ALD patient. Results demonstrated the hepatic CD24-
CD38int hepatic B cells contained a population which secreted both IFN-γ and IL-6 
cytokine, directly ex-vivo (55%) and following CpG stimulation (42%). This 
population was not enriched in CD24-CD38 B cells. One study has shown that 
subsets of CD24hiCD38hi transitional B cells, CD24hiCD27+ memory B cells, and 
naïve B cells from human peripheral blood, expressed IL-10 and the proinflammatory 
cytokine TNF-α simultaneously (521). Furthermore, this study highlighted that 
neutralization of IL-10 significantly inhibited transitional B cell-mediated suppression 
of autologous Th1 cytokine expression, and that blocking TNF-α increased the 
suppressive capacity of both memory and naïve B-cell subsets. The study thereby 
concludes that the ratio of IL-10/TNF-α expression may be a better indicator of 
regulatory function than IL-10 expression alone (521). 
http://jasn.asnjournals.org/content/25/7/1575.long Although neither liver nor blood 
CD24- B cells expressed IL-10/TNF-α simultaneously, it appears from Fig. 46D that 
a small percentage of the CD24- B cell population in matched blood and liver are 
capable of expressing IL-10 and IFN-γ simultaneously. However, this percentage is 
extremely low, and no differences are observed in this dual cytokine production 
between CD24- B cells directly ex-vivo compared to following stimulation. 
Nonetheless, our data has shown that CD24-CD38int B cells are rich in ABC 
markers, and ABCs are known to co-express IL-10 and IFN-γ simultaneously (483, 
484). It would be interesting to investigate the ratio of pro-inflammatory and anti-
inflammatory cytokine co-expression within this population further, as well as from a 
number of matched liver and blood samples going forward, in order to more 
accurately assess the regulatory capacity of B cell subsets in the liver. 
 
? ???
It was clear from Fig. 46B that although CD24-CD38int B cells could be stimulated 
by CpG, the CD24-CD38- hepatic B cell population was mainly unresponsive to this 
form of activation. Unlike the Buffa study suggested, the CD24-CD38- population did 
not produce significantly higher levels of TNF-α cytokine following 5h stimulation with 
CpG compared to other B cell subsets. 
 
Since hepatic CD24-CD38- B cells produced low amounts of cytokines in response 
to CpG stimulation, I decided to investigate the roles of range of TLR stimulations on 
hepatic B cells within a new cohort of explanted patient livers. Studies have shown 
that different B cell subsets are susceptible to variable forms of TLR stimulation. One 
study in particular investigated cytokine production of murine B cell subsets, 
examining the role of TLRs in secretion of IL-6, IL-10, IL-12 and IFN-γ by B cells, 
and found that activation of B cells by different TLR stimuli increased cytokine 
production (16, 77). In order to investigate the effects of TLR stimulations on CD24-
CD38- B cells, hepatic and blood B cells were co-cultured with a range of TLR 
stimuli and anti-BCR/CD40L to assess B cell subset cytokine profiles compared to 
unstimulated B cells (Fig. 47). CD24-CD38int B cells produced innate cytokines ex-
vivo (IL-10, IFN, IL-6) in the first patient cohort (Fig. 46B), and increased TNF-α 
following TLR9 stimulation in a second cohort of patients (Fig. 47A).? One 
explanation for this is that the donors were different i.e. different hepatic diseases. It 
is possible that B cells in certain chronic liver diseases produce different types and 
quantities of cytokines upon same stimulations. Further investigations into cytokine 
production from B cell subsets across hepatic diseases could be further investigated 
in the future to determine whether this is the case.?
?
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CD24-CD38- hepatic B cells appeared to be unresponsive to TLR4, TLR7, RP105 
and anti-BCR/CD40L stimulations when it came to IL-10, IFN-γ and IL-6 production. 
However, hepatic CD24-CD38- and CD24-CD38int B cells were both sensitive to 
CpG (TLR9) stimulation, where both CD24- B cell subsets produced a significantly 
higher percentage of TNF-α compared to unstimulated CD24- B cells following 
treatment (Fig. 47A). With regard to TLR9 stimulation of blood CD24-CD38- B cells, 
this increase in TNF-α production was absent. The liver encounters a constant influx 
of bacterial antigens through the portal vein from the gut (408). Previous studies 
have already shown that TLR9 signals directly activate human peripheral blood 
naive and memory B cell subsets to produce IL-1α, IL-1β, IL-6, TNF-α, IL-13, and IL-
10 cytokines (519). It is possible that bacterial antigens, which enter the liver, are 
internalized and processed by B cells into CpG-containing 
oligodeoxyribonucleotides. Binding of CpG peptides to TLR9 could elicit these TNF-
α cytokine responses from hepatic CD24- B cells through TLR9 stimulation. Studies 
have highlighted that ABCs can be stimulated to produce TNF-α via TL7/9 
stimulation (483, 484). As the CD24-CD38int B cell compartment has been shown to 
be enriched in ABC markers, it is possible that TNF-α production from this particular 
population is further indicative of CD24-CD38int B cells being representative of an 
ABC population. 
 
Fig. 48B, C, and D demonstrated that liver B cells contain populations that make 
innate type-cytokines without any stimulus. When attempting to induce this cytokine 
production from blood B cells, the CD24-CD38int compartment showed that it can be 
induced to make innate-type cytokines but not to levels similar to liver. Furthermore, 
stimulation of the hepatic CD24-CD38int subpopulation with TLR4, TLR7, TLR9 but 
? ???
not BCR/CD40L or RP105 induced significantly higher IL-6 production (Fig. 48C) 
compared to transitional liver B cells, a profile which was absent in the blood. This 
reinforces that CD24-CD38int B cells were more susceptible to TLR stimulation 
compared to blood CD24-CD38int B cells, and indicates that this population may be 
sensitive to stimulation by bacterial antigens from the gut. Previous studies have 
shown that stimulation of human B cells via TLR7 and TLR9 induced significantly 
higher IL-6 secretion compared to unstimulated B cells (519, 520, 522). More 
interestingly, I showed that the CD24-CD38int B cell subset contains a large 
proportion of non-switched memory, marginal zone B cells (Fig. 27B). Supportive of 
our results, one mouse study showed that MZ B cells produced pro-inflammatory 
cytokines, such as interleukin-6 (IL-6), and exacerbates systemic inflammatory 
responses to lipopolysaccharide (LPS) via TLR4 ligation (523). 
 
Overall, the CD24-CD38int hepatic B cells express an immunomodulatory 
phenotype, due to being able to produce significantly high levels of IL-10, as well as 
IL-6 and IFN-γ with specific treatment types. Again, this response was not replicated 
by blood CD24-CD38int B cells. Although contradictory to the Buffa study on aging 
blood B cells, hepatic CD24- B cells did not secrete significantly higher levels of 
TNF-α compared to other B cell subsets in blood or liver. Previous studies have 
termed CD19+CD24-CD38- B cells ‘new memory B cells’ (477). However, our 
functional data demonstrates that the cytokine profiles of both CD24-CD38- and 
CD24-CD38int B cells differ (in some cases significantly) to that of memory B cells, 
implying this subset in the liver may not be representative of a memory subset. 
Differences in cytokine profiles between memory and CD24- B cells also exist, 
implying that the hepatic CD24-CD38- and CD24-CD38int B cells I identified in the 
? ???
liver may be different to those described as a ‘new inflammatory memory’ 
CD19+CD24-CD38- B cell subset in the Buffa study (477).  
 
Studies have shown that in mice, ABCs were refractory to CD40 and BCR 
stimulation and instead were activated by TLR7 and TLR9 stimulation resulting in 
increased IL-10 and IL-4 production (479, 512). ABC phenotypes are induced with 
TLR stimulation in the presence of IFN-γ, IL-4 and IL-21. Figure 32 & 34 
demonstrated that CD24-CD38int B cells were rich in ABC markers T-bet and 
CD11c. In line with our theory that CD24- B cells may include a population of ‘age-
associated B cells’, I decided to stimulate hepatic B cell populations with TLR7 in 
combination with IL-21 and IFN-γ with and without BCR/CD40 stimulation, which the 
literature has reported to specifically expand and activate ABC populations (479, 
512). Results from Fig. 49 indicated that cytokine production from CD24-CD38- and 
CD24-CD38int hepatic B cell populations did not increase significantly following any 
of the combinations of stimuli compared to unstimulated CD24- B cells. This also 
proved to be true for CD24- B cells in the blood, indicating that it is possible that 
these populations are exhausted rather than ABCs, or that hepatic ABCs require 
different stimuli to induce activation and cytokine secretion. The recent study by 
Thorarinsdottir et al. investigating human CD21-/lo ABC-like cells in human blood, 
found that CD24lo B cells within this population were more difficult to stimulate ex 
vivo unless performed with BCR, R848 and IL-2 (485). It is possible that the ABC-
like cells we find in the liver are a similar population, which can only be stimulated in 
the same way. 
 
? ???
Literature states describes CD24-CD38int B cells as being a type of GC B cells (488, 
510). Although CD24- B cells look like they could be present in lymphoid follicles in 
the liver which resemble similar structures to those found in SLOs, our previous 
findings have shown that CD24-CD38int B cells are significantly enriched in donor 
liver compared to SLOs such as perihepatic lymph nodes and spleen. Furthermore, 
given that the cytokine profiles of hepatic CD24- B cells differ from hepatic memory 
and plasma cell populations, as well as blood CD24-CD38int B cells, it is more likely 
that these cells are representative of an inflammatory B cell population.   
 
In this chapter, I have characterised the localization and cytokine production of the 
novel CD24-CD38- and CD24-CD38int B cells in the liver. I show that CD24-CD38int 
B cells expressed immunomodulatory cytokines compared to other major B cell 
subsets, and produced significantly higher TNF-α levels following TLR9 stimulation 
compared to unstimulated B cells. Furthermore, CD24-CD38int B cells localized 
around bile ducts and fibrotic tracts in PBC patients, implying that these cells may 
play a contributing role in chronic hepatic disease. The function of CD24-CD38- B 
cells was less clear. Although numbers were enriched in PBC livers, this population 
produced low percentages of cytokines following BCR and TLR stimulations 
compared to other B cell subsets. Consequently, it is possible that these B cells 
were representative of a more unresponsive B cell population, much like the 
dampened T cell responses which have been previously demonstrated in the liver 
(273, 274). Nevertheless, like the CD24-CD38int hepatic B cell population, CD24-
CD38- liver B cells produced significantly higher TNF-α percentages following TLR9 
stimulation compared to unstimulated B cells, indicating that this population may 
exert some pro-inflammatory effects. Overall, I have shown that cytokine secretion 
? ???
differs between hepatic and peripheral blood B cells, and that blood B cells are 
difficult to stimulate in vitro. Furthermore, cytokine secretion from hepatic B cell 
subsets are dependent on the type of stimulation, which could highlight the role of B 
cell subsets, and particularly CD24- B cells in the liver.  
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6.1. GENERAL DISCUSSION 
?
Research over the recent years has confirmed that B cells are a diverse multifaceted 
immune cell population (93, 116, 138, 139, 524). Much like CD4+ and CD8+ T cells 
which are comprised of effector and regulatory T cells, B cell subsets can be 
protective or pro-inflammatory (525, 526). Despite massive biological differences 
between mouse and man, classification of B cell subsets have been based on 
murine models, where the phenotypic characterization of B cell subsets has been 
well established. Phenotypic profiles have also been established to identify stages of 
B cell maturation in human lymph node and bone marrow. Due to their phenotypic 
complexity, peripheral blood circulating B cell subsets have been poorly defined until 
recently. Consequently, over the last few years many different approaches have 
been proposed to characterize mature B cell populations in human peripheral blood, 
including ‘newer’ B cell populations such as ‘B1-type’ cells (386), double negative 
memory B cells (155), marginal zone B cells (134, 195)  and Bregs (93).   
 
Despite the lack of consensus over methods of human B cell characterization (138, 
144, 188, 189, 527, 528), it has been proven that disturbed B cell homeostasis and 
impaired B cell development play a role in several immunological diseases (58, 296, 
349, 529, 530). For example, B cell dysfunction has been associated with fibrosis in 
human skin and lung, where B cell gene signatures have been found to characterize 
skin biopsies from systemic sclerosis patients (531). Moreover, a B cell line 
established from the lung tissue of a patient with scleroderma has been shown to 
augment proliferation and inflammatory responses likely to lead to fibrotic changes 
(532). B cells have also been implicated in autoimmune diseases such as multiple 
sclerosis, where an increased frequency of (GM-CSF)-expressing human memory B 
? ???
cell subsets and IL-10-expressing B cells, are found to be enriched in multiple 
sclerosis patients compared to healthy controls (525). In rheumatoid arthritis, a 
distinct population of FcRL4+ B cells in the synovial tissue and fluid expressed high 
levels of TNF-α and RANKL mRNA, indicating that these cells play a role in bone 
destruction and inflammation (529). 
 
The liver is an organ rich in immune cells. In addition to the presence of large 
numbers of resident macrophages known as Kupffer cells, the liver also contains 
monocytes, T cells, NK cells, and NKT cells (249). Interestingly, there have been few 
studies investigating the role of B cells in the adult liver, which constitute 5–10% of 
the human hepatic lymphocyte population (5). Research on hepatic B cells in mice is 
also scarce, which is surprising considering that the murine embryonic liver is a well-
studied site of origin for B cells (533). This may be because the liver is often seen as 
a conduit for blood cells; however recent studies have identified liver resident CD8+ 
T cells (534, 535), and NK cells (536-538). The Cuff et al. study capitalized on the 
HLA mismatch of donors and recipients for liver transplants, and demonstrated that 
there was a long lived Eomeshi NK cell population that originated from the donor and 
did not recirculate (536). It is therefore likely that liver resident B cell populations also 
exist.  
 
There have been many studies which support B cells playing a contributing role in 
chronic hepatic disease, where patients suffering from ALD, HCV, and PBC exhibit 
immune-mediated liver damage, including persistent inflammation, cellular damage, 
regeneration, and fibrosis (539). One recent study used IHC to investigate the 
proportion of CD20+ B cells across hepatic diseases, and discovered that B cells 
? ???
significantly accumulated in the liver tissues of CLD patients. These B cells mainly 
clustered in the portal areas of liver tissues and correlated with inflammatory grades 
(287). Other studies have found that ectopic lymphoid structures containing B and T 
cells are enriched in the livers of patients with chronic HCV, and that these 
structures function as microniches for tumor progenitor cells in hepatocellular 
carcinoma (421). This implies that the etiology of the chronic hepatic inflammatory 
environment is very likely to specify the type of intrahepatic inflammation present 
and its consequences (223, 422).  
Murine studies have shown that hepatic fibrosis is attenuated in the liver in the 
absence of B cells in a T cell and antibody-independent manner (282), and that B 
cell depletion in AIH mouse models reduced liver inflammation and improved liver 
function following treatment with a single dose of anti-CD20 (58). However, 
conflicting studies demonstrate that B cell depletion exacerbated PBC-like diseases 
in murine models (405), highlighting a novel disease-protective role, and suggesting 
that B cell depletion therapy in humans with PBC should be approached with 
caution. As well as contributing to hepatic autoimmune diseases, B cells have also 
been found to have a protective role in viral diseases, where clinical studies have 
shown that rituximab mediated B cell depletion in HBV patients resulted in latent 
HBV reactivation (398), and that rituximab treatment in HCV patients resulted in 
increased viral loads in the blood (540). Conversely, in peripheral blood naïve B cell 
frequencies were higher in HCV patients with more severe hepatic fibrosis (541). 
Collectively, these studies further support both protective and contributing roles for B 
cells in end stage hepatic disease pathogenesis.  
 
? ???
Given that the majority of chronic liver conditions are either immune mediated or 
facilitate immune damage, and given that little is known about the role of B cells in 
the adult liver, I decided to thoroughly investigate the role of hepatic B cells in human 
end-stage chronic liver disease. By establishing which B cell subpopulations exist in 
the human liver in health and in end stage disease, an insight would be gained into B 
cell contribution to disease pathogenesis. Ultimately, B cells may provide novel 
therapeutic targets for treating chronic liver disease in the future. For example, 
rituximab is a drug already investigated in the treatment of patients suffering from 
autoimmune liver diseases PBC and AIH by depleting total CD20+ B cells (30, 31). 
Understanding which B cell subsets may be responsible for pathogenesis would 
allow the targeting of subset specific depletion, which may ameliorate liver 
inflammation. As B cell subsets may have protective and pathogenic roles, targeting 
B cell subsets would provide an important toggle switch for inflammation. 
Furthermore, one may not wish to deplete the entire B cell compartment and expose 
the patient to infection, which is one of the complications of rituximab therapy (542).  
All B cell subsets detected using our extensive custom 18 antigen marker flow 
cytometry panels, were present in the blood as well as in matched liver samples. 
When quantified, it appeared that diseased liver harboured more activated B cells 
(centroblasts, double negative memory (CD27-IgD-) (Fig. 27) compared to matched 
blood which contained more naïve B cells. This is justifiable given that antigen rich 
blood enters the liver via the portal vein from the gut (408), and may result in 
constant uptake of antigen via APCs such as B cells, leading to their activation. 
Furthermore, as most of these livers were chronically inflamed, an influx of activated 
? ???
immune cells into the organ contributing to local inflammation and damage would be 
expected.  
I characterised the total number of CD19+ B cells across hepatic diseases such as 
autoimmune (PBC, PSC), dietary mediated (NASH, ALD), viral (HCV, HBV) and 
donor livers. PBC livers appeared to contain the highest proportion of CD19+ B cells. 
However, the total number of CD19+ B cells did not vary significantly between any 
hepatic diseases (Fig. 21). This was also true for the number of B cell subsets per 
gram of liver tissue between liver diseases; with the exception of naïve mature B 
cells, which were enriched in PBC livers compared to donors. This flow cytometry 
data was in agreement with our IHC data, which demonstrated CD20+ B cells were 
significantly enriched in PBC patients compared to PSC patients (Fig. 22). A similar 
study corroborated our data, using IHC staining to show that CD20+ B cells were 
increased more significantly in the liver tissues of PBC patients compared with HBV, 
AIH and ALD patients (287). It is likely that some B cells are lost during the 
mechanical digestion process of the liver tissue due to being trapped within the 
fibrotic areas in the liver, making it difficult to isolate and quantify larger aggregates 
of B cells. Liver slices were washed vigorously to remove blood cells. Consequently, 
it is likely that the absolute B cell numbers from liver homogenates are being 
underestimated. Hence, IHC data are more accurate for absolute B cell number 
calculations compared to flow cytometry. 
Whilst characterizing B cell subsets in the liver, I noticed that CD24- B cells were 
highly enriched in the liver (Fig. 26B), and that this population could be further 
separated into CD24-CD38- and CD24-CD38int subsets (Fig. 26A). CD24 
downregulation has been associated with decreased cell proliferation; decreased 
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motility, immunomodulation and both increased and decreased susceptibility to 
apoptosis (445, 543). I found that both CD24-CD38- and CD24-CD38int B cells were 
enriched in diseased livers, compared to matched blood, and that CD24-CD38int B 
cells were also enriched in donor livers compared to secondary lymphoid organs. 
Collectively, these data suggests that CD24- B cells may be preferentially recruited 
to the liver, or are representative of a liver-resident population. This is important in 
deducing whether CD24- B cells have an immunosurveillance/homeostatic role in 
the liver or whether they are recruited to the liver in the presence of inflammation 
and disease. It is also possible that these cells are generated in the liver, and are 
derived from another B cell subset such as transitional, memory, naïve or even 
progenitor B cells. Sorting these subsets and performing BCR sequence analyses 
would address clonal relationships between B cell subsets (544).  
CD24- B cells are a heterogeneous population, but while CD24-CD38- B cells 
contained more IgD+ naïve cells in diseased and donor liver, they represented more 
of a non-switched memory population in the blood (Fig. 27). Similarly, CD24-
CD38int B cells contained a majority naïve and non-switched memory phenotype in 
diseased livers (which was not the case in donor livers) and non-switched memory 
majority in blood (Fig. 27). In order to accurately assess the role and significance of 
CD24-CD38int B cells in hepatic disease, future work could involve targeted 
depletion of CD24-CD38int B cells in mice, or expansion via adoptive transfer of this 
specific subpopulation in mouse models of hepatic inflammation. To begin this 
investigation, I would need to identify whether these CD24- (HSA-) B cell populations 
exist in mice. Although CD24 can be used in mouse and human tissue to identify 
distinct B cell subsets (113), we still know very little regarding the functional 
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differences between mouse and human CD24 antigen. Furthermore, the B cell 
compartment differs hugely between human and mice (113). Given that murine 
CD38 is down-regulated on GC B cells and mature plasma cells (545), and is 
expressed highly on human plasma cells (546), it is possible that equivalent CD24-
CD38- and CD24-CD38int hepatic B cell populations in mice may have a different 
functional phenotype, making these CD24- B cells difficult to locate in mice. 
After establishing that B cells were enriched in PBC, I showed that CD24-CD38- B 
cells were significantly increased in PBC compared to donor livers, implying that this 
B cell subset may be involved in the pathogenesis of PBC. Of note, this was the only 
B cell subset that was increased in PBC compared to other end stage diseases. I 
therefore attribute the increase of B cells in PBC to the increased CD24-CD38- 
subset. IHC staining helped us to further establish that within PBC patients, CD24-
CD38- B cells clustered in aggregates in the vicinity of bile ducts and fibrotic tracts, 
and CD24-CD38+ B cells were mainly located around the bile ducts and within 
fibrotic scar tissue, which again hinted towards the role of CD24- B cells in hepatic 
disease pathogenesis. 
 
Previous findings demonstrate that cirrhotic livers harbor large numbers of NKT cells 
and that activated NKT cells drive fibrogenesis in NASH livers (547). However, I 
found that CD1d expression on CD24- populations was significantly increased in 
donor livers compared to some other chronic diseased livers, especially those from 
dietary injury (Fig. 29 & 30). Hepatic NKT cells, which patrol the liver, enhance 
inflammatory responses in the presence of liver injury via pro-inflammatory cytokines 
and by activating HSCs (548). As CD1d expression is highest on APCs, this may 
? ???
hint that CD24- B cells may be responsible for mediating NKT cell activation (549), 
and that NKT activation may be impaired in the presence of certain chronic liver 
diseases.  
 
CD24-CD38- B cells have been previously described by Buffa et al. 2013, where this 
population was enriched in the blood of aged patients (477). There have since have 
been numerous reports on age-associated B cells (ABCs), a population which 
responds poorly to BCR/CD40 ligation and are instead stimulated by TLRs to 
preferentially secrete antibodies, IL-10 and IL-4 (479, 483). One recent study, 
described a B cell subset with an ABC-like phenotype, CD21- B cells, to exist in 
human blood. This subset contained a CD38-CD24lo B cell population (485). I 
therefore wanted to investigate whether hepatic CD24-CD38- and CD24-CD38int B 
cell populations contained age-related populations. Although neither CD24- hepatic 
B cell population correlated with end-stage liver disease patient age (Fig. 31), ABC 
markers were enriched in the CD24-CD38- B cell compartment in healthy donor 
blood, and within the CD24-CD38int compartment in end-stage disease livers (Fig. 
34). This further highlighted possible functional differences between blood and liver 
B cells, and implied that hepatic CD24-CD38int B cells may be activated in the 
absence of T cells via TLRs. ABCs have been reported to be activated with TLR7 
and IL-21 or TLR7 and IFN-γ (83, 84, 479, 512). Using a combination of these 
stimuli, our data showed that stimulation did not induce greater cytokine productions 
from either hepatic CD24- B cell population following stimulation compared to 
unstimulated. This implies that hepatic ABCs may require different stimuli, as 
described in the Thorarinsdottir et al. study, where CD21-CD38-CD24lo B cells could 
only be stimulated in vitro with BCR, R848 and IL-2 (485). Alternatively, it is also 
? ???
possible that these hepatic CD24- B cell populations are unresponsive to stimulation 
in vitro. 
 
Upon stimulation, B cells can secret pro-inflammatory cytokines such as IL-6 and 
TNF-α, thereby perpetuating inflammatory responses (550). In the AIH animal model 
for example, CD45+CD19+ B cells in the liver secreted significantly higher 
percentages of both IFN-γ and TNF-α compared to C57BL/6 littermates, contributing 
to a pro-inflammatory hepatic microenvironment (58). On the other hand, Bregs have 
been associated with inhibiting inflammation through IL-10, IL-35 and TGF-β 
production, which prevents pathogenic T cell expansion and limits damage (14, 551-
553). In this way, B cells may play both positive and negative regulatory roles in 
chronic liver disease pathogenesis.  
The Buffa study described the age-associated CD24-CD38- B cell subset as a pro-
inflammatory TNF-α secreting population, following stimulation with CpG (TLR9 
stimulation) for 5 hours (477). With the same stimuli CD24-CD38int B cells 
expressed both pro-inflammatory (IL-6 & IFN-γ) and anti-inflammatory (IL-10) 
cytokines in the liver compared to some other B cell subsets. This was not the case 
for blood CD24-CD38int B cells, which did not respond to this form of stimulation and 
produced low levels of cytokine following stimulation (Fig. 46B). The hepatic CD24-
CD38- B cell population also initially demonstrated very little cytokine secretion 
following stimulation compared to other B cell subsets (Fig. 46B).  
When tested with different TLR stimulations, CD24-CD38int B cells were again found 
to be pro-inflammatory directly ex-vivo, producing IFN-γ and IL-6 prior to simulation. 
12% of CD24-CD38int B cells also produced anti-inflammatory cytokine IL-10 
? ???
following BCR+CD40, TLR7, TLR9 and RP105 stimulation, which is over that which 
has been previously reported for Breg IL-10 production (93). As these pro-
inflammatory CD24-CD38int B cells were previously shown surrounding bile ducts in 
PBC IHC stains, it is possible that this population is involved in direct or indirect 
targeted destruction of bile ducts in PBC. However, where CD24-CD38int B cells 
demonstrate significantly higher IL-10 production compared to memory B cells 
following stimulation, it is possible that they also have a protective role in end stage 
liver disease. The importance of IL-10 has been highlighted in mice where Crohn’s-
like colitis developed in IL-10-deficient mice generated by gene targeting (554, 555). 
IL-10 has also proven to regulate hepatic injury in vivo. IL-10 exerted antifibrogenic 
effects during CCl4-induced hepatic fibrogenesis (556) and administration of 
recombinant IL-10 in mice challenged with Con A dramatically reduced pro-
inflammatory cytokine secretion, apoptosis of hepatocytes, hepatic neutrophil 
infiltrate and delayed hepatic necrosis (557, 558). Given that IL-10 has played a role 
in protecting against hepatic injury, it is possible that in the presence of hepatic 
disease, CD24-CD38int hepatic B cells respond by producing IL-10 to control liver 
inflammation by inhibiting antigen presentation to T cells, T cell cytokine production 
(559) and neutrophil chemokine production (560, 561). Alternatively, it is possible 
that IL-10 production exacerbates hepatic conditions such as PBC by enhancing 
proliferation and differentiation of plasma cells and IgM synthesis (507, 562). This 
can be assessed further in future work by comparing the cytokine production of 
CD24- B cells between end stage liver diseases and donor livers.   
 
By comparison, hepatic CD24-CD38- B cells were unresponsive to most TLR 
stimulations, with the exception of TLR9 stimulation, which triggered significantly 
? ???
higher percentages of TNF-α secretion compared to unstimulated CD24-CD38- B 
cells. This was also true for the CD24-CD38int B cells (Fig. 47). This contradicted 
findings from the previous patient cohort (Fig. 46), where I was unable to stimulate 
CD24-CD38- hepatic cells with TLR9, highlighting possible differences in B cell 
susceptibility to stimulation in patients suffering from different hepatic diseases. 
Considering CD24-CD38- B cells are enriched in the liver of PBC patients and 
produce TNF-α, and that CD24-CD38int B cells surround bile ducts and secrete 
TNF-α, IFN-γ and IL-6, the presence of pro-inflammatory cytokine secretion in the 
liver is intriguing as these cells may contribute to PBC disease pathogenesis. Zhao 
et al. 2011 has shown that TNF-α and IL-6 were elevated in PBC patient blood, and 
another study demonstrated that mRNA encoding TNF-α, IFN-γ, IL-6, IL-12 and IL-
23 were elevated in the livers of PBC mouse models (autoimmune cholangitis mice) 
II (563, 564). It is possible that TNF-α produced by hepatic CD24-CD38- and CD24-
CD38int B cells and IFN-γ produced by CD24-CD38int B cells can be destructive for 
BEC in PBC by increasing BEC expression of ICAM-1, HLA class I, and HLA class 
(564, 565), which has been previously shown. This in turn could increase antigen 
presentation to T helper cells, where T cells have been found to infiltrate near bile 
ducts in PBC patients (566), causing T cell activation and cytotoxic immune 
mediated bile duct damage. It is also possible that TNF-α secreted by CD24- B cells 
in the liver stimulate BEC to produce IL-8 and monocyte chemotactic protein-1, as 
this has been previously shown to promote recruitment of neutrophils and 
lymphocytes, which could contribute to pathological inflammation of bile ducts (567). 
To continue elucidating the possible function of hepatic CD24- B cells in liver 
damage, further investigation to assess the effects of CD24- B cell cytokine 
? ???
secretion on other hepatic cells such as BEC within specific hepatic diseases is 
required. 
One possibility is that both CD24-CD38- and CD24-CD38int B cells are related. It is 
true that CD38 expression is gained as CD24- GC B cells differentiate into plasma 
blasts and plasma cells. Therefore it is possible that CD24-CD38- and CD24-
CD38int B cells represent an earlier stage of B cell differentiation. However, given 
that these populations localize to different areas within the liver, produce different 
cytokines and differ in terms of proportions of naïve and non-switched memory cells, 
it is unlikely that these populations are related. Further investigations involving 
sorting these subsets and performing BCR sequence analyses would address clonal 
relationships between these B cell subsets, therefore confirming whether these 
subsets are related.  
 
All findings from this PhD project, with regard to B cell subsets in human liver and 
blood, are summarized in Figure 50 below. 
 
 
 
 
 
 
 
 
 
? ???
 
Figure 50 – A diagram summarizing the main findings of this project with 
regard to human B cells in blood and liver. Both general B cells and B cell 
subsets are described, with a particular focus on CD24-CD38- and CD24-CD38int B 
cells. 
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6.2. FUTURE WORK 
?
Despite the thorough characterisation of B cell subsets in the liver, the additional 
mechanisms of hepatic B cells which may affect the pathogenesis of chronic liver 
disease still remains elusive. Going forward, it would be interesting to characterize 
the function of these hepatic CD24- B cell subsets further. Firstly, whether these 
populations are liver resident or whether they home to the liver could be established. 
This could be investigated by staining CD24- B cells for chemokine receptors such 
as CXCR6, CXCR3, and CXCR4, adhesion molecules VCAM-1 and ICAM-1, and 
integrin αEβ7, which have been implicated in lymphocyte recruitment to biliary 
epithelium (382, 568, 569). Establishing this would indicate whether CD24- B cells 
have an immunosurveillance/homeostatic role in the liver, or whether they are 
recruited to the liver to play a role under certain conditions such as inflammation. 
The ontogeny of these cells could also be investigated, so that if they are found to 
play a role in hepatic disease, we can target their genesis therapeutically. This could 
be performed by BCR sequencing to analyse clonal relationships between B cell 
subsets (299, 301, 331). 
Given that CD24-CD38- B cells are enriched in PBC livers, investigating antibody 
production, antigen specificity and class switching of these cells, would aid in further 
elucidating the function of this population. Establishing these characteristics may 
also result in the identification of characteristic hyperimmunoglobulin G (IgG) and 
circulating autoantibodies participating in the pathogenesis of autoimmune liver 
diseases such as PBC. Investigations into the stimulation of CD24-CD38- B cells 
could be conducted using TLRs in combination with the presence of various 
cytokines and soluble factors such as BAFF. This will create a more realistic 
? ???
microenvironment reflective of that found in the liver (544, 570). Furthermore, the 
effects of TLRs and anti-BCR/CD40L on CD24-CD38- B cells can once again be 
tested, however this time different types of cytokine production could be established 
such as IL-35, TGF-β, IL-2, IL4 and IL-12 (16). This will inform us how and if this 
population promotes or suppresses immune responses in the liver. Antibody 
production could be investigated from hepatic B cells by isolating them from human 
liver tissue, and culturing them for various time points before harvesting the 
supernatants and detecting supernatant IgA, IgG and IgM via ELISA. The presence 
of autoantibodies (AMAs) can also be tested following culture of CD24- B cell 
subsets, by harvesting supernatants and using them in ELISA, immunoblotting and 
indirect immunofluorescence experiments. 
It would be interesting to investigate the competency of hepatic B cells to present 
antigen, as they may be involved in T cell co-stimulation. To do this B cell subsets 
can be sorted from PBC livers and measured for their ability to present autoantigen 
to activate T cells in vitro. Investigating the mRNA expression of hepatic CD24- B 
cell populations compared to blood CD24- B cells and other hepatic B cell subsets 
using transcriptomic analysis would be equally useful. This would help us to identify 
whether there are specific molecules that define these subsets, much like FoxP3+ 
for Tregs. Consequently, in a clinical setting, this would further indicate whether 
these B cells are responsible for driving or controlling hepatic disease. 
 
 
 
? ???
6.3. CONCLUSION 
?
Overall, the aim of this project was to characterise and quantify B cell subsets in 
human liver across end-stage hepatic diseases, and to identify the significance of B 
cells in hepatic disease. Addressing these aims would further assist in our 
understanding of whether specific B cell subsets can be targeted therapeutically 
(knocked out or activated) to treat chronic end stage liver disease.  
Our data supports that B cell subset proportions in the liver varied to those in 
matched blood, and that total B cells were enriched in PBC patients. I also 
demonstrated that CD24-CD38- and CD24-CD38int B cells were enriched in end 
stage diseased livers compared to matched blood, and that CD24-CD38- B cells 
were enriched in PBC compared to donor livers. Both hepatic CD24- B cell 
populations also responded to TLR9 stimulation to produce a higher percentage of 
TNF-α compared to unstimulated CD24- B cells, and directly ex vivo, CD24-CD38int 
B cells also expressed IL-6, IL-10 and IFN-γ. These CD24-CD38int B cells were 
located around bile ducts and within the fibrotic tracts of PBC patients, further 
indicating a possible pathogenic role of CD24- B cells in hepatic disease. 
These findings have improved our understanding of B cell subsets in the blood and 
liver, both in the presence and absence of chronic liver disease. In conclusion, our 
study highlights that B cells may play a pathological role in hepatic inflammation in 
chronic liver disease patients caused by different etiologies. Our data phenotyped 
hepatic B cell subsets and revealed their cytokine production potential, which hints to 
an immunomodulatory role. However, more detailed functional studies of intrahepatic 
B cell subsets, particularly CD24- B cells, are still required in chronic liver disease 
patients and healthy controls to fully elucidate their function.  
? ???
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